Compound serving as DDR1 kinase inhibitor, and medicine
Patent Information
- Application Number
- MYPI2025000175
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-11-21
- Filing Date
- 2023-11-20
- Publication Date
- 2024-05-21
AI Technical Summary
Current treatments for DDR1-related diseases are limited to symptomatic relief and do not effectively address the underlying pathological processes, highlighting the need for specific DDR1 kinase inhibitors to provide new therapeutic options.
Development of substituted bicyclic heterocyclic compounds with DDR1 kinase inhibitory activity, including specific pharmaceutical compounds and their pharmaceutically acceptable salts or solvates, which selectively target and inhibit the DDR1 kinase.
These compounds demonstrate excellent DDR1 kinase inhibitory activity, potentially offering new treatment methods for DDR1-related diseases by effectively targeting and inhibiting the DDR1 kinase, thereby addressing the limitations of existing treatments.
Abstract
Description
Compounds and drugs as DDR1 kinase inhibitors
[0001] The present invention relates to substituted bicyclic heterocyclic compounds useful as DDR1 kinase inhibitors and pharmaceuticals containing said compounds.
[0002] Discoidin Domain Receptor 1 (DDR1) is a tyrosine kinase receptor belonging to the discoidin domain receptor family and is known to be involved in cell proliferation, differentiation, migration, invasion, and adhesion. It is mainly expressed in epithelial cells of the lung, kidney, mammary gland, and digestive tract.
[0003] DDR1 transmits collagen signals into cells by binding to its ligand, collagen, via its discoidin domain. DDR1 is characterized by its ability to recognize not only fibrous collagens such as type I but also basement membrane collagens such as type IV collagen as its ligand. When DDR1 binds to collagen, specific tyrosine residues in the kinase domain present on the cytoplasmic side of the receptor are phosphorylated, and molecules having Src homology 2 or phosphotyrosine binding domains bind to it, activating various downstream signal pathways.
[0004] DDR1 activation is involved in various kidney diseases. DDR1 activation is involved in the pathology of various kidney diseases, including Alport syndrome (Non-Patent Documents 1 and 2), which is caused by a type IV collagen gene mutation, as well as IgA nephropathy (Non-Patent Document 3), Goodpature syndrome (Non-Patent Document 4), lupus nephritis (Non-Patent Document 4), ANCA (anti-neutrophil cytoplasmic antibody)-associated nephritis (Non-Patent Document 5), and diabetic nephropathy (Non-Patent Document 6).
[0005] DDR1 activation has also been reported to be involved in various fibrotic diseases, such as pulmonary fibrosis (Non-Patent Document 7) and liver cirrhosis (Non-Patent Document 8).
[0006] Furthermore, it has been reported that DDR1 is involved in the function of Th17 cells, which are involved in autoimmune diseases and allergies (Non-Patent Document 9). Th17 cells are involved in the pathogenesis of diseases such as rheumatoid arthritis, multiple sclerosis, ulcerative colitis, and Crohn's disease.
[0007] It has also been reported to be involved in the pathogenesis of cancer-related conditions, such as acute myeloid leukemia (Non-Patent Document 10), acute lymphocytic leukemia (Non-Patent Document 11), chronic lymphocytic leukemia (Non-Patent Document 12), Hodgkin's lymphoma (Non-Patent Document 13), glioma (Non-Patent Document 14), non-small cell lung cancer (Non-Patent Document 15), breast cancer (Non-Patent Document 16), ovarian cancer (Non-Patent Document 17), prostate cancer (Non-Patent Document 18), and colorectal cancer (Non-Patent Document 19).
[0008] DDR1 has also been reported to be involved in pathological conditions such as systemic lupus erythematosus (Non-Patent Document 5), osteoarthritis (Non-Patent Document 20), heparin-induced thrombocytopenia (Non-Patent Document 21), atherosclerosis (Non-Patent Document 22), and vitiligo vulgaris (Non-Patent Document 23).
[0009] Most of the treatments for these diseases are limited to symptomatic treatment, suppression of disease progression, and improvement of quality of life, and efficient treatment is extremely difficult. Therefore, it is thought that DDR1 inhibitors can provide a new treatment for these DDR1-related diseases.
[0010] Gross et al., Matrix Biol. 2010 Jun;29(5):346-56.Richter et al., ACS Chem Biol. 2019 Jan 18;14(1):37-49.Hahn et al., Int J Mol Med. 2010 May;25(5):785-91.Kerroch et al., FASEB J. 2012 Oct;26(10):4079-91.Moll et al., J Transl Med. 2018 Jun 1;16(1):148.Salem et al., J Am Soc Nephrol. 2019 Oct;30(10):2000-2016.Matsuyama et al., J Immunol. 2005 May 15;174(10):6490-8.Shackel et al., Am J Pathol. 2002 Feb;160(2):641-54.Azreq et al., Oncotarget. 2016 Jul 19;7(29):44975-44990.Favreau et al., Cancer Med. 2014 Apr;3(2):265-72.Guo et al., Exp Ther Med. 2019 Mar;17(3):1593-1600.Barisione et al., Blood Cancer J. 2017 Jan 6;6(1):e513.Cader et al., Blood. 2013 Dec 19;122(26):4237-45.Ram et al., J Neurooncol. 2006 Feb;76(3):239-48.Miao et al., Med Oncol. 2013;30(3):626.Zhong et al., Oncol Rep. 2019 Dec;42(6):2844-2854.Heinzelmann-Schwarz et al., Clin Cancer Res. 2004 Jul 1;10(13):4427-36.Azizi et al., J Cell Physiol. 2019 Nov;234(11):19539-19552.Le et al., Front Cell Dev Biol. 2020 Jun 3;8:412. Han et al. , PLoS One. 2020 Apr 24;15(4):e0231501. Witten et al. , J Mol Med. 2018 Aug; 96(8):765-775. Franco et al. , Circ Res. 2008 May 23;102(10):1202-11. Almasi-Nasrabadi et al. , Gene. 2019 Jun 5;700:17-22. ;
[0011] An object of the present invention is to provide a compound having DDR1 kinase inhibitory activity, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
[0012] The present inventors have found that the compounds described below, or pharmaceutically acceptable salts thereof, or solvates thereof, have excellent DDR1 kinase inhibitory activity, and have completed the present invention.
[0013] That is, the present invention includes the following aspects (Item 1) to (Item 22): (Item 1) Formula (I) [Wherein A is (In the formula, Y 1 , Y 2 , Y 3 and Y 4 are each independently N or C—R 5 wherein the Y 1 , Y 2 , Y 3 and Y 4 Of these, a maximum of two are N, and the rest are C-R. 5 and R 5 is hydrogen, halogen, cyano, alkoxy, or optionally substituted C 1 -C 6 alkyl, where the dashed line indicates the point of attachment, or (In the formula, R 6a , R 6b , R 6c , R 6d , R 6e , R 6f , R 6g and R 6h are each independently hydrogen, halogen, cyano or optionally substituted C1 -C 6 alkyl, the dashed line indicates the point of attachment, B is an optionally substituted 3-8 membered saturated or unsaturated monocyclic nitrogen-containing heterocycle, X is N or C-R 7 where R 7 is hydrogen, halogen, cyano or optionally substituted C 1 -C 6 alkyl, R 1 are each independently hydrogen, halogen, cyano, oxo, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 1 -C 6 Alkoxy, hydroxy, carboxy, alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, aminoalkyl, alkylcarbonylamino, C 3 -C 10 Cycloalkyl, C 3 -C 6 is selected from the group consisting of cycloalkenyl, heterocycloalkyl, aryl, and heteroaryl, each of which is optionally substituted; R 2 and R 3 are each independently hydrogen, halogen or optionally substituted C 1 -C 6 alkyl, R 4 is hydrogen, halogen, cyano, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 1 -C 6or R is selected from the group consisting of alkoxy, hydroxy, carboxy, alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, aminoalkyl, alkylcarbonylamino, monocyclic or bicyclic saturated carbocycle, monocyclic or bicyclic unsaturated carbocycle, monocyclic or bicyclic saturated heterocycle, and monocyclic or bicyclic unsaturated heterocycle, each of which is optionally substituted; or 4 is -CONR 8 R 9 where R 8 and R 9 each independently represents hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 10 Cycloalkyl, C 3 -C 6 selected from the group consisting of cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, each of which is optionally substituted; or R 8 and R 9 are taken together with the atoms to which they are attached to form an optionally substituted 5- to 10-membered monocyclic or bicyclic saturated heterocycle or a 5- to 10-membered monocyclic or bicyclic unsaturated heterocycle, m is an integer from 0 to 3, n is an integer from 0 to 3, and Het is a 5- to 10-membered monocyclic or bicyclic saturated heterocycle or a 5- to 10-membered monocyclic or bicyclic unsaturated heterocycle, or a pharmaceutically acceptable salt thereof, or a solvate thereof. (Item 2) A compound of formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof. [In the formula, B, R 1 , R 2 , R 3 , R 4 , Het, X, Y 1 , Y 2 , Y 3 , Y 4Item 3: The compound according to item 1, wherein the compound of formula (I) is of formula (III): [In the formula, B, R 1 , R 2 , R 3 , R 4 , R 6a , R 6b , R 6c , R 6d , R 6e , R 6f , R 6g , R 6h , Het, X, m and n are as defined in formula (I), or a pharmaceutically acceptable salt thereof, or a solvate thereof. 1 are each independently hydrogen, halogen, oxo, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, amino, monoalkylamino, dialkylamino, aminoalkyl, alkylcarbonylamino, C 3 -C 10 The compound according to any one of items 1 to 3, or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein R is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, each of which may be optionally substituted. (Item 5) R 4 But hydrogen, halogen, cyano, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 1 -C 6 Alkoxy, hydroxy, carboxy, alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, aminoalkyl, alkylcarbonylamino, C 3 -C 10 Cycloalkyl, C 3 -C 6The compound according to any one of items 1 to 4, wherein R is selected from the group consisting of cycloalkenyl, heterocycloalkyl, aryl, and heteroaryl, each of which may be optionally substituted, or a pharmaceutically acceptable salt thereof, or a solvate thereof. (Item 6) R 4 Ga-CONR 8 R 9 where R 8 and R 9 each independently represents hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 10 Cycloalkyl, C 3 -C 6 is selected from the group consisting of cycloalkenyl, heterocycloalkyl, aryl, and heteroaryl, each of which is optionally substituted; or R 8 and R 9 (Item 7) The compound according to any one of Items 1 to 4, wherein X is N, or a pharmaceutically acceptable salt thereof, or a solvate thereof. (Item 8) The compound according to any one of Items 1 to 6, wherein X is C-R 7 where R 7 is hydrogen, halogen, cyano or optionally substituted C 1 -C 6(Item 9) A compound or a pharmaceutically acceptable salt thereof selected from the group consisting of the following compounds (1) to (295), or a solvate thereof: (1) 2-(4-chloro-3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-5-fluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (2) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (3) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (4) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-5-chloro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (5) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-6-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (6) 2-{3-[1-(2-aminopyridine-4-carbonyl)-3-methylazetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (7) 2-{3-[1-(2-amino-4-methyl-1,3-thiazole-5-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-(3,3-dimethylmorpholin-4-yl)ethan-1-one (8) 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one(9) 4-[4-(4-fluoro-1-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-1H-indazol-3-yl)piperidine-1-carbonyl]pyridin-2-amine (10) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)piperidin-4-yl]-4-fluoro-1H-indol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (11) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (12) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-5-methyl-1H-pyrazolo[4,3-b]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (13) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-pyrazolo[4,3-c]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (14) 4-{3-[4-fluoro-1-({5-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-3-yl}methyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]azetidine-1-carbonyl}pyridin-2-amine (15) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-methyl-1H-pyrazolo[3,4-b]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (16) 2-{3-[1-(6-aminopyridazine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one(17) 2-[4,6-difluoro-3-(1-{1H-pyrazolo[3,4-b]pyridine-4-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (18) 5-fluoro-4-[3-(1-{[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (19) 4-{3-[1-({1-[(3,3-difluorocyclobutyl)methyl]-1H-1,2,3-triazol-4-yl}methyl)-4-fluoro-1H-indazol-3-yl]azetidine-1-carbonyl}pyridin-2-amine hydrochloride (20) 4-[3-(4-fluoro-1-{[5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (21) 2-{3-[1-(2-amino-5-fluoropyrimidine-4-carbonyl)azetidin-3-yl]-5-chloro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (22) 2-{3-[1-(2-amino-5-fluoropyrimidine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (23) 2-{3-[1-(2-amino-5-fluoropyrimidine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (24) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,5,6,7-tetrahydro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one(25) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5,5-difluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (26) 2-(4-chloro-3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-5-fluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide p-toluenesulfonate (27) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one methanesulfonate (28) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (29) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one methanesulfonate (30) 2-(3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-4,6-difluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (31) 2-(3-{1-[6-(cyclopropylamino)pyrimidine-4-carbonyl]azetidin-3-yl}-4,6-difluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide (32) 2-[4,6-difluoro-3-(1-{2-[(oxetan-3-yl)amino]pyridine-4-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-N-(2,2,2-trifluoroethyl)acetamide(33) 2-[4,6-difluoro-3-(1-{1H-pyrrolo[2,3-b]pyridine-4-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (34) 4-(3-{4-fluoro-1-[(1-phenyl-1H-1,2,3-triazol-4-yl)methyl]-1H-indazol-3-yl}azetidine-1-carbonyl)pyridin-2-amine (35) 4-(3-{1-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]-4-fluoro-1H-indazol-3-yl}azetidine-1-carbonyl)pyridin-2-amine hydrochloride (36) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]ethan-1-one (37) 4-[3-(1-{[1-(cyclopropylmethyl)-1H-1,2,3-triazol-4-yl]methyl}-4-fluoro-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine hydrochloride (38) 4-{3-[4-fluoro-1-({1-[(oxetan-3-yl)methyl]-1H-1,2,3-triazol-4-yl}methyl)-1H-indazol-3-yl]azetidine-1-carbonyl}pyridin-2-amine (39) 4-{4-[1-({1-[(3,3-difluorocyclobutyl)methyl]-1H-1,2,3-triazol-4-yl}methyl)-4-fluoro-1H-indazol-3-yl]piperidine-1-carbonyl}pyridin-2-amine (40) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (41) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride(42) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (43) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one p-toluenesulfonate (44) 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2S)-2-[(trifluoromethoxy)methyl]pyrrolidin-1-yl]ethan-1-one di-p-toluenesulfonate (45) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (46) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide p-toluenesulfonate (47) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)-1,2,3,6-tetrahydropyridin-4-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (48) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)piperidin-4-yl]-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (49) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)piperidin-4-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one(50) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (51) 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one hydrochloride (52) 4-[3-(1-{[1-(2,2,2-trifluoroethyl)-1H-1,2,3-triazol-4-yl]methyl}-4-fluoro-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine hydrochloride (53) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (54) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (55) 4-{3-[4-fluoro-1-({3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}methyl)-1H-indazol-3-yl]azetidine-1-carbonyl}pyridin-2-amine (56) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-[(trifluoromethoxy)methyl]pyrrolidin-1-yl]ethan-1-one (57) 4-(3-{1-[(4,4-difluorocyclohexyl)methyl]-4,6-difluoro-1H-indazol-3-yl}azetidine-1-carbonyl)pyridin-2-amine(58) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2S)-2-[(trifluoromethoxy)methyl]pyrrolidin-1-yl]ethan-1-one di-p-toluenesulfonate (59) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (60) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (61) 2-[4-chloro-3-(1-{1H-pyrrolo[2,3-b]pyridine-4-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-N-(2,2,2-trifluoroethyl)acetamide (62) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-chloro-1H-indazol-1-yl}-N-(2,2,2-trifluoroethyl)acetamide (63) 2-(4-chloro-3-{1-[2-(methylamino)pyridine-4-carbonyl]azetidin-3-yl}-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide (64) 2-(4-chloro-3-{1-[2-(ethylamino)pyridine-4-carbonyl]azetidin-3-yl}-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (65) 2-(3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-4-fluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (66) 2-(3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-4,7-difluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide hydrochloride(67) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-chloro-5-fluoro-1H-indazol-1-yl}-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (68) 2-(3-{1-[2-(cyclobutylamino)pyridine-4-carbonyl]azetidin-3-yl}-4-fluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (69) 2-(4-bromo-3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-5-fluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (70) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-bromo-5-fluoro-1H-indazol-1-yl}-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (71) 2-[4-fluoro-3-(1-{2-[(oxan-4-yl)amino]pyridine-4-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (72) 2-(3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-4,6-difluoro-1H-indazol-1-yl)-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (73) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one hydrochloride (74) 2-[4,6-difluoro-3-(1-{2-[(1-methylcyclopropyl)amino]pyridine-4-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride(75) 2-[3-(1-{2-[(4,4-difluorocyclohexyl)amino]pyridine-4-carbonyl}azetidin-3-yl)-4,6-difluoro-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (76) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-(pyrrolidin-1-yl)ethan-1-one (77) 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (78) 2-{3-[1-(2-amino-5-methylpyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (79) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-methylmorpholin-4-yl]ethan-1-one hydrochloride (80) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(3R)-3-methylmorpholin-4-yl]ethan-1-one hydrochloride (81) 2-{3-[1-(2-aminopyridine-4-carbonyl)piperidin-4-yl]-4-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (82) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one(83) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(3R)-3-(propan-2-yl)morpholin-4-yl]ethan-1-one (84) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R,6S)-2,6-dimethylmorpholin-4-yl]ethan-1-one (85) 2-{3-[1-(6-aminopyridine-3-carbonyl)piperidin-4-yl]-4-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (86) 2-(3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]piperidin-4-yl}-4-fluoro-1H-indazol-1-yl)-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (87) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (88) 2-[4,6-difluoro-3-(1-{2-[(oxan-4-yl)amino]pyridine-4-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (89) 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one hydrochloride (90) 2-{3-[1-(2-aminopyridine-4-carbonyl)piperidin-4-yl]-4-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one(91) 2-{3-[1-(2-aminopyridine-4-carbonyl)piperidin-4-yl]-4-fluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (92) 4-[3-(1-{[1-(cyclobutylmethyl)-1H-1,2,3-triazol-4-yl]methyl}-4-fluoro-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine hydrochloride (93) 2-(3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-4-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl)-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (94) 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-4-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (95) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one hydrochloride (96) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (97) 2-{3-[1-(2-amino-1,3-thiazole-5-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (98) 2-(3-{1-[2-(cyclopropylamino)-1,3-thiazole-5-carbonyl]azetidin-3-yl}-4,6-difluoro-1H-indazol-1-yl)-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one(99) 2-(3-{1-[2-(cyclopropylamino)-4-methyl-1,3-thiazole-5-carbonyl]azetidin-3-yl}-4,6-difluoro-1H-indazol-1-yl)-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (100) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (101) 2-[4,6-Difluoro-3-(1-{imidazo[1,2-a]pyridine-3-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (102) 2-[4,6-Difluoro-3-(1-{pyrazolo[3,2-b][1,3]thiazole-7-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (103) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]propan-1-one hydrochloride (104) 4-[3-(4-fluoro-1-{[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (105) 2-{3-[1-(2-amino-1,3-oxazole-5-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (106) 2-{3-[1-(2-amino-4-methyl-1,3-thiazole-5-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one(107) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-2-fluoro-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (108) 2-{3-[1-(2-aminopyridine-4-carbonyl)piperidin-4-yl]-4-fluoro-1H-indol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (109) 4-(3-{4-fluoro-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-1H-indazol-3-yl}azetidine-1-carbonyl)pyridin-2-amine (110) 2-{3-[1-(2-amino-4-methyl-1,3-oxazole-5-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (111) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-4,4-difluoro-2-(fluoromethyl)pyrrolidin-1-yl]ethan-1-one (112) 4-[3-(4-fluoro-1-{[4-(trifluoromethyl)phenyl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine hydrochloride (113) 4-[3-(4-fluoro-1-{[3-(trifluoromethyl)phenyl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine hydrochloride (114) 4-[3-(4-fluoro-1-{[2-(trifluoromethyl)phenyl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine hydrochloride (115) 4-[3-(4-fluoro-1-{[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine hydrochloride(116) 4-[3-(4-fluoro-1-{[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (117) 4-{3-[4-fluoro-1-({5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}methyl)-1H-indazol-3-yl]azetidine-1-carbonyl}pyridin-2-amine (118) 2-{3-[1-(2-amino-1,3-thiazole-5-carbonyl)piperidin-4-yl]-4-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (119) 2-{3-[1-(2-amino-4-methyl-1,3-thiazole-5-carbonyl)piperidin-4-yl]-4-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (120) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-pyrazolo[4,3-b]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (121) 2-(3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (122) 2-{3-[1-(2-amino-4-methyl-1,3-thiazole-5-carbonyl)azetidin-3-yl]-1H-pyrazolo[4,3-b]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (123) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(3S)-3-(trifluoromethyl)morpholin-4-yl]ethan-1-one(124) 2-{3-[1-(2-aminopyridine-4-carbonyl)-1,2,3,6-tetrahydropyridin-4-yl]-4-fluoro-1H-indol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (125) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(3S)-3-(difluoromethoxy)pyrrolidin-1-yl]ethan-1-one (126) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(3R)-3-(difluoromethoxy)pyrrolidin-1-yl]ethan-1-one (127) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-(2,2-dimethylpyrrolidin-1-yl)ethan-1-one (128) 4-[3-(4-fluoro-1-{[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (129) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (130) 2-(3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-5-methyl-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (131) 2-{3-[1-(6-aminopyrimidine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one(132) 2-{4,6-difluoro-3-[1-(pyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (133) 2-{4,6-difluoro-3-[1-(3-methoxypyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (134) 4-[4-(4-fluoro-1-{[6-(trifluoromethyl)pyridin-3-yl]methyl}-1H-indazol-3-yl)piperidine-1-carbonyl]pyridin-2-amine (135) 2-{3-[1-(2-aminopyridine-4-carbonyl)piperidin-4-yl]-4-fluoro-1H-indol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (136) 2-{3-[1-(2-aminopyridine-4-carbonyl)piperidin-4-yl]-4-fluoro-1H-indol-1-yl}-1-[(2S)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (137) 4-[3-(4-fluoro-1-{[5-(oxan-4-yl)-1,2,4-oxadiazol-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (138) 4-[3-(4-fluoro-1-{[3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl]methyl}-1H-indazol-3-yl)azetidin-1-carbonyl]pyridin-2-amine (139) 2-(3-{1-[2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carbonyl]azetidin-3-yl}-4,6-difluoro-1H-indazol-1-yl)-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (140) 2-{4,6-difluoro-3-[1-(1H-indazole-5-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one(141) 2-[4,6-difluoro-3-(1-{1H-pyrazolo[4,3-b]pyridine-5-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (142) 2-{4,6-difluoro-3-[1-(3-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (143) 2-{3-[1-(3-chloropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (144) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-chloro-5-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (145) 2-{3-[1-(2-amino-3-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (146) 4-{3-[4-fluoro-1-({5-[1-(trifluoromethyl)cyclobutyl]-1,2,4-oxadiazol-3-yl}methyl)-1H-indazol-3-yl]azetidine-1-carbonyl}pyridin-2-amine hydrochloride (147) 4-{3-[4-fluoro-1-({5-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-3-yl}methyl)-1H-indazol-3-yl]azetidine-1-carbonyl}pyridin-2-amine (148) 4-[3-(4-fluoro-1-{[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine(149) 2-{3-[1-(2-amino-4-chloro-1,3-thiazole-5-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (150) 4-[3-(4-fluoro-1-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-1H-pyrazolo[3,4-c]pyridin-3-yl)azetidine-1-carbonyl]pyridin-2-amine (151) 4-[3-(4-fluoro-1-{[4-(trifluoromethyl)phenyl]methyl}-1H-pyrazolo[3,4-c]pyridin-3-yl)azetidine-1-carbonyl]pyridin-2-amine (152) 4-{3-[4,6-difluoro-1-(3-phenylprop-2-yn-1-yl)-1H-indazol-3-yl]azetidine-1-carbonyl}pyridin-2-amine (153) 4-[3-(4-fluoro-1-{[5-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (154) 4-[3-(4-fluoro-1-{[5-(6-methylpyridazin-3-yl)-1,2,4-oxadiazol-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (155) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (156) 4-{3-[1-(3-cyclopropylprop-2-yn-1-yl)-4,6-difluoro-1H-indazol-3-yl]azetidine-1-carbonyl}pyridin-2-amine (157) 4-(3-{4,6-difluoro-1-[(1-phenylazetidin-3-yl)methyl]-1H-indazol-3-yl}azetidine-1-carbonyl)pyridin-2-amine(158) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-(1,2,3,4-tetrahydroquinolin-1-yl)ethan-1-one (159) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-(3,4-dihydro-2H-1,4-benzoxazin-4-yl)ethan-1-one (160) 4-[3-(4-fluoro-1-{[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]methyl}-1H-pyrazolo[3,4-c]pyridin-3-yl)azetidine-1-carbonyl]pyridin-2-amine (161) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-(6-bromo-2,3-dihydro-1H-indol-1-yl)ethan-1-one (162) 2-{4,6-Difluoro-3-[1-(oxane-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (163) 2-{4,6-Difluoro-3-[1-(2-hydroxypyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (164) 2-{4,6-difluoro-3-[1-(1H-pyrazole-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (165) 2-{4,6-difluoro-3-[1-(5-methyl-1H-pyrazole-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one(166) 2-(4,6-difluoro-3-{1-[5-(trifluoromethyl)-1H-pyrazole-4-carbonyl]azetidin-3-yl}-1H-indazol-1-yl)-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (167) 4-[3-(4,6-difluoro-1-{[1-(2,2,2-trifluoroethyl)azetidin-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (168) 4-[3-(5-methyl-1-{[4-(trifluoromethyl)phenyl]methyl}-1H-pyrazolo[3,4-c]pyridin-3-yl)azetidine-1-carbonyl]pyridin-2-amine (169) 2-{3-[1-(1H-1,2,3-benzotriazole-5-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (170) 4-[3-(4-fluoro-1-{[3-(3-fluoropyridin-4-yl)-1,2,4-oxadiazol-5-yl]methyl}-1H-pyrazolo[3,4-c]pyridin-3-yl)azetidine-1-carbonyl]pyridin-2-amine (171) 4-(3-{1-[(2,3-dihydro-1H-inden-2-yl)methyl]-4,6-difluoro-1H-indazol-3-yl}azetidine-1-carbonyl)pyridin-2-amine (172) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-(6-cyclopropyl-2,3-dihydro-1H-indol-1-yl)ethan-1-one (173) 2-{3-[1-(2-amino-4-methyl-1,3-thiazole-5-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one(174) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)piperidin-4-yl]-4-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (175) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-[(trifluoromethoxy)methyl]pyrrolidin-1-yl]ethan-1-one (176) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-(2,2-dimethylmorpholin-4-yl)ethan-1-one (177) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-(3,3-dimethylmorpholin-4-yl)ethan-1-one (178) 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-5-methyl-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one dihydrochloride (179) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]ethan-1-one (180) 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (181) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one(182) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(3S,5S)-3,5-dimethylmorpholin-4-yl]ethan-1-one (183) 2-{3-[1-(2-amino-4-methyl-1,3-thiazole-5-carbonyl)azetidin-3-yl]-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2S)-2-[(trifluoromethoxy)methyl]pyrrolidin-1-yl]ethan-1-one p-toluenesulfonate (184) 2-{3-[1-(2-amino-3-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one p-toluenesulfonate (185) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5-methyl-1H-pyrazolo[4,3-b]pyridin-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one p-toluenesulfonate (186) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5-methyl-1H-pyrazolo[4,3-b]pyridin-1-yl}-1-(3,3-dimethylmorpholin-4-yl)ethan-1-one p-toluenesulfonate (187) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-(3,3-dimethylmorpholin-4-yl)ethan-1-one (188) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-(3,3-dimethylmorpholin-4-yl)ethan-1-one (189) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-N-tert-butylacetamide(190) 2-{3-[1-(2-amino-3-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-(3,3-dimethylmorpholin-4-yl)ethan-1-one (191) 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-(3,3-dimethylmorpholin-4-yl)ethan-1-one (192) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (193) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (194) 2-{3-[1-(2-amino-3-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (195) 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (196) 2-{3-[1-(2-amino-3-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (197) 2-{3-[1-(2-amino-4-methyl-1,3-thiazole-5-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (198) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-tert-butylacetamide(199) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-tert-butylacetamide (200) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-5-methyl-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (201) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5-methyl-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (202) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-5-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (203) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (204) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5-chloro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (205) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-5-chloro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (206) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5-chloro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (207) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-5-chloro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one(208) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(1-methoxy-2-methylpropan-2-yl)acetamide (209) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(4-methyloxan-4-yl)acetamide (210) 2-{3-[1-(2-amino-5-chloropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (211) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(2,2,2-trifluoroethyl)acetamide (212) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-[(2R)-1,1,1-trifluoropropan-2-yl]acetamide (213) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-[(2S)-1,1,1-trifluoropropan-2-yl]acetamide (214) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(3,3-difluorocyclobutyl)acetamide (215) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (216) 4-[3-(4-fluoro-1-{[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (217) 4-[3-(1-{[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine(218) 4-[3-(1-{[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (219) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]ethan-1-one (220) tert-Butyl 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}acetate (221) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-(2,2-dimethylpyrrolidin-1-yl)ethan-1-one (222) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2R)-2-ethylpyrrolidin-1-yl]ethan-1-one (223) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-{2-azabicyclo[3.1.0]hexan-2-yl}ethan-1-one (224) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(dicyclopropylmethyl)acetamide (225) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(2,2-difluorocyclopentyl)acetamide (226) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(4-fluorophenyl)acetamide (227) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-[2-(trifluoromethoxy)ethyl]acetamide(228) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]ethan-1-one (229) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(cyclopropylmethyl)-N-methylacetamide (230) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(3S)-3-methoxypyrrolidin-1-yl]ethan-1-one (231) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(3R)-3-methoxypyrrolidin-1-yl]ethan-1-one (232) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-{2-oxa-6-azaspiro[3.4]octan-6-yl}ethan-1-one (233) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(oxan-4-yl)acetamide (234) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(2-cyclopropylpropan-2-yl)acetamide (235) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(4,4-difluorocyclohexyl)acetamide (236) (2S)-1-(2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}acetyl)pyrrolidine-2-carbonitrile (237) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-4,4-difluoro-2-(fluoromethyl)pyrrolidin-1-yl]ethan-1-one(238) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-indazol-1-yl}-N-{bicyclo[2.2.1]heptan-2-yl}acetamide (239) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-indazol-1-yl}-N-{bicyclo[1.1.1]pentan-1-yl}acetamide (240) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (241) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-5-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (242) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-indazol-1-yl}-N-(2,2-difluoroethyl)acetamide (243) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-[trans-2-fluorocyclopropyl]acetamide (244) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(1-cyanocyclopropyl)acetamide (245) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-[(1R,2S)-2-fluorocyclopropyl]acetamide (246) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-[(1S,2R)-2-fluorocyclopropyl]acetamide (247) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(1-methyl-1H-pyrazol-5-yl)acetamide(248) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(2,2-difluorocyclopropyl)acetamide (249) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-ethyl-N-(2,2,2-trifluoroethyl)acetamide (250) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(3,3-difluorocyclobutyl)-N-methylacetamide (251) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-cyclopropyl-N-(2,2,2-trifluoroethyl)acetamide (252) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-cyclopropyl-N-methylacetamide (253) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-(propan-2-yl)acetamide (254) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-(oxetan-3-yl)acetamide (255) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-(oxan-4-yl)acetamide (256) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-[(3,3-difluorocyclobutyl)methyl]-N-methylacetamide (257) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-(4,4-difluoropiperidin-1-yl)ethan-1-one(258) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-{8-oxa-3-azabicyclo[3.2.1]octan-3-yl}ethan-1-one (259) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[3-(trifluoromethyl)piperidin-1-yl]ethan-1-one (260) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-(4-methylpiperazin-1-yl)ethan-1-one (261) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-[(2S)-1,1,1-trifluoropropan-2-yl]acetamide (262) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-[(2R)-1,1,1-trifluoropropan-2-yl]acetamide (263) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N,N-diethylacetamide (264) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-[2-(morpholin-4-yl)ethyl]acetamide (265) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(2-methoxyethyl)-N-methylacetamide (266) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2R,6S)-2,6-dimethylpiperidin-1-yl]ethan-1-one(267) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N,N-bis(propan-2-yl)acetamide (268) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-tert-butyl-N-methylacetamide (269) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(2,2-difluoroethyl)-N-methylacetamide (270) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)-3-methylazetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (271) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)-3-methylazetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (272) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(difluoromethyl)pyrrolidin-1-yl]ethan-1-one (273) 2-{3-[1-(2-aminopyridine-4-carbonyl)-3-methylazetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (274) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5-chloro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (275) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-6-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one(276) 2-{3-[1-(2-amino-5-fluoropyrimidine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (277) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (278) 2-{3-[1-(2-amino-5-fluoropyrimidine-4-carbonyl)azetidin-3-yl]-5-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (279) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5,6-difluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (280) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (281) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)-3-hydroxyazetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (282) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-5,6-difluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (283) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-5,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (284) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-6-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide(285) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)-3-fluoroazetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (286) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-6-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (287) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-4-chloro-5-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (288) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-5-methyl-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (289) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (290) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-5-chloro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (291) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5-methoxy-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (292) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-5-methyl-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (293) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-5-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide(294) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5,5-dimethyl-4,5,6,7-tetrahydro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one, and (295) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-5,5-dimethyl-4,5,6,7-tetrahydro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one. (Item 10) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one, or a pharmaceutically acceptable salt thereof, or a solvate thereof. (Item 11) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride, or a solvate thereof. (Item 12) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-6-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide, or a pharmaceutically acceptable salt thereof, or a solvate thereof. (Item 13) 2-{3-[1-(2-aminopyridine-4-carbonyl)-3-methylazetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one, or a pharmaceutically acceptable salt thereof, or a solvate thereof. (Item 14) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one, or a pharmaceutically acceptable salt thereof, or a solvate thereof. (Item 15)2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one methanesulfonate, or a solvate thereof. (Item 16) A pharmaceutical composition comprising the compound according to any one of items 1 to 15, or a pharmaceutically acceptable salt thereof, or a solvate thereof. (Item 17) A DDR1 kinase inhibitor comprising, as an active ingredient, the compound according to any one of items 1 to 15, or a pharmaceutically acceptable salt thereof, or a solvate thereof. (Item 18) A method for inhibiting DDR1 kinase, comprising administering the compound according to any one of items 1 to 15, or a pharmaceutically acceptable salt thereof, or a solvate thereof to a subject in need thereof. (Item 19) A preventive or therapeutic agent for a disease involving DDR1 kinase, comprising the compound according to any one of items 1 to 15, or a pharmaceutically acceptable salt thereof, or a solvate thereof. (Item 20) A therapeutic agent for treating Alport syndrome, IgA nephropathy, Goodpature syndrome, anti-glomerular basement membrane nephritis, lupus nephritis, ANCA-associated nephritis, diabetic nephropathy, purpura nephritis, focal segmental glomerulosclerosis, chronic renal failure, minimal change nephrotic syndrome, mesangial proliferative glomerulonephritis, membranoproliferative glomerulonephritis, crescentic glomerulonephritis, membranous nephropathy, pulmonary fibrosis, myelofibrosis, hepatic fibrosis, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, glioma, non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, prostate cancer, colorectal cancer, or osteoarthritis, comprising the compound according to any one of Items 1 to 15 or a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient. (Item 21) A method for preventing or treating a disease involving DDR1 kinase, comprising administering the compound according to any one of items 1 to 15, or a pharmaceutically acceptable salt thereof, or a solvate thereof, to a subject in need thereof. (Item 22)Item 16. A method for preventing or treating Alport syndrome, IgA nephropathy, Goodpature syndrome, anti-glomerular basement membrane nephritis, lupus nephritis, ANCA-associated nephritis, diabetic nephropathy, purpura nephritis, focal segmental glomerulosclerosis, chronic renal failure, minimal change nephrotic syndrome, mesangial proliferative glomerulonephritis, membranoproliferative glomerulonephritis, crescentic glomerulonephritis, membranous nephropathy, pulmonary fibrosis, myelofibrosis, hepatic fibrosis, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, glioma, non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, prostate cancer, colorectal cancer, or osteoarthritis, comprising administering the compound according to any one of Items 1 to 15, or a pharmaceutically acceptable salt thereof, or a solvate thereof, to a subject in need thereof. (Item 23) The compound according to any one of Items 1 to 15, or a pharmaceutically acceptable salt thereof, or a solvate thereof, for use in the prevention or treatment of a disease involving DDR1 kinase. (Item 24) The compound according to any one of Items 1 to 11, or a pharmaceutically acceptable salt thereof, or a solvate thereof, for use in the prevention or treatment of Alport syndrome, IgA nephropathy, Goodpature syndrome, anti-glomerular basement membrane nephritis, lupus nephritis, ANCA-associated nephritis, diabetic nephropathy, purpura nephritis, focal segmental glomerulosclerosis, chronic renal failure, minimal change nephrotic syndrome, mesangial proliferative glomerulonephritis, membranoproliferative glomerulonephritis, crescentic glomerulonephritis, membranous nephropathy, pulmonary fibrosis, myelofibrosis, hepatic fibrosis, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, glioma, non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, prostate cancer, colorectal cancer, or osteoarthritis. (Item 25) Use of the compound according to any one of Items 1 to 15, or a pharmaceutically acceptable salt thereof, or a solvate thereof, in the manufacture of an agent for preventing or treating a disease involving DDR1 kinase.Item 16. Use of the compound according to any one of Items 1 to 15, or a pharmaceutically acceptable salt thereof, or a solvate thereof, in the manufacture of an agent for preventing or treating Alport syndrome, IgA nephropathy, Goodpature syndrome, anti-glomerular basement membrane nephritis, lupus nephritis, ANCA-associated nephritis, diabetic nephropathy, purpura nephritis, focal segmental glomerulosclerosis, chronic renal failure, minimal change nephrotic syndrome, mesangial proliferative glomerulonephritis, membranoproliferative glomerulonephritis, crescentic glomerulonephritis, membranous nephropathy, pulmonary fibrosis, myelofibrosis, hepatic fibrosis, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, glioma, non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, prostate cancer, colorectal cancer, or osteoarthritis.
[0014] The definitions of the terms used in this specification are explained in detail below.
[0015] As used herein, "halogen" refers to a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom. In particular, a fluorine atom or a chlorine atom is preferred.
[0016] As used herein, "alkyl" includes, for example, straight or branched chain alkyl groups of 1 to 8 carbon atoms (C 1 -C 8 ), preferably 1 to 6 carbon atoms (C 1 -C 6 Specific examples include alkyl having a group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, isoamyl, —CH(CH 2 CH 3 ) 2 , hexyl, isohexyl, -CH 2 CH 2 C(CH 3 ) 3 , -CH 2 CH (CH 2 CH 3 ) 2 , heptyl, isoheptyl, octyl, isooctyl, and the like.
[0017] As used herein, "alkenyl" refers to, for example, an alkenyl having 2 to 8 carbon atoms (C 2 -C 8 ) straight-chain or branched-chain alkenyl. Specific examples include ethenyl, 1-propenyl, 2-propenyl, 1-methyl-2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-4-pentenyl, etc. Alkenyl having 2 to 6 carbon atoms is preferred, and alkenyl having 2 to 4 carbon atoms is more preferred.
[0018] As used herein, "alkynyl" refers to, for example, an alkynyl group having 2 to 8 carbon atoms (C 2 -C 8 ) straight-chain or branched-chain alkynyl. Specific examples include ethynyl, 1-propynyl, 2-propynyl, 1-methyl-2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-4-pentynyl, etc. Alkynyl having 2 to 6 carbon atoms is preferred, and alkynyl having 2 to 4 carbon atoms is more preferred.
[0019] The alkyl moiety of "alkylcarbonyl," "monoalkylamino," "dialkylamino," and "aminoalkyl" used herein can be the same as the above-mentioned "alkyl."
[0020] As used herein, "haloalkyl" includes, for example, the above-mentioned "alkyl" in which one to three hydrogen atoms have been substituted by the above-mentioned "halogen". Specific examples include fluoromethyl, chloromethyl, fluoroethyl, difluoromethyl, dichloromethyl, difluoroethyl (e.g., 2,2-difluoroethyl), trifluoromethyl, trichloromethyl, trifluoroethyl (e.g., 2,2,2-trifluoroethyl), and the like.
[0021] As used herein, "alkoxy" refers to, for example, straight or branched chain alkyl groups of 1 to 8 carbon atoms (C 1 -C 8 ), preferably 1 to 6 carbon atoms (C 1 -C 6 Specific examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentyloxy, n-hexyloxy, n-heptyloxy, and n-octyloxy.
[0022] As used herein, "haloalkoxy" includes, for example, groups in which one to three hydrogen atoms of the above-mentioned "alkoxy" are substituted by the above-mentioned "halogen." Specific examples include fluoromethoxy, chloromethoxy, fluoroethoxy, difluoromethoxy, dichloromethoxy, difluoroethoxy (e.g., 2,2-difluoroethoxy), trifluoromethoxy, trichloromethoxy, trifluoroethoxy (e.g., 2,2,2-trifluoroethoxy), and the like.
[0023] As used herein, "cycloalkyl" refers to, for example, a group having 3 to 10 carbon atoms (C 3 -C 10 Specific examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.1.0]pentyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, and bicyclo[3.2.1]octyl, adamantyl (tricyclo[3.3.1.1]octyl), and the like. 3,7 ] decanyl) and the like.
[0024] As used herein, "halocycloalkyl" includes, for example, the above-mentioned "cycloalkyl" in which one to three hydrogen atoms have been substituted by the above-mentioned "halogen". Specific examples include 2-fluorocyclopropyl, 3,3-difluorocyclobutyl, 2,2-difluorocyclopentyl, 4,4-difluorocyclohexyl, etc.
[0025] As used herein, "cycloalkenyl" refers to, for example, cycloalkenyls having 3 to 10 carbon atoms (C 3 -C 10 and a monocyclic, bicyclic, or tricyclic unsaturated hydrocarbon group having one or two double bonds in the molecule. Specific examples include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, etc.
[0026] As used herein, "heterocycloalkyl" includes, for example, monocyclic or bicyclic saturated heterocyclic rings each having 1 to 4 heteroatoms selected from a nitrogen atom, a sulfur atom, and an oxygen atom in the ring and 4 to 10 ring-constituting atoms. Specific examples include azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 1,3-dioxolanyl, 1,4-dioxolanyl, tetrahydrothiophenyl, and the like.
[0027] As used herein, "aryl" includes, for example, monocyclic, bicyclic, or tricyclic aromatic hydrocarbon groups having 6 to 14 carbon atoms. Specific examples include phenyl, 1-naphthyl, 2-naphthyl, 1-anthryl, 2-anthryl, 9-anthryl, 1-phenanthryl, 2-phenanthryl, 3-phenanthryl, 4-phenanthryl, and 10-phenanthryl. Phenyl is particularly preferred.
[0028] As used herein, the term "heteroaryl" may refer to a monocyclic or bicyclic aromatic heterocyclic group having 1 to 4 heteroatoms selected from a nitrogen atom, a sulfur atom, and an oxygen atom in the ring and 5 to 10 ring atoms. Specific examples include furyl (e.g., 2-furyl, 3-furyl), thienyl (e.g., 2-thienyl, 3-thienyl), pyrrolyl (e.g., 2-pyrrolyl, 3-pyrrolyl), imidazolyl (e.g., 2-imidazolyl, 4-imidazolyl), pyrazolyl (e.g., 3-pyrazolyl, 4-pyrazolyl), triazolyl (e.g., 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,3-triazolyl), and the like. oxazolyl (for example, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl), isoxazolyl (for example, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), oxadiazolyl (for example, 1,3,4-oxadiazol-2-yl), thiazolyl (for example, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl), thiadiazolyl, isoxazolyl, isothiazolyl (e.g., 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl), pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), pyridazinyl (e.g., 3-pyridazinyl, 4-pyridazinyl), pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl), pyrazinyl (e.g., 2-pyrazinyl), benzimidazolyl (e.g., 2-benzimidazolyl, 4- benzimidazolyl, 5-benzimidazolyl, 6-benzimidazolyl, 7-benzimidazolyl), indazolyl (for example, 3-indazolyl, 4-indazolyl, 5-indazolyl, 6-indazolyl, 7-indazolyl), isoquinolyl (for example, 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 6-isoquinolyl, 7-isoquinolyl, 8-isoquinolyl).More preferred are furyl (e.g., 2-furyl, 3-furyl), imidazolyl (e.g., 2-imidazolyl, 4-imidazolyl), thiazolyl (e.g., 2-thiazolyl, 4-thiazolyl, 5-thiazolyl), pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), pyridazinyl (e.g., 3-pyridazinyl, 4-pyridazinyl), and pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl).
[0029] "Carbocycle" means a ring structure composed of carbon atoms, and "carbocycle" includes the above-mentioned "cycloalkyl", "cycloalkenyl", and "aryl".
[0030] The term "heterocycle" refers to a cyclic structure composed of carbon atoms and one or more heteroatoms selected from, for example, a nitrogen atom, a sulfur atom, and an oxygen atom, and includes the above-mentioned "heterocycloalkyl" and "heteroaryl".
[0031] As used herein, the term "3- to 8-membered saturated or unsaturated monocyclic nitrogen-containing heterocycle" refers to, for example, a saturated or unsaturated monocyclic heterocycle having 1 to 4 nitrogen atoms in the ring and 3 to 8 ring-constituting atoms. Specific examples include aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, azocanyl, pyrrolyl (e.g., 2-pyrrolyl, 3-pyrrolyl), imidazolyl (e.g., 2-imidazolyl, 4-imidazolyl), pyrazolyl (e.g., 3-pyrazolyl, 4-pyrazolyl), triazolyl (e.g., 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2, 3-triazol-4-yl), tetrazolyl (for example, 5-tetrazolyl), pyridyl (for example, 2-pyridyl, 3-pyridyl, 4-pyridyl), 1,2,3,6-tetrahydropyridyl, pyridazinyl (for example, 3-pyridazinyl, 4-pyridazinyl), pyrimidinyl (for example, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl), pyrazinyl (for example, 2-pyrazinyl), and the like.
[0032] As used herein, the term "5- to 10-membered monocyclic or bicyclic saturated heterocycle" refers to a monocyclic or bicyclic saturated heterocycle having 1 to 4 heteroatoms selected from a nitrogen atom, a sulfur atom, and an oxygen atom in the ring and consisting of 5 to 10 ring atoms. Specific examples include azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 1,3-dioxolanyl, 1,4-dioxolanyl, and tetrahydrothiophenyl.
[0033] As used herein, the term "5- to 10-membered monocyclic or bicyclic unsaturated heterocycle" refers to a monocyclic or bicyclic aromatic heterocycle or non-aromatic unsaturated heterocycle consisting of 5 to 10 constituent atoms and having 1 to 4 heteroatoms selected from, for example, a nitrogen atom, a sulfur atom, and an oxygen atom in the ring.Specific examples include furyl (e.g., 2-furyl, 3-furyl), thienyl (e.g., 2-thienyl, 3-thienyl), pyrrolyl (e.g., 2-pyrrolyl, 3-pyrrolyl), imidazolyl (e.g., 2-imidazolyl, 4-imidazolyl), pyrazolyl (e.g., 3-pyrazolyl, 4-pyrazolyl), triazolyl (e.g., 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,3-triazol-4-yl), tetrazolyl (e.g., 5-tetrazolyl), oxazolyl (e.g., 2-oxazolyl, 4-oxazolyl), oxazolyl (e.g., 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), oxadiazolyl (e.g., 1,3,4-oxadiazol-2-yl), thiazolyl (e.g., 2-thiazolyl, 4-thiazolyl, 5-thiazolyl), thiadiazolyl, isothiazolyl (e.g., 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl), pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), pyridazinyl (e.g., 3-pyridazinyl, 4-pyridazinyl), pyrimidinyl (e.g., , 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl), pyrazinyl (e.g., 2-pyrazinyl), benzimidazolyl (e.g., 2-benzimidazolyl, 4-benzimidazolyl, 5-benzimidazolyl, 6-benzimidazolyl, 7-benzimidazolyl), indazolyl (e.g., 3-indazolyl, 4-indazolyl, 5-indazolyl, 6-indazolyl, 7-indazolyl), pyrazolo[5,1-b]thiazolyl, azaidazolyl (e.g., 3-azaiidazolyl, 4-azaiidazolyl, 5-azaiidazolyl, 6-azaiidazolyl, zaindolyl, 7-azaindazolyl), benztriazolyl (for example, 5-benztriazolyl, 6-benztriazolyl), azaindolyl (for example, 5-azaindolyl, 6-azaindolyl, 7-azaindolyl), isoquinolyl (for example, 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 6-isoquinolyl, 7-isoquinolyl, 8-isoquinolyl), pyridonyl (for example, 2-pyridon-3-yl, 2-pyridon-4-yl, 2-pyridon-5-yl, 2-pyridon-6-yl).More preferred are furyl (e.g., 2-furyl, 3-furyl), imidazolyl (e.g., 2-imidazolyl, 4-imidazolyl), thiazolyl (e.g., 2-thiazolyl, 4-thiazolyl, 5-thiazolyl), oxazolyl (e.g., 2-oxazolyl, 4-oxazolyl, 5-oxazolyl), pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), pyridazinyl (e.g., 3-pyridazinyl, 4-pyridazinyl), pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl), pyrazinyl (e.g., 2-pyrazinyl), benzimidazolyl (e.g., 2-benzimidazolyl, 4-benzimidazolyl, 5-benzimidazolyl, 6-benz imidazolyl, 7-benzimidazolyl), indazolyl (e.g., 3-indazolyl, 4-indazolyl, 5-indazolyl, 6-indazolyl, 7-indazolyl), pyrazolo[5,1-b]thiazolyl, azaidazolyl (e.g., 3-azaindazolyl, 4-azaindazolyl, 5-azaindazolyl, 6-azaindazolyl, 7-azaindazolyl), benztriazolyl (e.g., 5-benztriazolyl, 6-benztriazolyl), azaindolyl (e.g., 5-azaindazolyl, 6-azaindazolyl, 7-azaindazolyl), pyridonyl (e.g., 2-pyridon-3-yl, 2-pyridon-4-yl, 2-pyridon-5-yl, 2-pyridon-6-yl).
[0034] "Cyano" refers to a group represented by -CN.
[0035] "Oxo" refers to a group represented by =O.
[0036] "Carbonyl" refers to a group represented by -(C=O)-.
[0037] "Hydroxy" refers to a group represented by --OH.
[0038] "Optionally substituted" means that the specified group may be substituted or unsubstituted, i.e., substituted or unsubstituted. For example, "optionally substituted alkyl" means both unsubstituted and substituted alkyl. Examples of substituents substituting the specified group include the above-defined alkyl, haloalkyl, alkoxy, cycloalkyl, halocycloalkyl, heterocycloalkyl, halogen, cyano, oxo, hydroxy, amino, aryl, or heteroaryl, as well as combinations thereof (e.g., alkyl, alkoxy, cycloalkyl, heterocycloalkyl, amino, aryl, or heteroaryl substituted with at least one substituent selected from the group consisting of alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocycloalkyl, halogen, cyano, oxo, hydroxy, amino, aryl, and heteroaryl). The number of substituents substituting the specified group is, for example, 1 to 3, preferably 1 or 2, and more preferably 1.
[0039] In the compounds of formulas (I) to (III), preferred embodiments of each group represented by a symbol are shown below. Examples of the compounds of formulas (I) to (III) include all combinations of specific examples of each group shown below.
[0040] A is preferably (In the formula, Y 1 , Y 2 , Y 3 and Y 4 are each independently N or C—R 5 wherein the Y 1 , Y 2 , Y 3 and Y 4 At most one of them is N, and the others are C-R 5 and R 5 is hydrogen, halogen (e.g., fluorine atom, chlorine atom), alkoxy (e.g., methoxy), or optionally substituted C 1 -C 6alkyl (e.g., methyl), where the dashed line indicates the point of attachment; or (In the formula, R 6a , R 6b , R 6c , R 6d , R 6e , R 6f , R 6g and R 6h are each independently hydrogen, halogen (e.g., fluorine atom), or optionally substituted C 1 -C 6 A is more preferably: (In the formula, Y 1 , Y 2 , Y 3 and Y 4 is C-R 5 and R 5 is hydrogen and the dashed line indicates the point of attachment).
[0041] B is preferably an optionally substituted 4- to 6-membered saturated or unsaturated monocyclic nitrogen-containing heterocycle, more preferably C 1 -C 6 It is azetidinyl, piperidinyl or 1,2,3,6-tetrahydropyridyl, which may be substituted by alkyl (eg, methyl), and particularly preferred is azetidinyl.
[0042] X is preferably N or C—R 7 where R 7 is preferably hydrogen, more preferably N.
[0043] R 1 are preferably each independently hydrogen, halogen, oxo, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, amino, monoalkylamino, dialkylamino, aminoalkyl, alkylcarbonylamino, C 3 -C 10R is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, each of which is optionally substituted. 1 are more preferably each independently hydrogen, halogen (e.g., fluorine atom, chlorine atom), oxo, C 1 -C 6 alkyl (e.g., methyl), amino, or monoalkylamino (e.g., methylamino, ethylamino), wherein amino may be substituted by cycloalkyl (e.g., cyclopropyl, cyclobutyl, 1-methylcyclopropyl), or heterocycloalkyl (e.g., oxetanyl, tetrahydropyranyl), and C 1 -C 6 The alkyl may be substituted with 1 to 3 halogen atoms (e.g., fluorine atoms). 1 More preferably, each independently is hydrogen, halogen (for example, a fluorine atom), or amino.
[0044] R 2 and R 3 are preferably each independently hydrogen or halogen (for example, a fluorine atom).
[0045] R 4 is preferably hydrogen, halogen, cyano, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 1 -C 6 Alkoxy, hydroxy, carboxy, alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, aminoalkyl, alkylcarbonylamino, C 3 -C 10 Cycloalkyl, C 3 -C 6 R is selected from the group consisting of cycloalkenyl, heterocycloalkyl, aryl, and heteroaryl, each of which is optionally substituted. 4 is more preferably C 2 -C6 (1) C is selected from the group consisting of alkynyl (e.g., ethynyl), carboxy, monocyclic or bicyclic saturated carbocycle (e.g., cyclohexyl), monocyclic or bicyclic unsaturated carbocycle (e.g., phenyl, 2,3-dihydro-1H-indenyl), monocyclic or bicyclic saturated heterocycle (e.g., azetidinyl), and monocyclic or bicyclic unsaturated heterocycle (e.g., pyridyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-triazolyl), 2 -C 6 Alkynyl is C 3 -C 10 (2) carboxy is optionally substituted with C 1 -C 6 (3) a monocyclic or bicyclic saturated carbocycle may be substituted with a halogen atom (e.g., a fluorine atom); (4) a monocyclic or bicyclic unsaturated carbocycle may be substituted with a haloalkyl group (e.g., trifluoromethyl); (5) a monocyclic or bicyclic saturated heterocycle may be substituted with an aryl group (e.g., phenyl) or a haloalkyl group (e.g., 2,2,2-trifluoroethyl); and a monocyclic or bicyclic unsaturated heterocycle may be substituted with a substituent selected from the following group: (i) a haloalkyl group (e.g., trifluoromethyl, 2,2,2-trifluoroethyl); (ii) a C substituted with a haloalkyl group (e.g., trifluoromethyl). 3 -C 6 (iii) heterocycloalkyl (e.g., tetrahydropyranyl); (iv) aryl (e.g., phenyl) optionally substituted with halogen (e.g., fluorine atom) or haloalkyl (e.g., trifluoromethyl); (v) halogen (e.g., fluorine atom) or C 1 -C 6(vi) heteroaryl (e.g., pyridyl, pyridazinyl) optionally substituted with alkyl (e.g., methyl), and (vi) halocycloalkyl (e.g., 3,3-difluorocyclobutyl, 4,4-difluorocyclohexyl), aryl (e.g., phenyl), C 3 -C 10 C optionally substituted with cycloalkyl (e.g., cyclopropyl) or heterocycloalkyl (e.g., oxetanyl) 1 -C 6 Alkyl (e.g., methyl).
[0046] Also, R 4 is preferably —CONR 8 R 9 where R 8 and R 9 each independently represents hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 10 Cycloalkyl, C 3 -C 6 is selected from the group consisting of cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, each of which is optionally substituted, or R 8 and R 9 are taken together with the atoms to which they are attached to form an optionally substituted 5- to 10-membered monocyclic or bicyclic saturated heterocycle or a 5- to 10-membered monocyclic or bicyclic unsaturated heterocycle. More preferably, R 8 and R 9 each independently represents hydrogen, C 1 -C 6 Alkyl, C 3 -C 6 (1) C is selected from the group consisting of cycloalkyl, heterocycloalkyl, and heteroaryl, each of which is optionally substituted; 1-C 6 The alkyl is, for example, methyl, ethyl, isopropyl, or tert-butyl, and may be substituted with a substituent selected from the following group: (i) halogen (e.g., fluorine atom), (ii) C 1 -C 6 (iii) haloalkoxy (e.g., trifluoromethoxy); (iv) heterocycloalkyl (e.g., tetrahydropyranyl, morpholinyl); (v) halocycloalkyl (e.g., 3,3-difluorocyclobutyl); and (vi) aryl (e.g., phenyl) optionally substituted with halogen (e.g., fluorine atom); (2) C 3 -C 6 Cycloalkyl is, in particular, cyclobutyl, cyclopentyl, cyclohexyl, which may be substituted with halogen (e.g., fluorine atom), cyano, (3) heterocycloalkyl is, for example, oxetanyl, tetrahydropyranyl, which may be substituted with, and (4) heteroaryl is, for example, pyrazolyl, which may be substituted with halogen (e.g., fluorine atom). 8 and R 9 preferably, together with the atoms to which they are attached, form an optionally substituted 5- to 10-membered monocyclic or bicyclic saturated heterocycle or an optionally substituted 5- to 10-membered monocyclic or bicyclic unsaturated heterocycle, wherein more preferably, (1) the 5- to 10-membered monocyclic or bicyclic saturated heterocycle is, for example, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azabicyclo[3.1.0]hexanyl, azaspiro[3.4]octanyl, bicyclo[2.2.1]heptanyl, bicyclo[1.1.1]pentanyl, azabicyclo[3.2.1]octanyl, and is optionally substituted with a substituent selected from the following group: (i) a halogen (e.g., a fluorine atom, a bromine atom), (ii) a hydroxy group, C 1 -C 6 C optionally substituted with alkoxy (e.g., methoxy), haloalkoxy (e.g., trifluoromethoxy) or heterocycloalkyl (e.g., morpholinyl). 1-C 6 alkyl (e.g., methyl, ethyl, isopropyl); (iii) C 1 -C 6 (iv) haloalkyl (e.g., fluoromethyl, difluoromethyl, trifluoromethyl); (v) C 3 -C 6 Cycloalkyl (e.g., cyclopropyl), (vi) haloalkoxy (e.g., difluoromethoxy), and (vii) cyano, and (2) 5- to 10-membered monocyclic or bicyclic unsaturated heterocycles are, for example, 1,2,3,4-tetrahydroquinolinyl, 3,4-dihydro-2H-1,4-benzoxazinyl, 2,3-dihydro-1H-indolyl.
[0047] Particularly preferably, R 4 is -CONR 8 R 9 where R 8 and R 9 are taken together with the atoms to which they are attached to form a 5-membered monocyclic saturated heterocycle (eg, pyrrolidinyl) substituted with haloalkyl (eg, trifluoromethyl).
[0048] m is preferably an integer of 0 to 2, and more preferably an integer of 2.
[0049] n is preferably an integer of 0 to 1, and more preferably an integer of 1.
[0050] Het is preferably a 5- to 10-membered monocyclic or bicyclic unsaturated heterocycle, more preferably pyridyl, pyrimidinyl, 1,3-thiazolyl, pyridazinyl, 1H-pyrazolo[3,4-b]pyridyl, 1H-pyrrolo[2,3-b]pyridyl, 1,3-thiazolyl, imidazo[1,2-a]pyridyl, pyrazolo[3,2-b][1,3]thiazolyl, 1,3-oxazolyl, 1H-indazolyl, pyrazolyl, or 1H-1,2,3-benzotriazolyl, and even more preferably pyridyl.
[0051] The compound of the present invention can be produced using known compounds or intermediates that can be easily synthesized from known compounds, for example, by the methods described below, the Examples described below, or known methods. In producing the compound of the present invention, if the raw material has a substituent that affects the reaction, it is common to first protect the raw material with an appropriate protecting group by a known method before carrying out the reaction. The protecting group can be deprotected by a known method after the reaction.
[0052] The abbreviations used in this specification have the following meanings. The following abbreviations are used in the examples: TFA: trifluoroacetic acid AZADOL (registered trademark): 2-azaadamantane-N-hydroxyl Pd—C: palladium-carbon PdCl 2 (PPh 3 ) 2 : Bis(triphenylphosphine)palladium(II) dichloride Pd(OAc) 2 : Palladium(II) acetate Pd(dppf)Cl 2 ・CH 2 Cl 2: [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane adduct Xantphos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene BINAP: 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl Boc: tert-butoxycarbonyl HATU: O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate HBTU: O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate EDCI: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDCI.HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride DMTMM: 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride HOBt: 1-hydroxybenzotriazole THF: tetrahydrofuran DMF: dimethylformamide DMA: dimethylacetamide DMSO: dimethyl sulfoxide NMP: N-methylpyrrolidone DIPEA: N,N-diisopropylethylamine DMAP: 4-dimethylaminopyridine NMM: 4-methylmorpholine DAST: (diethylamino)sulfur trifluoride MS: mass spectrometry LCMS: high-performance liquid chromatography mass spectrometry ESI: electrospray ionization M: molar concentration (mol / L)
[0053] Unless otherwise specified, the reactions in each step in the following production methods are carried out according to known methods, for example, those described in "Comprehensive Organic Transformations: A Guide to Functional Group Preparations 2nd Edition" by R.C. Larock, John Wiley & Sons Inc. , 1999, "Experimental Chemistry Lectures" edited by the Chemical Society of Japan, 4th edition, Maruzen, 1992, "Strategies in Organic Synthesis Learned from Named Reactions" by L. Kuerti and B. Czako, translated and supervised by Tomioka Kiyoshi, Kagaku Dojin, 2006, "Latest Organic Synthesis Methods: Design and Strategy" by G. S. Zweifel and M. H. Nantz, translated by Hiyama Tamijiro, Kagaku Dojin, 2009, or the methods described in the examples can be suitably modified or combined for use.
[0054] Synthesis of compound (G-1) (Y 1 , Y 2 , Y 3 , Y 4 , R 1 , R 2 , R 3 , R 4 , B has the same meaning as above. 1 represents a protecting group, examples of which include tert-butoxycarbonyl (hereinafter referred to as "Boc"), benzyloxycarbonyl (hereinafter referred to as "Cbz"), and benzyl (hereinafter referred to as "Bn"). 1 represents chloro, bromo, and triflate.)
[0055] Step 1: This step involves reacting Compound A-1, which is commercially available or synthesized by a known method, with Compound B-1, which is commercially available or synthesized by a known method, in a solvent such as THF or diethyl ether in the presence of lithium diisopropylamide (LDA) at −78° C. to 0° C., preferably −78° C. to −60° C., more preferably −78° C., for 30 minutes to 12 hours, preferably 30 minutes to 6 hours, more preferably 30 minutes to 3 hours, to obtain Compound C-1. LDA may be commercially available or may be prepared from diisopropylamine and n-butyllithium (n-BuLi).
[0056] Step 2: This step involves oxidizing the hydroxyl group of compound C-1 to obtain D-1. This reaction can be carried out using 2-azaadamantane-N-oxyl (AZADOL registered trademark), 2,2,6,6-tetramethylpiperidine-1-oxyl radical (TEMPO), Dess-Martin reagent, or the like, in a solvent such as dichloromethane or dichloroethane at 0°C to room temperature for 30 minutes to 24 hours, preferably 30 minutes to 6 hours, and more preferably 30 minutes to 3 hours, to synthesize D-1. In reactions using AZADOL or TEMPO, iodobenzene diacetate, sodium hypochlorite (NaOCl), or the like is typically used as a co-oxidant.
[0057] Step 3: This step is a step in which compound D-1 is reacted with hydrazine monohydrate in a solvent such as dioxane or THF at room temperature to reflux temperature, preferably dioxane, at 100°C for 1 hour to 48 hours, preferably 8 hours to 24 hours, to obtain compound Ea-1.
[0058] Step 4: This step is a step in which compound Ea-1 is alkylated with alkylating agent F-1 in the presence of a base to obtain compound G-1, and can be carried out in accordance with a known method for alkylation reactions. The reaction can be carried out by reacting compound Ea-1 with alkylating agent F-1 in the presence of a base such as sodium hydride, potassium hydride, potassium carbonate, sodium carbonate, or cesium carbonate in a solvent such as dimethylformamide or tetrahydrofuran at 0°C to 120°C, preferably room temperature to 120°C, for 1 hour to 48 hours, preferably 1 hour to 12 hours.
[0059] The above C-1 and D-1 can also be produced by the following method. (Y 1 , Y 2 , Y 3 , Y 4 ,B.,P.G. 1 has the same meaning as above. 2 represents Br or I.)
[0060] Route 1 This step is a step of reacting a commercially available or synthesized compound A-2 by a known method with B-1 in the presence of butyllithium (n-BuLi) in a solvent such as THF or diethyl ether at −78° C. to 0° C., preferably −78° C. to −60° C., more preferably −78° C., for 30 minutes to 12 hours, preferably 30 minutes to 6 hours, more preferably 30 minutes to 3 hours, to obtain a compound C-1.
[0061] Route 2 This step is a step of obtaining compound D-1 by reacting compound A-1, which is commercially available or synthesized by a known method, with compound B-2, which is commercially available or synthesized by a known method, in a solvent such as THF or diethyl ether in the presence of butyllithium (n-BuLi) at −78° C. to 0° C., preferably −78° C. to 60° C., more preferably −78° C., for 30 minutes to 12 hours, preferably 30 minutes to 6 hours, more preferably 30 minutes to 3 hours.
[0062] Synthesis of compound (G-2) (A, R 1 , R 2 , R 3 , R 4 , B, X1 , P.G. 1 has the same meaning as above. 3 represents I, Cl, or Br)
[0063] Step 1: This step involves halogenating compound H-1, which is commercially available or has been synthesized by a known method, to obtain J-1. The halogenation can be carried out by a reaction typically used for halogenating aromatic rings. Compound H-1 can be reacted with chlorine, bromine, iodine, N-chlorosuccinimide (NCS), or N-bromosuccinimide (NBS) in a solvent such as dichloromethane, dichloroethane, carbon tetrachloride, or DMF at 0° C. to room temperature for 30 minutes to 48 hours, preferably 1 hour to 12 hours, to obtain compound J-1.
[0064] Step 2 This step is a step in which compound J-1 is alkylated using alkylating agent F-1 in the presence of a base to obtain compound K-1. K-1 can be obtained by carrying out the reaction under the same conditions as in Step 4 in the synthesis of compound (G-1) above.
[0065] Step 3: This step is a step of obtaining compound G-2 by Negishi coupling reaction between compound K-1 and L-1. In this reaction, compound K-1 is reacted with tetrakistriphenylphosphine palladium (hereinafter referred to as "Pd(PPh 3 ) 4 "), palladium(II) acetate (hereinafter referred to as "Pd(OAc) 2 "), bis(triphenylphosphine)palladium(II) dichloride (hereinafter referred to as "Pd(PPh 3 ) 2 Cl 2 "), [1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II)-dichloromethane adduct (hereinafter referred to as "Pd(dppf) 2 Cl 2Compound G-2 can be obtained by adding a palladium catalyst such as L-1, which is commercially available or synthesized by a known method, to the reaction mixture under a nitrogen atmosphere or an argon atmosphere at 0° C. to 150° C., preferably 60° C. to 120° C., for 0.5 to 24 hours, preferably 1 to 12 hours.
[0066] Synthesis of Compound (I) (A, B, R 1 , R 2 , R 3 , R 4 ,Het,m,PG 1 has the same meaning as above.)
[0067] Step 1: This step is a step of deprotecting the protecting group of compound G-2 to obtain M-1, and can be introduced with reference to Wuts and Greene, "Greene's Protective Groups in Organic Synthesis," 4th Edition, John Wiley & Sons Inc., 2006, or P. J. Kocienski, "Protecting Groups," 3rd Edition, Thiemes, 2005.
[0068] Step 2 This step is a step of obtaining compound (I) by condensing compound M-1 with compound N-1 or a reactive compound N-1 thereof in the presence of a condensing agent. In this reaction, Compound M-1, Compound N-1, an organic base such as TEA, DIPEA, N,N-dimethylaniline, or DBU, 1,1′-carbonyldiimidazole (hereinafter referred to as “CDI”), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (hereinafter referred to as “EDCI”), diisopropylcarbodiimide (hereinafter referred to as “DIC”), diethyl cyanophosphonate, O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (hereinafter referred to as “HBTU”), O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium Compound (I) can be obtained by carrying out the reaction in the presence of a condensing agent such as hexafluorophosphate (hereinafter referred to as "HATU") at 0°C to 50°C, preferably room temperature to 50°C. In this step, reactive compounds for compound N-1 include those typically used in amide condensation reactions, such as acid halides (e.g., acid chlorides and acid bromides), mixed acid anhydrides, imidazolides, and activated amides. In this step, additives such as 1-hydroxybenzotriazole (hereinafter referred to as "HOBt"), N-hydroxysuccinimide, and 1-hydroxy-7-azabenzotriazole (hereinafter referred to as "HOAt") can also be added, if necessary.
[0069] Synthesis of Compound (I-2) (R 4 -CONR 8 R 9 in the case of) (A, B, PG 1 , R 1 ,Het,R 8 , R 9 , m has the same meaning as above. A represents methyl, ethyl, n-propyl, or t-butyl)
[0070] Step 1: This step is a step in which the protecting group of compound G-2 is deprotected to obtain M-2, and synthesis can be performed with reference to Wuts and Greene, "Greene's Protective Groups in Organic Synthesis," 4th Edition, John Wiley & Sons Inc., 2006, or P. J. Kocienski, "Protecting Groups," 3rd Edition, Thiemes, 2005.
[0071] Step 2 This step is a step in which compound M-2 is condensed with compound N-1 or a reactive compound thereof in the presence of a condensing agent to obtain compound O-2, which can be synthesized by the same method as in Step 2 in the synthesis of compound (I) above.
[0072] Step 3 This step is to remove the protecting group (PG) of compound O-2. 2 ) to obtain P-2, which can be synthesized with reference to "Greene's Protective Groups in Organic Synthesis" by Wuts and Greene, 4th Edition, John Wiley & Sons Inc., 2006, or "Protecting Groups" by P. J. Kocienski, 3rd Edition, Thiemes, 2005.
[0073] Step 4 This step is a step in which compound Q-1 is condensed with compound P-2 or a reactive compound thereof in the presence of a condensing agent to obtain compound I-2, which can be synthesized by the same method as in Step 2 in the synthesis of compound (I) above.
[0074] In addition, in the synthesis of I-2, compound I-2 can also be obtained by switching the order of Step 1-Step 2 and Step 3-Step 4. A is deprotected (hydrolyzed) to obtain a carboxylic acid, which is then condensed with Q-1. Subsequently, the amine obtained by deprotecting PG1 is condensed with N-1 to synthesize I-2.
[0075] The compound of the present invention can be used as a pharmaceutical directly, or can be used in the form of a pharmaceutically acceptable salt, solvate, or solvate of a salt by known methods. Examples of pharmaceutically acceptable salts include salts of mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid; salts of organic acids such as acetic acid, malic acid, lactic acid, citric acid, tartaric acid, maleic acid, succinic acid, fumaric acid, p-toluenesulfonic acid, benzenesulfonic acid, and methanesulfonic acid; salts of alkali metals such as lithium, potassium, and sodium; salts of alkaline earth metals such as magnesium and calcium; and salts of organic bases such as ammonium salts. These salts can be formed by commonly used methods.
[0076] For example, when the compound of the present invention is a hydrochloride salt, the free base of the compound of the present invention can be obtained by dissolving it in hydrochloric acid, an alcohol solution of hydrogen chloride, an ethyl acetate solution of hydrogen chloride, a 1,4-dioxane solution of hydrogen chloride, a cyclopentyl methyl ether solution of hydrogen chloride, or a diethyl ether solution of hydrogen chloride.
[0077] The compound of the present invention may take up solvent molecules to form a solvate when left in the air or when recrystallized, and such solvates are also included in the compound of the present invention. Examples of such solvates include solvates with solvent molecules such as methanol solvate, ethanol solvate, isopropyl alcohol solvate, butanol solvate, dimethyl sulfoxide solvate, and acetonitrile solvate, as well as monohydrates and dihydrates.
[0078] Some of the compounds of the present invention have asymmetric carbon atoms, and both optical isomers and mixtures thereof are included in the present invention. Stereoisomers can be produced, for example, by optical resolution of a racemate using an optically active acid (tartaric acid, dibenzoyltartaric acid, mandelic acid, 10-camphorsulfonic acid, etc.) by a known method, taking advantage of its basicity, or by using a pre-prepared optically active compound as a starting material. Alternatively, stereoisomers can also be produced by optical resolution using a chiral column or asymmetric synthesis.
[0079] As shown in the test examples below, the compound of the present invention has DDR1 kinase inhibitory activity.
[0080] Thus, one embodiment of the present invention provides a DDR1 kinase inhibitor comprising a compound of the present invention.
[0081] Furthermore, in one embodiment of the present invention, there is provided a method of inhibiting DDR1 kinase, comprising administering a compound of the present invention to a subject in need thereof.
[0082] Furthermore, in one embodiment of the present invention there is provided a compound of the present invention for use in inhibiting DDR1 kinase.
[0083] Furthermore, one embodiment of the present invention provides use of a compound of the present invention in the manufacture of a DDR1 kinase inhibitor.
[0084] One embodiment of the present invention provides a preventive or therapeutic agent for a disease involving DDR1 kinase, which comprises the compound of the present invention.
[0085] Furthermore, one embodiment of the present invention provides a method for preventing or treating a disease associated with DDR1 kinase, which comprises administering the compound of the present invention to a subject in need thereof.
[0086] Furthermore, in one embodiment of the present invention, there is provided a compound of the present invention for use in the prevention or treatment of a disease in which DDR1 kinase is involved.
[0087] Furthermore, one embodiment of the present invention provides use of the compound of the present invention in the manufacture of an agent for the prophylaxis or treatment of a disease involving DDR1 kinase.
[0088] Examples of diseases to which the compound of the present invention can be applied include Alport syndrome, IgA nephropathy, Goodpature syndrome, anti-glomerular basement membrane nephritis, lupus nephritis, ANCA-associated nephritis, diabetic nephropathy, purpura nephritis, focal segmental glomerulosclerosis, chronic renal failure, minimal change nephrotic syndrome, mesangial proliferative glomerulonephritis, membranoproliferative glomerulonephritis, crescentic glomerulonephritis, membranous nephropathy, pulmonary fibrosis, myelofibrosis, hepatic fibrosis, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, glioma, non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, prostate cancer, colorectal cancer, and osteoarthritis.
[0089] Therefore, one embodiment of the present invention provides a preventive or therapeutic agent for the above-mentioned diseases, which contains the compound of the present invention.
[0090] Furthermore, one embodiment of the present invention provides a method for preventing or treating the above-mentioned diseases, which comprises administering the compound of the present invention to a subject in need thereof.
[0091] Furthermore, in one embodiment of the present invention, there is provided a compound of the present invention for use in the prevention or treatment of the above-mentioned diseases.
[0092] Furthermore, one embodiment of the present invention provides use of the compound of the present invention in the manufacture of an agent for the prophylaxis or treatment of the above-mentioned diseases.
[0093] "Subject" refers to a human or non-human animal having or suspected of having a disease in which DDR1 is involved or a disease in which DDR1 is involved. In one embodiment of the invention, the subject is a mammal. In one embodiment of the invention, the subject is a human.
[0094] The compound of the present invention can be used as a therapeutic agent for the above-mentioned various diseases in mammals such as humans, mice, rats, rabbits, dogs, cats, cows, horses, pigs, and monkeys, either as such or in the form of a pharmaceutical composition containing, for example, 0.001% to 99.5%, preferably 0.1% to 90%, either as such or mixed with a pharmacologically acceptable carrier or the like.
[0095] The carrier may be one or more conventional pharmaceutically acceptable solid, semi-solid, or liquid diluents, fillers, and other formulation auxiliaries. The pharmaceutical composition of the present invention is preferably administered in a dosage unit form. The pharmaceutical composition may be administered intramuscularly, orally, intravenously, topically (transdermally, by eye drop, intraperitoneally, intrapleurally, etc.), or rectally. The pharmaceutical composition of the present invention is administered in a dosage form suitable for these administration methods.
[0096] The pharmaceutical dosage is desirably adjusted taking into consideration the patient's condition, such as age, body weight, type and severity of disease, the route of administration, the type of compound of the present invention, whether or not it is a salt, and the type of salt, but typically, in the case of oral administration to an adult, the amount of the active ingredient of the compound of the present invention or a pharmaceutically acceptable salt thereof is within the range of 0.01 mg to 5 g per adult, preferably 1 mg to 500 mg per adult, per day. In some cases, a lower dose may be sufficient, or conversely, a higher dose may be required. Typically, the compound is administered once a day or in divided doses, or in the case of intravenous administration, it can be administered as a bolus or continuously for up to 24 hours.
[0097] The compounds of the present invention can be used alone or in combination with additional therapeutic agents, such as angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin II A T1 receptor blockers (ARBs). Examples of ARBs include candesartan, losartan, valsartan, olmesartan, azilsartan, irbesartan, and telmisartan. Examples of ACE inhibitors include ramipril, lisinopril, enalapril, imidapril, and trandolapril.
[0098] One or more hydrogen, carbon, and / or other atoms of the compounds of the present invention may be substituted with isotopes of hydrogen, carbon, and / or other atoms, respectively. Examples of such isotopes include 2H, 3H, 11C, 13C, 14C, 15N, 18O, 17O, 31P, 32P, 35S, 18F, 123I, and 36Cl, i.e., hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine. Compounds substituted with such isotopes are also useful as pharmaceuticals, and include all radiolabeled compounds of the compounds of the present invention.
[0099] The compounds of the present invention can be produced from known compounds or intermediates that can be easily prepared from known compounds, for example, by the following methods, the Examples described below, or known methods.
[0100] When the solvents, reagents, and raw materials used in each step in the following production methods are commercially available, the commercially available products can be used as they are. Furthermore, the compounds obtained in each step in the production methods described below and the raw materials used may form salts, which can be converted into other types of salts or free forms by known methods. Conversely, when the compounds obtained in each step in the following production methods and the raw materials used are in free forms, they can be converted into the desired salts by known methods. Examples of such salts include the same salts as those used for the compounds of the present invention described above.
[0101] In the production of the compound of the present invention, when the raw material has a substituent that may affect the reaction, a protecting group may be introduced into the substituent in advance by a known method, and the target compound can be obtained by removing the protecting group after the reaction, as necessary. Examples of such a protecting group include the protecting groups described in Wuts and Greene, "Greene's Protective Groups in Organic Synthesis," 4th Edition, John Wiley & Sons Inc., 2006, or P.J. Kocienski, "Protecting Groups," 3rd Edition, Thieme, 2005, and the like, and these may be appropriately selected depending on the reaction conditions.
[0102] The compounds obtained in each step of the following production methods can be isolated or purified in accordance with conventional methods, such as solvent extraction, concentration, distillation, sublimation, recrystallization, reprecipitation, and chromatography, or can be used in the next step in the form of a reaction mixture or a crude product.
[0103] The present invention will be explained in more detail below by way of Reference Examples, Examples, and Test Examples, but the present invention is not limited to these examples alone.
[0104] MS was measured by LCMS. ESI was used as the ionization method. The observed mass spectrometry values are expressed as m / z.
[0105] The LCMS measurement conditions are as follows: Analytical instrument: ACQUITY UPLC MS / PDA system (Waters Corporation) Mass spectrometer: ACQUITY QDa detector or Waters 3100 MS detector Photodiode array detector: ACQUITY PDA detector (UV detection wavelength: 210 to 400 nm) Column: Acquity BEH C18, 1.7 μm, 2.1 × 50 mm Flow rate: 0.5 mL / min Column temperature: 40°C Solvent: Solution A: 0.1% formic acid / H 2 Solution B: 0.1% formic acid / acetonitrile (v / v; the same applies below)
[0106] 1 H-NMR spectra were measured using a JNM-ECS400 nuclear magnetic resonance spectrometer (manufactured by JEOL RESONANCE Co., Ltd.). The observed peaks are expressed as chemical shift values δ (ppm) (s = singlet, d = doublet, t = triplet, q = quartet, brs = broad singlet, m = multiplet, dd = double doublet, dt = double triplet).
[0107] For microwave experiments, an Initiator 60 (Biotage) was used, which can achieve temperatures of 40-250°C and pressures up to 20 bar.
[0108] The conditions for measuring the angle of rotation are as follows: Analytical instrument: Automatic polarimeter SEPA-500 (manufactured by Horiba, Ltd.)
[0109] The compound names in this specification were determined using ACD / NAME (registered trademark, Advanced Chemistry Development Inc.), a naming software that complies with IUPAC rules, or ChemBioDraw (version 18.2, 19.1, or 20.1.1, manufactured by Cambridge Soft), or in accordance with the IUPAC nomenclature.
[0110] The r and s (lower case) in the compound names indicate the stereochemistry of the pseudo-asymmetric carbon atom according to IUPAC rules.
[0111] Reference Example 1 2-[3-(azetidin-3-yl)-4-chloro-5-fluoro-1H-indazol-1-yl]-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (compound RE-1) [Step 1] Preparation of intermediate RE-1A To a mixture of 2-chloro-1,4-difluorobenzene (1.2 g) and THF (11 mL), lithium diisopropylamide (1.08 M n-hexane / tetrahydrofuran solution, 7.50 mL) was added dropwise at −78°C. After stirring at −78°C for 1 hour, a solution of tert-butyl 3-formylazetidine-1-carboxylate (1.0 g) in THF (11 mL) was added dropwise, and the mixture was stirred at −78°C for 3 hours. Saturated aqueous ammonium chloride was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (1.65 g).
[0112] [Step 2] Preparation of intermediate RE-1B To a mixture of intermediate RE-1A (3.23 g) and dichloromethane (48 mL), iodobenzene diacetate (3.74 g) and AZADOL (registered trademark) (74 mg) were added in that order, and the mixture was stirred at room temperature for 4 hours. Saturated aqueous sodium bicarbonate was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (3.09 g). MS (m / z): 332.5 [M+H] +
[0113] [Step 3] Preparation of intermediate RE-1C A mixture of intermediate RE-1B (3.09 g), 1,4-dioxane (60 mL), and hydrazine monohydrate (4.54 mL) was stirred at 100°C overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (1.47 g). MS (m / z): 324.0 [M-H] -
[0114] [Step 4] Preparation of intermediate RE-1D Cesium carbonate (1.76 g) and ethyl 2-bromoacetate (0.600 mL) were added sequentially to a mixture of intermediate RE-1C (1.47 g) and DMF (23 mL) in an ice bath, and the mixture was stirred at room temperature for 3 hours. A saturated aqueous solution of ammonium chloride was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (1.76 g). MS (m / z): 412.3 [M+H] +
[0115] [Step 5] Preparation of intermediate RE-1E To a mixture of intermediate RE-1D (1.75 g), methanol (8.5 mL), and THF (8.5 mL), 2 M aqueous sodium hydroxide solution (10.6 mL) was added at room temperature, and the mixture was stirred overnight. The reaction mixture was concentrated under reduced pressure, diluted with water, and then acidified with 2 M hydrochloric acid in an ice bath. The precipitate was collected by filtration to give the title compound (1.56 g). MS (m / z): 382.4 [M-H] -
[0116] [Step 6] Preparation of intermediate RE-1F To a mixture of intermediate RE-1E (800 mg), DMF (6.9 mL), DIPEA (1.1 mL), and 2,2,2-trifluoroethanamine hydrochloride (367 mg), HATU (1.03 g) was added and stirred at room temperature for 3 hours. Saturated aqueous sodium bicarbonate was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (900 mg). MS (m / z): 463.4 [M-H] -
[0117] [Step 7] Preparation of Compound RE-1 To a mixture of intermediate RE-1F (78 mg) and methanol (1 mL), hydrogen chloride (2 M methanol solution, 1 mL) was added and stirred at room temperature overnight. The solvent was evaporated under reduced pressure to give the title compound (72 mg). MS (m / z): 365.5 [M+H] +
[0118] Reference Example 2 2-[3-(azetidin-3-yl)-4,6-difluoro-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (Compound RE-2) [Step 1] Preparation of intermediate RE-2A The title compound (9.74 g) was obtained by a method similar to that of Step 1 of Reference Example 1, except that 1,3,5-trifluorobenzene (7.49 g) was used instead of 2-chloro-1,4-difluorobenzene.
[0119] [Step 2] Preparation of intermediate RE-2B The title compound (9.49 g) was obtained by a method similar to that of Step 2 of Reference Example 1, except that Intermediate RE-2A (9.74 g) was used instead of Intermediate RE-1A.
[0120] [Step 3] Preparation of intermediate RE-2C The title compound (8.25 g) was obtained by a method similar to that of Step 3 of Reference Example 1, except that intermediate RE-2B (9.49 g) was used instead of intermediate RE-1B. MS (m / z): 308.3 [M−H] -
[0121] [Step 4] Preparation of intermediate RE-2D The title compound (6.2 g) was obtained by a method similar to that of Step 4 of Reference Example 1, except that intermediate RE-2C (5.0 g) was used instead of intermediate RE-1C. MS (m / z): 296.0 [M-Boc + 2H] +
[0122] [Step 5] Preparation of intermediate RE-2E The title compound (1.89 g) was obtained by a method similar to that of Step 5 of Reference Example 1, except that intermediate RE-2D (2.23 g) was used instead of intermediate RE-1D. MS (m / z): 366.4 [M−H] -
[0123] [Step 6] Preparation of intermediate RE-2F The title compound (1.32 g) was obtained by a method similar to Step 6 of Reference Example 1, except that Intermediate RE-2E (1.04 g) was used instead of Intermediate RE-1E and (2S)-2-(trifluoromethyl)pyrrolidine hydrochloride (596 mg) was used instead of 2,2,2-trifluoroethanamine hydrochloride. MS (m / z): 511.2 [M+Na] +
[0124] [Step 7] Preparation of Compound RE-2 The title compound (117 mg) was obtained by a method similar to Step 7 of Reference Example 1, except that Intermediate RE-2F (125 mg) was used instead of Intermediate RE-1F. MS (m / z): 389.1 [M+H] +
[0125] Reference Example 3 2-[3-(azetidin-3-yl)-4,6-difluoro-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one trifluoroacetate (Compound RE-3) To a mixture of intermediate RE-2F (100 mg) and dichloromethane (1 mL), trifluoroacetic acid (0.25 mL) was added and stirred at room temperature for 1 hour. The solvent was evaporated under reduced pressure to give the title compound (103 mg). MS (m / z): 389.1 [M+H] +
[0126] Reference Example 4 2-[3-(azetidin-3-yl)-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one trifluoroacetate (Compound RE-4) [Step 1] Preparation of intermediate RE-4A To a mixture of 3-iodo-2H-indazole (9.11 g) and DMF (75 mL), cesium carbonate (14.6 g) and methyl 2-bromoacetate (4.24 mL) were added sequentially under ice bath conditions. After stirring for 30 minutes under ice bath conditions, the mixture was stirred at room temperature for 1 hour. A saturated aqueous solution of ammonium chloride was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (12.69 g). MS (m / z): 317.0 [M+H]+
[0127] [Step 2] Preparation of intermediate RE-4B A reaction vessel containing zinc (3.62 g) was heated under reduced pressure using a heat gun for 3 minutes and purged with argon. After returning to room temperature, DMA (40 mL) was added, and after degassing with argon, 1,2-dibromoethane (0.341 mL) and chloro(trimethyl)silane (0.602 mL) were added and stirred at room temperature for 15 minutes. To this mixture, a solution of tert-butyl 3-iodoazetidine-1-carboxylate (11.2 g) in DMA (40 mL) was added dropwise using a dropping funnel. The mixture was stirred at room temperature for 1 hour to prepare a DMA solution of [1-(tert-butoxycarbonyl)azetidin-3-yl]zinc(II) iodide. Next, a mixture of intermediate RE-4A (5.00 g) and DMA (16 mL) was degassed with argon and then Pd(dppf)Cl 2 ・CH 2 Cl 2 (1.29 g) and copper(I) iodide (392 mg) were added. The previously prepared [1-(tert-butoxycarbonyl)azetidin-3-yl]zinc(II) iodide DMA solution was added to this at room temperature, and the mixture was stirred at 85°C for 1 hour. A saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (5.05 g). MS (m / z): 368.1 [M+Na] +
[0128] [Step 3] Preparation of intermediate RE-4C The title compound (4.99 g) was obtained by a method similar to that of Step 5 of Reference Example 1, except that intermediate RE-4B (5.08 g) was used instead of intermediate RE-1D. MS (m / z): 330.4 [M−H] -
[0129] [Step 4] Preparation of intermediate RE-4D To a mixture of intermediate RE-4C (150 mg), DMF (1.5 mL), DIPEA (0.235 mL), and (2S)-2-(trifluoromethyl)pyrrolidine hydrochloride (95 mg), HBTU (206 mg) was added and stirred at room temperature for 2 hours. Saturated aqueous sodium bicarbonate was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (200 mg). MS (m / z): 353.1 [M-Boc + 2H] +
[0130] [Step 5] Preparation of Compound RE-4 Trifluoroacetic acid (1 mL) was added to a mixture of intermediate RE-4D (200 mg) and dichloromethane (4 mL), and the mixture was stirred at room temperature for 1 hour. The solvent was evaporated under reduced pressure to give the title compound (211 mg). MS (m / z): 353.1 [M+H] +
[0131] Reference Example 5 2-[3-(azetidin-3-yl)-5-chloro-1H-indazol-1-yl]-N-methyl-N-(2,2,2-trifluoroethyl)acetamide trifluoroacetate (Compound RE-5) [Step 1] Preparation of intermediate RE-5A To a mixture of 2-bromo-4-chloro-1-fluorobenzene (2.57 g) and THF (20 mL), n-butyllithium (1.57 M n-hexane solution, 7.82 mL) was added dropwise at −78° C. After stirring at −78° C. for 1 hour, a solution of tert-butyl 3-[methoxy(methyl)carbamoyl]azetidine-1-carboxylate (2.0 g) (synthesized, for example, according to a method described in WO20129649) in THF (20 mL) was added dropwise, and the mixture was stirred at −78° C. for 1 hour. Saturated aqueous ammonium chloride was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (1.21 g). MS (m / z): 214.0 [M-Boc + 2H] +
[0132] [Step 2] Preparation of intermediate RE-5B A mixture of intermediate RE-5A (1.21 g), 1,4-dioxane (39 mL), and hydrazine monohydrate (0.940 mL) was stirred at 100°C for 2 days. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (635 mg). MS (m / z): 208.0 [M-Boc + 2H] +
[0133] [Step 3] Preparation of intermediate RE-5C The title compound (246 mg) was obtained by a method similar to that of Step 1 of Reference Example 4, except that intermediate RE-5B (200 mg) was used instead of 3-iodo-2H-indazole. MS (m / z): 402.3 [M+Na] +
[0134] [Step 4] Preparation of intermediate RE-5D The title compound (184 mg) was obtained by a method similar to that of Step 5 of Reference Example 1, except that intermediate RE-5C (246 mg) was used instead of intermediate RE-1D. MS (m / z): 364.3 [M−H] -
[0135] [Step 5] Preparation of intermediate RE-5E To a mixture of intermediate RE-5D (100 mg), acetonitrile (2 mL), 1-hydroxybenzotriazole monohydrate (50 mg), NMM (0.090 mL), and 2,2,2-trifluoro-N-methylethanamine hydrochloride (49 mg), EDCI.HCl (63 mg) was added and the mixture was stirred at room temperature for 2 hours. Saturated aqueous sodium bicarbonate was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure to give the title compound (123 mg). MS (m / z): 483.2 [M+Na] +
[0136] [Step 6] Preparation of Compound RE-5 The title compound (127 mg) was obtained by a method similar to Reference Example 3, except that Intermediate RE-5E (123 mg) was used instead of Intermediate RE-2F. MS (m / z): 361.2 [M+H] +
[0137] Reference Example 6 2-[3-(azetidin-3-yl)-6-fluoro-1H-indazol-1-yl]-N-methyl-N-(2,2,2-trifluoroethyl)acetamide trifluoroacetate (Compound RE-6) [Step 1] Preparation of intermediate RE-6A To a mixture of 6-fluoro-3-iodo-1H-indazole (synthesized, for example, according to the method described in Bioorganic Med. Chem. Lett., 2010, 20, 6998-7003) (897 mg) and DMF (7 mL), cesium carbonate (1.34 g) and methyl 2-bromoacetate (0.39 mL) were added sequentially under ice bath conditions. The mixture was stirred for 10 minutes under ice bath conditions and then stirred at room temperature for 2 hours. A saturated aqueous solution of ammonium chloride was added to the reaction mixture, which was then extracted with a mixed solvent of ethyl acetate and hexane. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (1.17 g). MS (m / z): 335.0 [M+H] +
[0138] [Step 2] Preparation of intermediate RE-6B A reaction vessel containing zinc (481 mg) was heated under reduced pressure using a heat gun for 5 minutes and purged with argon. After returning to room temperature, DMA (5.25 mL) was added, and after degassing with argon, 1,2-dibromoethane (0.045 mL) and chloro(trimethyl)silane (0.080 mL) were added and stirred at room temperature for 15 minutes. To this mixture, a solution of tert-butyl 3-iodoazetidine-1-carboxylate (1.49 g) in DMA (5.25 mL) was added dropwise using a dropping funnel. The mixture was stirred at room temperature for 1 hour to prepare a DMA solution of [1-(tert-butoxycarbonyl)azetidin-3-yl]zinc(II) iodide. Next, a mixture of intermediate RE-6A (1.17 g) and DMA (3.5 mL) was degassed with argon and then Pd(dppf)Cl 2 ・CH 2 Cl 2(286 mg) and copper(I) iodide (87 mg) were added. The previously prepared DMA solution of [1-(tert-butoxycarbonyl)azetidin-3-yl]zinc(II) iodide was added to this at room temperature, and the mixture was stirred at 85°C for 1 hour. Water was added to the reaction mixture, and the mixture was extracted with a mixed solvent of ethyl acetate and hexane. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (1.54 g). MS (m / z): 386.3 [M+Na] +
[0139] [Step 3] Preparation of intermediate RE-6C To a mixture of intermediate RE-6B (1.54 g), methanol (6 mL), and THF (6 mL), 2 M aqueous sodium hydroxide solution (6.36 mL) was added at room temperature, and the mixture was stirred for 2 hours. The reaction mixture was concentrated under reduced pressure, diluted with water, filtered, and acidified with 2 M hydrochloric acid in an ice bath. The precipitate was collected by filtration to give the title compound (1.03 g). MS (m / z): 348.2 [M-H] -
[0140] [Step 4] Preparation of intermediate RE-6D To a mixture of intermediate RE-6C (350 mg), acetonitrile (3 mL), 1-hydroxybenzotriazole monohydrate (184 mg), NMM (0.330 mL), and 2,2,2-trifluoro-N-methylethanamine hydrochloride (180 mg), EDCI.HCl (231 mg) was added and the mixture was stirred at room temperature overnight. Saturated aqueous sodium bicarbonate was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the mixture was purified by silica gel column chromatography to give the title compound (318 mg). MS (m / z): 467.3 [M+Na] +
[0141] [Step 5] Preparation of Compound RE-6 The title compound (285 mg) was obtained by a method similar to Reference Example 3, except that Intermediate RE-6D (318 mg) was used instead of Intermediate RE-2F. MS (m / z): 345.2 [M+H] +
[0142] Reference Example 7 2-[3-(3-methylazetidin-3-yl)-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one trifluoroacetate (Compound RE-7) [Step 1] Preparation of intermediate RE-7A EDCI.HCl (1.13 g) was added to a mixture of 3-methyl-1-[(2-methylpropan-2-yl)oxycarbonyl]azetidine-3-carboxylic acid (747 mg), acetonitrile (10 mL), HOBt (797 mg), NMM (2.30 mL), and N,O-dimethylhydroxylamine hydrochloride (677 mg), and the mixture was stirred at room temperature overnight. Saturated aqueous sodium bicarbonate was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure to give tert-butyl 3-[methoxy(methyl)carbamoyl]-3-methylazetidine-1-carboxylate. Subsequently, by a method similar to Step 1 of Reference Example 5, using 1-fluoro-2-iodobenzene (1.16 g) instead of 2-bromo-4-chloro-1-fluorobenzene and using tert-butyl 3-[methoxy(methyl)carbamoyl]-3-methylazetidine-1-carboxylate obtained above instead of tert-butyl 3-[methoxy(methyl)carbamoyl]azetidine-1-carboxylate, the title compound (688 mg) was obtained. MS (m / z): 194.2 [M-Boc+2H] +
[0143] [Step 2] Preparation of intermediate RE-7B A mixture of intermediate RE-7A (620 mg), DMA (7 mL), hydrazine monohydrate (1.03 mL), and potassium carbonate (438 mg) was reacted in a microwave reactor at 150°C for 3 hours. After cooling, a saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give tert-butyl 3-(1H-indazol-3-yl)-3-methylazetidine-1-carboxylate. Subsequently, the title compound (629 mg) was obtained by a method similar to that of Step 1 of Reference Example 4, except that the above tert-butyl 3-(1H-indazol-3-yl)-3-methylazetidine-1-carboxylate was used instead of 3-iodo-2H-indazole. MS (m / z): 260.3 [M-Boc + 2H] +
[0144] [Step 3] Preparation of intermediate RE-7C The title compound (466 mg) was obtained by a method similar to that of Step 5 of Reference Example 1, except that intermediate RE-7B (629 mg) was used instead of intermediate RE-1D. MS (m / z): 344.3 [M−H] -
[0145] [Step 4] Preparation of intermediate RE-7D To a mixture of intermediate RE-7C (100 mg), DMF (1.0 mL), DIPEA (0.150 mL), and (2S)-2-(trifluoromethyl)pyrrolidine hydrochloride (61 mg), HBTU (132 mg) was added and stirred overnight at room temperature. Saturated aqueous sodium bicarbonate was added to the reaction solution, and the mixture was extracted with ethyl acetate. The reaction solution was purified by silica gel column chromatography to obtain the title compound (108 mg). MS (m / z): 489.4 [M+Na] +
[0146] [Step 5] Preparation of Compound RE-7 The title compound (111 mg) was obtained by a method similar to Reference Example 3, except that Intermediate RE-7D (108 mg) was used instead of Intermediate RE-2F. MS (m / z): 367.3 [M+H] +
[0147] Reference Example 8 2-[3-(azetidin-3-yl)-1H-indazol-1-yl]-1-(3,3-dimethylmorpholin-4-yl)ethan-1-one trifluoroacetate (Compound RE-8) [Step 1] Preparation of intermediate RE-8A The title compound (100 mg) was obtained by a method similar to that of Step 4 of Reference Example 7, except that intermediate RE-4C (100 mg) was used instead of intermediate RE-7C and 3,3-dimethylmorpholine (45 mg) was used instead of (2S)-2-(trifluoromethyl)pyrrolidine hydrochloride. MS (m / z): 329.2 [M-Boc + 2H] +
[0148] [Step 2] Preparation of Compound RE-8 The title compound (96 mg) was obtained by a method similar to Reference Example 3, except that Intermediate RE-8A (100 mg) was used instead of Intermediate RE-2F. MS (m / z): 329.2 [M+H] +
[0149] Reference Example 9 2-[3-(azetidin-3-yl)-1H-indazol-1-yl]-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one trifluoroacetate (Compound RE-9) [Step 1] Preparation of intermediate RE-9A The title compound (135 mg) was obtained by a method similar to that of Step 4 of Reference Example 7, except that intermediate RE-4C (100 mg) was used instead of intermediate RE-7C and (2R)-2-(trifluoromethyl)morpholine hydrochloride (69 mg) was used instead of (2S)-2-(trifluoromethyl)pyrrolidine hydrochloride. MS (m / z): 369.1 [M-Boc + 2H] +
[0150] [Step 2] Preparation of Compound RE-9 The title compound (145 mg) was obtained by a method similar to Reference Example 3, except that Intermediate RE-9A (135 mg) was used instead of Intermediate RE-2F. MS (m / z): 369.1 [M+H] +
[0151] Reference Example 10 4-fluoro-3-(piperidin-4-yl)-1-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-1H-indazole trifluoroacetate (Compound RE-10) [Step 1] Preparation of intermediate RE-10A The title compound (3.98 g) was obtained by a method similar to that in Step 1 of Reference Example 1, except that 1,3-difluorobenzene (2.41 g) was used instead of 2-chloro-1,4-difluorobenzene and tert-butyl-4-formylpiperidine-1-carboxylate (3.00 g) was used instead of tert-butyl 3-formylazetidine-1-carboxylate.
[0152] [Step 2] Preparation of intermediate RE-10B The title compound (3.48 g) was obtained by a method similar to that of Step 2 of Reference Example 1, except that Intermediate RE-10A (3.98 g) was used instead of Intermediate RE-1A.
[0153] [Step 3] Preparation of intermediate RE-10C The title compound (3.31 g) was obtained by a method similar to that of Step 3 of Reference Example 1, except that intermediate RE-10B (3.48 g) was used instead of intermediate RE-1B. MS (m / z): 318.3 [M−H] -
[0154] [Step 4] Preparation of intermediate RE-10D To a mixture of intermediate RE-10C (50 mg) and acetonitrile (0.5 mL), cesium carbonate (77 mg) and 2-(bromomethyl)-5-(trifluoromethyl)pyridine (56 mg) were added sequentially, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was purified by silica gel column chromatography to obtain the title compound (34 mg). MS (m / z): 379.1 [M-Boc+2H] +
[0155] [Step 5] Preparation of Compound RE-10 The title compound (35 mg) was obtained by a method similar to Reference Example 3, except that intermediate RE-10D (34 mg) was used instead of intermediate RE-2F. MS (m / z): 379.2 [M+H] +
[0156] Reference Example 11 2-[4-fluoro-3-(piperidin-4-yl)-1H-indol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (Compound RE-11) [Step 1] Preparation of intermediate RE-11A A mixture of 4-fluoro-1H-indazole (750 mg), tert-butyl 4-oxopiperidine-1-carboxylate (1.22 g), potassium hydroxide (1.25 g), and methanol (18 mL) was stirred at 80°C overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate and then dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (660 mg). MS (m / z): 317.1 [M+H] +
[0157] [Step 2] Preparation of intermediate RE-11B 10% Pd—C (21 mg) was added to intermediate RE-11A (500 mg), methanol (53 mL), and ammonium formate (1.30 g), and the mixture was stirred at 80° C. overnight. Insoluble matter was filtered off through Celite (registered trademark), and the residue was concentrated under reduced pressure to give the title compound (400 mg). MS (m / z): 219.2 [M-Boc+2H] +
[0158] [Step 3] Preparation of intermediate RE-11C The title compound (450 mg) was obtained by a method similar to that of Step 4 of Reference Example 1, except that intermediate RE-11B (480 mg) was used instead of intermediate RE-1C. MS (m / z): 305.2 [M-Boc + 2H] +
[0159] [Step 4] Preparation of intermediate RE-11D The title compound (350 mg) was obtained by a method similar to that of Step 5 of Reference Example 1, except that intermediate RE-11C (450 mg) was used instead of intermediate RE-1D. MS (m / z): 375.2 [M−H] -
[0160] [Step 5] Preparation of intermediate RE-11E A mixture of intermediate RE-11D (100 mg), DMF (0.5 mL), DIPEA (0.138 mL), and HATU (121 mg) was stirred at room temperature for 15 minutes. To this was added (2S)-2-(trifluoromethyl)pyrrolidine hydrochloride (56 mg), and the mixture was stirred at room temperature for 1 hour. The reaction mixture was purified by silica gel column chromatography to obtain the title compound (120 mg). MS (m / z): 398.2 [M-Boc + 2H] +
[0161] [Step 6] Preparation of Compound RE-11 The title compound (85 mg) was obtained by a method similar to Step 7 of Reference Example 1, except that Intermediate RE-11E (120 mg) was used instead of Intermediate RE-1F. MS (m / z): 398.2 [M+H] +
[0162] Reference Example 12 tert-Butyl 3-(1-{2-oxo-2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethyl}-1H-indol-3-yl)azetidine-1-carboxylate (Compound RE-12) [Step 1] Preparation of intermediate RE-12A To a mixture of indole (1 g), potassium hydroxide (527 mg), and methanol (11 mL), tert-butyl 3-oxoazetidine-1-carboxylate (1.61 g) was added, and the mixture was stirred at 50°C overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate and then dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure to give the title compound (920 mg). MS (m / z): 287.2 [M-H] -
[0163] [Step 2] Preparation of intermediate RE-12B To a mixture of intermediate RE-12A (920 mg) and dichloromethane (6.4 mL), triethylsilane (3.82 mL) was added in an ice bath, followed by slow addition of trifluoroacetic acid (0.811 mL), and the mixture was stirred in an ice bath for 10 minutes. Saturated aqueous sodium bicarbonate was added to the reaction mixture, which was extracted with dichloromethane and then dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (370 mg). MS (m / z): 271.4 [M-H] -
[0164] [Step 3] Preparation of intermediate RE-12C The title compound (400 mg) was obtained by a method similar to that of Step 4 of Reference Example 1, except that intermediate RE-12B (370 mg) was used instead of intermediate RE-1C. MS (m / z): 259.1 [M-Boc + 2H] +
[0165] [Step 4] Preparation of intermediate RE-12D To a mixture of intermediate RE-12C (400 mg), methanol (10 mL), and THF (10 mL), 2M aqueous sodium hydroxide solution (2.79 mL) was added at room temperature, and the mixture was stirred for 2 hours. The reaction mixture was concentrated under reduced pressure, diluted with water, and then acidified with 2M hydrochloric acid in an ice bath. The solvent was evaporated under reduced pressure, and the mixture was purified by silica gel column chromatography to obtain the title compound (350 mg). MS (m / z): 329.1 [M-H] -
[0166] [Step 5] Preparation of Compound RE-12 The title compound (50 mg) was obtained by a method similar to Step 5 of Reference Example 11, except that intermediate RE-12D (50 mg) was used instead of intermediate RE-11D. MS (m / z): 352.1 [M-Boc + 2H] +
[0167] Reference Example 13 tert-Butyl 3-(5-methyl-1-{2-oxo-2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethyl}-1H-pyrazolo[4,3-b]pyridin-3-yl)azetidine-1-carboxylate (Compound RE-13) [Step 1] Preparation of intermediate RE-13A The procedure of Step 1 of Reference Example 5 was repeated, except that 2-bromo-3-fluoro-6-methylpyridine (1.00 g) was used instead of 2-bromo-4-chloro-1-fluorobenzene, and tert-butyl 3-formylazetidine-1-carboxylate (1.17 g) was used instead of tert-butyl 3-[methoxy(methyl)carbamoyl]azetidine-1-carboxylate to give the title compound (608 mg). MS (m / z): 297.1 [M+H] +
[0168] [Step 2] Preparation of intermediate RE-13B To a mixture of intermediate RE-13A (608 mg) and dichloromethane (10 mL), iodobenzene diacetate (793 mg) and AZADOL (registered trademark) (16 mg) were added in that order, and the mixture was stirred at room temperature for 2 hours. AZADOL (registered trademark) (16 mg) was added, and the mixture was further stirred at room temperature for 2 hours. Saturated aqueous sodium bicarbonate was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (542 mg). MS (m / z): 295.1 [M+H] +
[0169] [Step 3] Preparation of intermediate RE-13C The title compound (363 mg) was obtained by a method similar to that of Step 2 of Reference Example 5, except that intermediate RE-13B (542 mg) was used instead of intermediate RE-5A. MS (m / z): 289.2 [M+H] +
[0170] [Step 4] Preparation of intermediate RE-13D The title compound (359 mg) was obtained by a method similar to that of Step 4 of Reference Example 1, except that intermediate RE-13C (290 mg) was used instead of intermediate RE-1C. MS (m / z): 375.1 [M+H] +
[0171] [Step 5] Preparation of intermediate RE-13E The title compound (187 mg) was obtained by a method similar to that of Step 5 of Reference Example 1, except that intermediate RE-13D (359 mg) was used instead of intermediate RE-1D. MS (m / z): 347.1 [M+H] +
[0172] [Step 6] Preparation of Compound RE-13 The title compound (100 mg) was obtained by a method similar to Step 5 of Reference Example 11, except that Intermediate RE-13E (90 mg) was used instead of Intermediate RE-11D. MS (m / z): 468.3 [M+H] +
[0173] Reference Example 14 2-[3-(azetidin-3-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one ditrifluoroacetate (Compound RE-14) [Step 1] Preparation of intermediate RE-14A The title compound (1.62 g) was obtained by a method similar to that of Step 1 of Reference Example 1, except that 2-chloro-4-fluoropyridine (1.07 g) was used instead of 2-chloro-1,4-difluorobenzene.
[0174] [Step 2] Preparation of intermediate RE-14B The title compound (1.47 g) was obtained by a method similar to that of Step 2 of Reference Example 1, except that Intermediate RE-14A (1.62 g) was used instead of Intermediate RE-1A.
[0175] [Step 3] Preparation of intermediate RE-14C A mixture of intermediate RE-14B (1.37 g), 1,4-dioxane (28 mL), and hydrazine monohydrate (0.65 mL) was stirred at 100°C overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (0.79 g). MS (m / z): 309.1 [M+H] +
[0176] [Step 4] Preparation of intermediate RE-14D The title compound (1.04 g) was obtained by a method similar to that of Step 4 of Reference Example 1, except that intermediate RE-14C (0.79 g) was used instead of intermediate RE-1C. MS (m / z): 395.2 [M+H] +
[0177] [Step 5] Preparation of intermediate RE-14E 5% Pd—C (100 mg) was added to intermediate RE-14D (300 mg), ethyl acetate (7.6 mL), and triethylamine (0.21 mL), and the mixture was stirred overnight at room temperature under a hydrogen atmosphere (0.1 MPa). Insoluble matter was removed by filtration through Celite (registered trademark), and the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography to obtain the title compound (249 mg). MS (m / z): 361.2 [M+H] +
[0178] [Step 6] Preparation of intermediate RE-14F The title compound (210 mg) was obtained by a method similar to that of Step 5 of Reference Example 1, except that intermediate RE-14E (249 mg) was used instead of intermediate RE-1D. MS (m / z): 333.2 [M+H] +
[0179] [Step 7] Preparation of intermediate RE-14G The title compound (92 mg) was obtained by a method similar to that of Step 5 of Reference Example 11, except that intermediate RE-14F (100 mg) was used instead of intermediate RE-11D. MS (m / z): 454.3 [M+H] +
[0180] [Step 8] Preparation of Compound RE-14 A brown oil was obtained by a method similar to Reference Example 3, except that intermediate RE-14G (92 mg) was used instead of intermediate RE-2F. 39 mg of the oil was purified by silica gel column chromatography to obtain the title compound (30 mg). MS (m / z): 354.1 [M+H] +
[0181] Reference Example 15 3-{[3-(azetidin-3-yl)-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl]methyl}-5-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazole trifluoroacetate (Compound RE-15) [Step 1] Preparation of intermediate RE-15A The title compound (4.92 g) was obtained by a method similar to that of Step 1 of Reference Example 1, except that 3,5-difluoropyridine (2.80 g) was used instead of 2-chloro-1,4-difluorobenzene.
[0182] [Step 2] Preparation of intermediate RE-15B The title compound (4.64 g) was obtained by a method similar to that of Step 2 of Reference Example 1, except that Intermediate RE-15A (4.86 g) was used instead of Intermediate RE-1A.
[0183] [Step 3] Preparation of intermediate RE-15C A mixture of intermediate RE-15B (4.64 g), 1,4-dioxane (52 mL), and hydrazine monohydrate (1.16 mL) was stirred at 100°C overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (3.9 g). MS (m / z): 291.2 [M-H] -
[0184] [Step 4] Preparation of intermediate RE-15D The title compound (1.22 g) was obtained by a method similar to that of Step 4 of Reference Example 10, except that Intermediate RE-15C (1.0 g) was used instead of Intermediate RE-10C and 2-chloroacetonitrile (0.323 mL) was used instead of 2-(bromomethyl)-5-(trifluoromethyl)pyridine.
[0185] [Step 5] Preparation of intermediate RE-15E To a solution of potassium carbonate (0.95 g) in water (3.1 mL) was added a solution of hydroxylamine hydrochloride (0.48 g) and intermediate RE-15D (1.22 g) in ethanol (11.4 mL), and the mixture was stirred at room temperature for 3 hours. After the solvent was evaporated under reduced pressure, the residue was suspended in ethyl acetate and filtered through Celite (registered trademark), and insoluble matter was removed by filtration. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (0.72 g). MS (m / z): 365.1 [M+H] +
[0186] [Step 6] Preparation of intermediate RE-15F HATU (41 mg) was added to a mixture of intermediate RE-15E (39 mg), 1-(trifluoromethyl)cyclopropane-1-carboxylic acid (15 mg), DIPEA (0.019 mL), and DMF (0.3 mL), and the mixture was stirred at room temperature overnight. The mixture was then stirred at 120°C for 2 hours. After cooling, the reaction mixture was purified by silica gel column chromatography to obtain the title compound (27 mg). MS (m / z): 483.2 [M+H] +
[0187] [Step 7] Preparation of Compound RE-15 The title compound (28 mg) was obtained by a method similar to Reference Example 3, except that intermediate RE-15F (27 mg) was used instead of intermediate RE-2F. MS (m / z): 383.1 [M+H] +
[0188] Reference Example 16 2-[3-(azetidin-3-yl)-4-methyl-1H-pyrazolo[3,4-b]pyridin-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one ditrifluoroacetate (Compound RE-16) [Step 1] Preparation of intermediate RE-16A The same procedure as in Step 1 of Reference Example 5 was repeated, except that 3-bromo-2-fluoromethylpyridine (0.63 g) was used instead of 2-bromo-4-chloro-1-fluorobenzene, and tert-butyl 3-formylazetidine-1-carboxylate (0.74 g) was used instead of tert-butyl 3-[methoxy(methyl)carbamoyl]azetidine-1-carboxylate to give the title compound (0.57 g). MS (m / z): 197.1 [M-Boc+2H] +
[0189] [Step 2] Preparation of intermediate RE-16B The title compound (241 mg) was obtained by a method similar to that of Step 2 of Reference Example 1, except that intermediate RE-16A (0.57 g) was used instead of intermediate RE-1A. MS (m / z): 195.0 [M-Boc + 2H] +
[0190] [Step 3] Preparation of intermediate RE-16C The title compound (148 mg) was obtained by a method similar to that of Step 3 of Reference Example 1, except that intermediate RE-16B (241 mg) was used instead of intermediate RE-1B. MS (m / z): 289.1 [M+H] +
[0191] [Step 4] Preparation of intermediate RE-16D The title compound (166 mg) was obtained by a method similar to that of Step 4 of Reference Example 1, except that intermediate RE-16C (148 mg) was used instead of intermediate RE-1C. MS (m / z): 375.1 [M+H] +
[0192] [Step 5] Preparation of intermediate RE-16E The title compound (139 mg) was obtained by a method similar to that of Step 5 of Reference Example 1, except that intermediate RE-16D (166 mg) was used instead of intermediate RE-1D. MS (m / z): 347.1 [M+H] +
[0193] [Step 6] Preparation of intermediate RE-16F The title compound (88 mg) was obtained by a method similar to that of Step 5 of Reference Example 11, except that intermediate RE-16E (70 mg) was used instead of intermediate RE-11D. MS (m / z): 412.1 [M-(tBu+2H)] +
[0194] [Step 7] Preparation of Compound RE-16 The title compound (130 mg) was obtained by a method similar to Reference Example 3, except that intermediate RE-16F (88 mg) was used instead of intermediate RE-2F. MS (m / z): 368.0 [M+H] +
[0195] Reference Example 17 3-(azetidin-3-yl)-1-{[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]methyl}-1H-indazole trifluoroacetate (Compound RE-17) [Step 1] Preparation of intermediate RE-17A To a mixture of 1-fluoro-2-iodobenzene (8.31 g) and THF (62 mL), n-butyllithium (1.57 M n-hexane solution, 23.8 mL) was added dropwise at -78°C. After stirring at -78°C for 1 hour, a solution of tert-butyl 3-formylazetidine-1-carboxylate (4.6 g) in THF (62 mL) was added dropwise, and the mixture was stirred at -78°C for 1 hour. Saturated aqueous ammonium chloride was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure to give tert-butyl 3-[(2-fluorophenyl)(hydroxy)methyl]azetidine-1-carboxylate. To a mixture of the above tert-butyl 3-[(2-fluorophenyl)(hydroxy)methyl]azetidine-1-carboxylate and dichloromethane (124 mL), iodobenzene diacetate (9.6 g) and AZADOL® (190 mg) were added sequentially, and the mixture was stirred at room temperature for 2 hours. Iodobenzene diacetate (4.85 g) and AZADOL® (190 mg) were added, and the mixture was stirred at room temperature for 30 minutes. Saturated aqueous sodium bicarbonate was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (5.29 g). MS (m / z): 280.1 [M+H] +
[0196] [Step 2] Preparation of intermediate RE-17B A mixture of intermediate RE-17A (5.15 g), NMP (50 mL), and hydrazine monohydrate (8.99 mL) was stirred at 150°C for 2 days. After cooling, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate / n-hexane (1 / 1). The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (4.39 g). MS (m / z): 274.1 [M+H] +
[0197] [Step 3] Preparation of intermediate RE-17C To a mixture of intermediate RE-17B (200 mg) and acetonitrile (2.4 mL), cesium carbonate (358 mg) and 5-(chloromethyl)-3-(trifluoromethyl)-1,2,4-oxadiazole (205 mg) were added sequentially, and the mixture was stirred at room temperature for 4 hours, followed by stirring at 60°C overnight. 5-(chloromethyl)-3-(trifluoromethyl)-1,2,4-oxadiazole (137 mg) was added, and the mixture was stirred at room temperature for 72 hours. The reaction solution was purified by silica gel column chromatography to obtain the title compound (94 mg). MS (m / z): 422.2 [M-H] -
[0198] [Step 4] Preparation of Compound RE-17 The title compound (98 mg) was obtained by a method similar to Reference Example 3, except that intermediate RE-17C (94 mg) was used instead of intermediate RE-2F. MS (m / z): 324.0 [M+H] +
[0199] Reference Example 18 tert-Butyl 3-[1-({1-[(3,3-difluorocyclobutyl)methyl]-1H-1,2,3-triazol-4-yl}methyl)-4-fluoro-1H-indazol-3-yl]azetidine-1-carboxylate (Compound RE-18) [Step 1] Preparation of intermediate RE-18A The title compound (2.72 g) was obtained by a method similar to that of Step 1 of Reference Example 1, except that 1,3-difluorobenzene (1.85 g) was used instead of 2-chloro-1,4-difluorobenzene.
[0200] [Step 2] Preparation of intermediate RE-18B The title compound (2.39 g) was obtained by a method similar to that of Step 2 of Reference Example 1, except that Intermediate RE-18A (2.72 g) was used instead of Intermediate RE-1A. MS (m / z): 298.0 [M+H] +
[0201] [Step 3] Preparation of intermediate RE-18C The title compound (2.15 g) was obtained by a method similar to that of Step 3 of Reference Example 1, except that intermediate RE-18B (2.39 g) was used instead of intermediate RE-1B. MS (m / z): 290.3 [M−H] -
[0202] [Step 4] Preparation of Intermediate RE-18D To a mixture of Intermediate RE-18C (1.02 g) and DMF (12 mL), potassium carbonate (726 mg) and propargyl bromide (0.332 mL) were added successively, and the mixture was stirred at room temperature for 2 hours. A saturated aqueous solution of ammonium chloride was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (1.01 g). MS (m / z): 230.1 [M-Boc + 2H] +
[0203] [Step 5] Preparation of Compound RE-18 To a mixture of (3,3-difluorocyclobutyl)methyl 4-methylbenzenesulfonate (synthesized, for example, according to the method described in WO2014205234) (300 mg) and DMF (3 mL), sodium azide (84.7 mg) was added and stirred overnight at 120°C to prepare a DMF solution of 3-(azidomethyl)-1,1-difluorocyclobutane (approximately 0.36 mol / L). After cooling, copper(I) iodide (2.9 mg) was added to a mixture of the prepared 3-(azidomethyl)-1,1-difluorocyclobutane (DMF solution, approximately 0.36 mol / L, 0.839 mL), intermediate RE-18D (50 mg), DMF (2 mL), and methanol (0.2 mL), and the mixture was stirred at 60°C for 3 hours. The reaction solution was diluted with ethyl acetate, washed with saturated brine, and then dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (56 mg).
[0204] Reference Example 19 3-(azetidin-3-yl)-4-fluoro-1-{[5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl]methyl}-1H-indazole trifluoroacetate (Compound RE-19) [Step 1] Preparation of intermediate RE-19A The title compound (65 mg) was obtained by a method similar to that of Step 4 of Reference Example 10, using Intermediate RE-18C (40 mg) instead of Intermediate RE-10C and 2-(chloromethyl)-5-(4-fluorophenyl)-1,3,4-oxadiazole (35 mg) instead of 2-(bromomethyl)-5-(trifluoromethyl)pyridine. MS (m / z): 368.1 [M-Boc + 2H] +
[0205] [Step 2] Preparation of Compound RE-19 The title compound (67 mg) was obtained by a method similar to Reference Example 3, except that intermediate RE-19A (65 mg) was used instead of intermediate RE-2F. MS (m / z): 368.1 [M+H] +
[0206] Reference Example 20 2-[3-(azetidin-3-yl)-4-fluoro-1H-indazol-1-yl]-N-methyl-N-(2,2,2-trifluoroethyl)acetamide trifluoroacetate (Compound RE-20) [Step 1] Production of intermediate RE-20A The title compound (638 mg) was obtained by a method similar to that of Step 4 of Reference Example 1, except that intermediate RE-18C (500 mg) was used instead of intermediate RE-1C. MS (m / z): 278.0 [M-Boc + 2H] +
[0207] [Step 2] Preparation of intermediate RE-20B The title compound (476 mg) was obtained by a method similar to that of Step 5 of Reference Example 1, except that intermediate RE-20A (638 mg) was used instead of intermediate RE-1D. MS (m / z): 348.4 [M−H] -
[0208] [Step 3] Preparation of intermediate RE-20C The title compound (81 mg) was obtained by a method similar to that of Step 5 of Reference Example 5, except that intermediate RE-20B (64 mg) was used instead of intermediate RE-5D. MS (m / z): 468.3 [M+Na] +
[0209] [Step 4] Preparation of Compound RE-20 The title compound (84 mg) was obtained by a method similar to Reference Example 3, except that intermediate RE-20C (81 mg) was used instead of intermediate RE-2F. MS (m / z): 345.2 [M+H] +
[0210] Reference Example 21 2-[3-(azetidin-3-yl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one trifluoroacetate (Compound RE-21) [Step 1] Preparation of intermediate RE-21A By a method similar to that in Step 1 of Reference Example 4, using 3-iodo-4,5,6,7-tetrahydro-1H-indazole (synthesized, for example, according to the method described in US2014171432) (1.63 g) instead of 3-iodo-2H-indazole, the title compound and a mixture of about 10% regioisomers (2.14 g) were obtained. MS (m / z): 321.1 [M+H] +
[0211] [Step 2] Preparation of intermediate RE-21B The title compound (0.39 g) was obtained by a method similar to that of Step 2 of Reference Example 4, except that Intermediate RE-21A (2.14 g) obtained in Step 1 of Reference Example 21 was used instead of Intermediate RE-4A. MS (m / z): 372.3 [M+Na] +
[0212] [Step 3] Preparation of intermediate RE-21C The title compound (34 mg) was obtained by a method similar to that of Step 5 of Reference Example 1, except that intermediate RE-21B (0.39 g) was used instead of intermediate RE-1D. MS (m / z): 334.2 [M−H] -
[0213] [Step 4] Preparation of intermediate RE-21D The title compound (16 mg) was obtained by a method similar to that of Step 5 of Reference Example 11, except that intermediate RE-21C (34 mg) was used instead of intermediate RE-11D. MS (m / z): 457.3 [M+H] +
[0214] [Step 5] Preparation of Compound RE-21 The title compound (16 mg) was obtained according to the method of Reference Example 3, except that Intermediate RE-21D (16 mg) was used instead of Intermediate RE-2F. MS (m / z): 357.2 [M+H] +
[0215] Reference Example 22 2-[3-(azetidin-3-yl)-5,5-difluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one trifluoroacetate (Compound RE-22) [Step 1] Preparation of intermediate RE-22A A reaction vessel containing diethyl ether (30 mL) was ice-cooled, and 60% sodium hydride (596 mg) was added. Ethanol (0.087 mL) was then added and the mixture was stirred in an ice bath for 20 minutes. A solution of 4,4-difluorocyclohexan-1-one (2.0 g) and ethyl formate (1.80 mL) in diethyl ether (10 mL) was added dropwise using a dropping funnel over 10 minutes. The temperature was gradually returned to room temperature, and the mixture was stirred overnight. Ethanol (0.3 mL) was then added to the reaction mixture, which was then stirred at room temperature for 1 hour. Water was added to the reaction mixture, which was then washed with diethyl ether. The aqueous layer was acidified with 2 M hydrochloric acid and extracted with diethyl ether. The organic layer was washed with saturated brine and then dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure to give the title compound (1.35 g). MS (m / z): 163.1 [M+H] +
[0216] [Step 2] Preparation of intermediate RE-22B To a mixture of intermediate RE-22A (1.35 g) and methanol (8.3 mL), hydrazine monohydrate (0.487 mL) was added dropwise, and the mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (0.65 g). MS (m / z): 159.1 [M+H] +
[0217] [Step 3] Preparation of intermediate RE-22C To a mixture of intermediate RE-22B (0.65 g) and DMF (8.2 mL), potassium hydroxide (0.92 g) and iodine (2.1 g) were added in that order under ice cooling, and the mixture was stirred at room temperature overnight. A saturated aqueous solution of sodium thiosulfate was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and then dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (468 mg). MS (m / z): 284.8 [M+H] +
[0218] [Step 4] Preparation of intermediate RE-22D By following the procedure of Step 1 of Reference Example 4, using intermediate RE-22C (468 mg) instead of 3-iodo-2H-indazole, the title compound and a mixture (582 mg) of about 24% regioisomers were obtained. MS (m / z): 356.8 [M+H] +
[0219] [Step 5] Preparation of intermediate RE-22E The title compound (360 mg) was obtained by a method similar to that of Step 2 of Reference Example 4, except that intermediate RE-22D (582 mg) was used instead of intermediate RE-4A. MS (m / z): 408.3 [M+Na] +
[0220] [Step 6] Preparation of intermediate RE-22F The title compound (103 mg) was obtained by a method similar to that of Step 5 of Reference Example 1, except that intermediate RE-22E (360 mg) was used instead of intermediate RE-1D. MS (m / z): 370.2 [M−H] -
[0221] [Step 7] Preparation of intermediate RE-22G The title compound (60 mg) was obtained by a method similar to that of Step 5 of Reference Example 11, except that intermediate RE-22F (50 mg) was used instead of intermediate RE-11D. MS (m / z): 515.3 [M+Na] +
[0222] [Step 8] Preparation of Compound RE-22 The title compound (62 mg) was obtained by a method similar to Reference Example 3, except that intermediate RE-22G (60 mg) was used instead of intermediate RE-2F. MS (m / z): 393.3 [M+H] +
[0223] Reference Example 23 2-(cyclopropylamino)pyridine-4-carboxylic acid (compound RE-23) [Step 1] Preparation of intermediate RE-23A To a mixture of 2-fluoropyridine-4-carbonitrile (500 mg), NMP (4.0 mL), and DIPEA (2.1 mL), cyclopropanamine (0.57 mL) was added and the mixture was stirred at 80°C overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate / n-hexane (1 / 1). The organic layer was washed with saturated brine and then dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (550 mg).
[0224] [Step 2] Production of Compound RE-23 Potassium hydroxide (970 mg) was added to a mixture of intermediate RE-23A (550 mg), ethanol (2 mL), and water (2 mL), and the mixture was stirred at 80°C overnight. The solvent was evaporated under reduced pressure, and 2M hydrochloric acid was added to the residue to adjust the pH to 7-8. The precipitate was collected by filtration to obtain the title compound (313 mg). MS (m / z): 179.1 [M+H] +
[0225] Reference Example 24 2-amino-5-fluoropyridine-4-carboxylic acid hydrochloride (compound RE-24) A mixture of tert-butyl 2-bromo-5-fluoropyridine-4-carboxylate (synthesized, for example, according to the method described in WO202186879) (2.00 g), tert-butyl carbonate (1.02 g), Xantphos (168 mg), cesium carbonate (3.30 g), and 1,4-dioxane (24 mL) was degassed with argon and then purified with Pd(OAc). 2(33 mg) was added and the mixture was stirred at 90°C overnight. Insoluble matter was filtered off through Celite (registered trademark), and the mother liquor was washed successively with water and saturated brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure to give tert-butyl 2-{[(tert-butoxy)carbonyl]amino}-5-fluoropyridine-4-carboxylate. Next, a mixture of the obtained tert-butyl 2-{[(tert-butoxy)carbonyl]amino}-5-fluoropyridine-4-carboxylate and hydrogen chloride (4 M solution in 1,4-dioxane, 9 mL) was stirred at 70°C for 6 hours. After cooling, the resulting precipitate was collected by filtration to give the title compound (1.33 g). MS (m / z): 157.0 [M+H] +
[0226] Reference Example 25 2-amino-3-methylpyridine-4-carboxylic acid trifluoroacetate (Compound RE-25) [Step 1] Preparation of intermediate RE-25A A mixture of methyl 2-chloro-3-methylpyridine-4-carboxylate (2.50 g), (4-methoxyphenyl)methanamine (2.63 mL), rac-BINAP (839 mg), cesium carbonate (13.2 g), and 1,4-dioxane (45 mL) was degassed with argon and then treated with Pd(OAc). 2 (151 mg) was added and the mixture was stirred at 100°C overnight. Insoluble matter was filtered off using Celite (registered trademark), and the mother liquor was washed with saturated brine and then dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (4.07 g). MS (m / z): 287.1 [M+H] +
[0227] [Step 2] Preparation of intermediate RE-25B The title compound (4.02 g) was obtained by a method similar to that of Step 5 of Reference Example 1, except that Intermediate RE-25A (4.07 g) was used instead of Intermediate RE-1D. MS (m / z): 273.0 [M+H] +
[0228] [Step 3] Preparation of Compound RE-25 A mixture of intermediate RE-25B (1.64 g) and trifluoroacetic acid (20 mL) was stirred at 70° C. overnight. The mixture was concentrated under reduced pressure, and the residue was slurry washed with ethyl acetate to obtain the title compound (1.25 g). MS (m / z): 153.0 [M+H] +
[0229] Reference Example 26 2-amino-5-fluoropyrimidine-4-carboxylic acid (compound RE-26) [Step 1] Preparation of intermediate RE-26A A mixture of 4-chloro-5-fluoropyrimidin-2-amine (1.36 g), tributyl(1-ethoxyvinyl)tin (3.66 g), and DMF (18 mL) was degassed with argon and then diluted with PdCl 2 (PPh 3 ) 2 (129 mg) was added and the mixture was stirred at 90°C overnight. Water was added to the reaction mixture and the mixture was extracted with ethyl acetate / n-hexane (1 / 4). The organic layer was washed with saturated brine and then dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (1.46 g). MS (m / z): 184.2 [M+H] +
[0230] [Step 2] Preparation of intermediate RE-26B To a mixture of intermediate RE-26A (1.46 g) and 1,4-dioxane (24 mL), a solution of sodium periodate (3.41 g) in water (24 mL) and potassium permanganate (252 mg) were added at room temperature. Thereafter, potassium permanganate (252 mg) was added three times every two hours, and the mixture was stirred for another two hours. Saturated aqueous sodium bicarbonate was added to the reaction mixture, which was then diluted with ethyl acetate and filtered through Celite (registered trademark), and insoluble matter was removed by filtration. The mother liquor was extracted with ethyl acetate. The organic layer was washed with saturated brine and then dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure to give the title compound (400 mg). MS (m / z): 186.2 [M+H] +
[0231] [Step 3] Preparation of Compound RE-26 The title compound (140 mg) was obtained by a method similar to Step 5 of Reference Example 1, except that Intermediate RE-26B (400 mg) was used instead of Intermediate RE-1D. MS (m / z): 158.1 [M+H] +
[0232] Reference Example 27 tert-Butyl 6-(cyclopropylamino)pyrimidine-4-carboxylate (Compound RE-27) Cyclopropylamine (77 mg) was added to a mixture of tert-butyl 6-chloropyrimidine-4-carboxylate (synthesized, for example, according to the method described in US9598419,2017,B1) (58 mg), DIPEA (0.01 mL), and ethanol (1 mL), and the mixture was reacted in a microwave reaction apparatus at 140° C. for 1 hour. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (46 mg). 1 H-NMR (400MHz, CDCl 3 ) δ8.66 (s, 1H), 7.32 (s, 1H), 5.69 (brs, 1H), 2.62 (s, 1H), 1.63 (s, 9H), 0.92-0.90 (m, 2H), 0.65-0.62 (m, 2H)
[0233] Reference Example 28 2-(1-methylcyclopropylamino)pyridine-4-carboxylic acid (compound RE-28) [Step 1] Preparation of intermediate RE-28A To a mixture of 2-fluoropyridine-4-carbonitrile (200 mg), DIPEA (0.85 mL), and NMP (1.6 mL), 1-methylcyclopropan-1-amine hydrochloride (77 mg) was added, and the mixture was allowed to react overnight at 80°C. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and then dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (110 mg). 1 H-NMR (400MHz, CDCl 3 ) δ8.18 (d, 1H), 6.89 (s, 1H), 6.78 (dd, 1H), 5.53 (brs, 1H), 1.39 (s, 3H), 0.83-0.75 (m, 4H)
[0234] [Step 2] Production of Compound RE-28 Potassium hydroxide (0.2 g) was added to a mixture of intermediate RE-28A (110 mg), ethanol (2 mL), and water (2 mL), and the mixture was allowed to react overnight at 80°C. The solvent was evaporated under reduced pressure, and the residue was adjusted to pH 7-8 with 2 M hydrochloric acid. The resulting precipitate was collected by filtration and washed with water. The mixture was dried to obtain the title compound (63 mg). 1 H-NMR (400MHz, DMSO-d6) δ8.12 (d, 1H), 7.10 (s, 1H), 7.03 (s, 1H), 6.92 (dd, 1H), 1.32 (s, 3H), 0.65 (d, 4H)
[0235] Reference Example 29 2-[(4,4-difluorocyclohexyl)amino]pyridine-4-carboxylic acid (compound RE-29) Compound RE-29 was prepared following a synthetic route similar to that described for compound RE-28 using 4,4-difluorocyclohexan-1-amine hydrochloride. 1 H-NMR (400 MHz, DMSO-d6) δ 8.09 (d, 1H), 6.99 (s, 1H), 6.86-6.83 (m, 2H), 3.95 (brs, 1H), 2.06-1.92 (m, 6H), 1.60-1.51 (m, 2H) Reference Example 30 2-[3-(azetidin-3-yl)-4-chloro-1H-indazol-1-yl]-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (Compound RE-30)
[0236] [Step 1] Production of intermediate RE-30A The title compound was obtained by a method similar to that of Step 1 of Reference Example 1, except that 1-chloro-3-fluorobenzene was used instead of 2-chloro-1,4-difluorobenzene. MS (m / z): 316.1 [M+H] +
[0237] [Step 2] Preparation of intermediate RE-30B To a mixture of intermediate RE-30A (600 mg) and dichloromethane (19 mL), sodium hydrogen carbonate (479 mg) and 1,1-triacetoxy-1,1-dihydro-1,2-benzoiodoxol-3-(1H)-one (1.21 g) were added under ice-cooling, and the mixture was stirred at room temperature overnight. Saturated aqueous sodium bicarbonate was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (557 mg). 1 H-NMR (400MHz, CDCl 3 ) δ7.39-7.33 (m, 1H), 7.24 (d, 1H), 7.07 (t, 1H), 4.23-4.20 (m, 2H), 4.09 (t, 2H), 3.97-3.88 (m, 1H), 1.45 (s, 9H)
[0238] [Step 3] Preparation of Intermediate RE-30 Compound RE-30 was synthesized starting from intermediate RE-30B according to a procedure similar to that described in Steps 3 to 7 of Reference Example 1 for the preparation of compound RE-1. MS (m / z): 347.0 [M+H] +
[0239] Reference Example 31 2-[3-(azetidin-3-yl)-4,7-difluoro-1H-indazol-1-yl]-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (Compound RE-31)
[0240] [Step 1] Preparation of intermediate RE-31A A mixture of intermediate RE-1B (1.34 g), ethanol (10 mL), and hydrazine monohydrate (3.94 mL) was reacted in a microwave reactor at 140°C for 1 hour. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (218 mg). MS (m / z): 310.5 [M+H] +
[0241] [Step 2] Preparation of intermediate RE-31B Cesium carbonate (276 mg) and propyl 2-bromoacetate (153 mg) were added sequentially to a mixture of intermediate RE-31A (218 mg) and DMF (3.5 mL) in an ice bath, and the mixture was stirred at room temperature. A saturated aqueous solution of ammonium chloride was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (238 mg). 1 H-NMR (400MHz, CDCl 3 ) δ7.00-6.90 (m, 1H), 6.70-6.60 (m, 1H), 5.22 (s, 2H), 4.40-4.27 (m, 4H), 4.25 -4.17 (m, 1H), 4.16-4.11 (m, 2H), 1.70-1.59 (m, 2H), 1.46 (s, 9H), 0.89 (t, 3H)
[0242] [Step 3] Preparation of Compound RE-31 Compound RE-31 was synthesized starting from intermediate RE-31A according to a procedure similar to that described in Steps 5 to 7 of Reference Example 1 for the preparation of compound RE-1. MS (m / z): 349.0 [M+H] +
[0243] Reference Example 32 2-[3-(azetidin-3-yl)-4-bromo-5-fluoro-1H-indazol-1-yl]-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (Compound RE-32)
[0244] [Step 1] Preparation of intermediate RE-32A The title compound was obtained by a method similar to that of Step 1 of Reference Example 1, except that 2-bromo-1,3-difluorobenzene was used instead of 2-chloro-1,4-difluorobenzene. 1 H-NMR (400MHz, CDCl 3 ) δ7.12-7.02 (m, 2H), 5.38 (t, 1H), 4.19-4.10 (m, 1H), 4.06-3.98 (m, 1H), 3.87-3 .80 (m, 1H), 3.65-3.60 (m, 1H), 3.30-3.18 (m, 1H), 2.59-2.51 (m, 1H), 1.44 (s, 9H)
[0245] [Step 2] Preparation of intermediate RE-32B The title compound was obtained according to a method similar to that of Step 2 of Reference Example 30, except that Intermediate RE-32A was used instead of Intermediate RE-30A. 1 H-NMR (400MHz, CDCl 3 ) δ7.22-7.16 (m, 1H), 7.14-7.09 (m, 1H), 4.37-4.30 (m, 2H), 4.10 (t, 2H), 3.97-3.88 (m, 1H), 1.45 (s, 9H)
[0246] [Step 3] Preparation of intermediate RE-32C Intermediate RE-32C was synthesized starting from Intermediate RE-32B following a procedure similar to that described in Steps 1 to 2 of Reference Example 31 for the preparation of Intermediate RE-31B. 1 H-NMR (400MHz, CDCl 3 ) δ7.22-7.16 (m, 2H), 5.10 (s, 2H), 4.37-4.30 (m, 4H), 4.15-4.11 (m, 3H), 1.70-1.61 (m, 2H), 1.45 (s, 9H), 0.89 (t, 3H)
[0247] [Step 4] Preparation of Compound RE-32 Compound RE-32 was synthesized starting from intermediate RE-32C according to a procedure similar to that described in Steps 5 to 7 of Reference Example 1 for the preparation of compound RE-1. MS (m / z): 407.1 [M−H] -
[0248] Reference Example 33 tert-Butyl 3-(4-methyl-1-{2-oxo-2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethyl}-1H-pyrazolo[4,3-c]pyridin-3-yl)azetidine-1-carboxylate (Compound RE-33)
[0249] [Step 1] Preparation of intermediate RE-33A Compound RE-14D (200 mg), trimethylboroxine (70 mg), potassium carbonate (280 mg), Pd(dppf)Cl 2 ・CH 2 Cl 2A mixture of 41 mg of toluene and 1,4-dioxane (2.5 mL) was degassed and then stirred at 110°C for 5 hours under an argon atmosphere. A saturated aqueous solution of ammonium chloride was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (98 mg). MS (m / z): 375.1 [M+H] +
[0250] [Step 2] Preparation of Compound RE-33 To a mixture of intermediate RE-33A (98 mg), methanol (1 mL), and THF (1 mL), 2M aqueous sodium hydroxide solution (1 mL) was added at room temperature, and the mixture was stirred overnight. The reaction mixture was concentrated under reduced pressure, diluted with water, and then acidified with 2M hydrochloric acid in an ice bath. Saturated sodium bicarbonate water was added to the mixture to neutralize it, and the solvent was concentrated. DMF (2 mL) was added to the residue, followed by DIPEA (0.2 mL), (2S)-2-(trifluoromethyl)pyrrolidine hydrochloride (60 mg), and HATU (129 mg), and the mixture was stirred at room temperature for 2 hours. Saturated aqueous sodium bicarbonate was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (97 mg). MS (m / z): 468.2 [M+H] +
[0251] Reference Example 34 tert-Butyl 3-(1-{2-oxo-2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethyl}-1H-pyrazolo[4,3-b]pyridin-3-yl)azetidine-1-carboxylate (Compound RE-34)
[0252] [Step 1] Preparation of intermediate RE-34A To a mixture of 3-fluoropyridine (674 mg) and THF (9 mL), lithium diisopropylamide (1.08 M n-hexane / tetrahydrofuran solution, 6.4 mL) was added dropwise at −78° C. After stirring at −78° C. for 1 hour, a solution of tert-butyl 3-[methoxy(methyl)carbamoyl]azetidine-1-carboxylate (1.13 g) (synthesized, for example, according to a method described in WO20129649) in THF (9 mL) was added dropwise, and the mixture was stirred at −78° C. for 2 hours. After stirring at room temperature for 2 hours, saturated aqueous ammonium chloride was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (490 mg). MS (m / z): 281.0 [M+H] +
[0253] [Step 2] Preparation of intermediate RE-34B The title compound was obtained by a method similar to that of Step 1 of Reference Example 31, except that Intermediate RE-34A was used instead of Intermediate RE-1B. MS (m / z): 275.1 [M+H] +
[0254] [Step 3] Preparation of Compound RE-34 Compound RE-34 was synthesized starting from intermediate RE-34B according to a procedure similar to that described in Steps 1 and 2 of Reference Example 33 for the preparation of compound RE-33. MS (m / z): 454.3 [M+H] +
[0255] Reference Example 35 tert-Butyl 3-(5-methyl-1-{[4-(trifluoromethyl)phenyl]methyl}-1H-pyrazolo[3,4-c]pyridin-3-yl)azetidine-1-carboxylate (Compound RE-35)
[0256] [Step 1] Preparation of intermediate RE-35A The title compound was obtained by a method similar to that of Step 1 of Reference Example 34, except that 2-chloro-5-fluoropyridine was used instead of 3-fluoropyridine. 1 H-NMR (400MHz, CDCl 3) δ8.43 (d, 1H), 7.76 (d, 1H), 4.22-4.15 (m, 4H), 4.08-3.95 (m, 1H), 1.44 (s, 9H)
[0257] [Step 2] Preparation of intermediate RE-35B The title compound was obtained by a method similar to that of Step 1 of Reference Example 31, except that Intermediate RE-35A was used instead of Intermediate RE-1B. MS (m / z): 309.1 [M+H] +
[0258] [Step 3] Preparation of intermediate RE-35C To a mixture of intermediate RE-35B (100 mg) and DMF (2 mL), cesium carbonate (211 mg) and 1-(bromomethyl)-4-(trifluoromethyl)benzene (116 mg) were added under ice-cooling, and the mixture was stirred for 1 hour. Saturated aqueous ammonium chloride was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (134 mg). MS (m / z): 467.2 [M+H] +
[0259] [Step 4] Preparation of Compound RE-35 Intermediate RE-35C (134 mg), trimethylboroxine (72 mg), potassium carbonate (159 mg), Pd(dppf)Cl 2 ・CH 2 Cl 2 A mixture of Pd(dppf)Cl (23 mg) and 1,4-dioxane (1.4 mL) was degassed and then stirred at 110°C under an argon atmosphere for 5 hours. 2 ・CH 2 Cl 2 (23 mg) was added and the mixture was stirred at 90°C overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (58 mg). MS (m / z): 447.3 [M+H] +
[0260] Reference Example 36 tert-Butyl 3-(5-methyl-1-{2-oxo-2-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethyl}-1H-pyrazolo[3,4-c]pyridin-3-yl)azetidine-1-carboxylate (Compound RE-36)
[0261] [Step 1] Preparation of intermediate RE-36A Intermediate RE-35B (280 mg), trimethylboroxine (171 mg), potassium carbonate (376 mg), Pd(dppf)Cl 2 ・CH 2 Cl 2 A mixture of (148 mg) and 1,4-dioxane (3 mL) was reacted in a microwave reactor at 130°C for 1 hour, and then stirred at 150°C for 1 hour. Trimethylboroxine (0.8 mL) was added, and the reaction was continued in a microwave reactor at 180°C for 5 minutes. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (66 mg). MS (m / z): 289.2 [M+H] +
[0262] [Step 2] Preparation of intermediate RE-36B Intermediate RE-36B was synthesized starting from intermediate RE-36A according to a procedure similar to that described in Steps 4 to 5 of Reference Example 1 for the preparation of intermediate RE-1E. MS (m / z): 347.1 [M+H] +
[0263] [Step 3] Preparation of Compound RE-36 A mixture of intermediate RE-36B (30 mg), (2R)-2-(trifluoromethyl)morpholine hydrochloride (20 mg), HBTU (39 mg), DMF (0.3 mL), and DIPEA (0.004 mL) was stirred at room temperature overnight. The reaction mixture was purified by silica gel column chromatography to obtain the title compound (40 mg). MS (m / z): 484.3 [M+H] +
[0264] Reference Example 37 2-[3-(azetidin-3-yl)-5-methyl-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one trifluoroacetate (Compound RE-37)
[0265] [Step 1] Preparation of intermediate RE-37A The title compound was obtained by a method similar to that of Step 1 of Reference Example 5, except that 2-bromo-1-fluoro-4-methylbenzene was used instead of 2-bromo-4-chloro-1-fluorobenzene. MS (m / z): 294.0 [M+H] +
[0266] [Step 2] Preparation of intermediate RE-37B A mixture of intermediate RE-37A (1.87 g), 1,4-dioxane (64 mL), and hydrazine monohydrate (1.55 mL) was stirred at 100°C for 3 days. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain tert-butyl 3-(5-methyl-1H-indazol-3-yl)azetidine-1-carboxylate. Cesium carbonate (644 mg) and methyl bromoacetate (330 mg) were added to a mixture of the obtained tert-butyl 3-(5-methyl-1H-indazol-3-yl)azetidine-1-carboxylate (473 mg) and DMF (8 mL) under ice-cooling, and the mixture was stirred at room temperature for 1 hour. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give tert-butyl 3-[1-(2-ethoxy-2-oxoethyl)-5-methyl-1H-indazol-3-yl]azetidine-1-carboxylate. To a mixture of the obtained tert-butyl 3-[1-(2-ethoxy-2-oxoethyl)-5-methyl-1H-indazol-3-yl]azetidine-1-carboxylate (467 mg), methanol (2 mL), and THF (2 mL), 2M aqueous sodium hydroxide solution (1.9 mL) was added at room temperature and stirred overnight. The reaction mixture was concentrated under reduced pressure, diluted with water, and acidified with 2M hydrochloric acid in an ice bath. The precipitate was collected by filtration to give the title compound (383 mg). MS (m / z): 344.2 [M-H] -
[0267] [Step 3] Preparation of intermediate RE-37C The title compound was obtained by a method similar to that of Step 4 of Reference Example 4, except that Intermediate RE-37B was used instead of Intermediate RE-4C. MS (m / z): 467.3 [M+H]
[0268] [Step 4] Preparation of Compound RE-37 Trifluoroacetic acid (1 mL) was added to a mixture of intermediate RE-37C (171 mg) and dichloromethane (4 mL), and the mixture was stirred at room temperature for 1 hour. The solvent was evaporated under reduced pressure, and toluene was added to the resulting residue, which was then evaporated under reduced pressure. Ethyl acetate and hexane were then added, and the solvent was evaporated under reduced pressure to give the title compound (145 mg). MS (m / z): 367.2 [M+H] +
[0269] Reference Example 38 2-[3-(azetidin-3-yl)-5-fluoro-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one trifluoroacetate (Compound RE-38)
[0270] [Step 1] Preparation of intermediate RE-38A The title compound was obtained by a method similar to that of Step 1 of Reference Example 5, except that 1,4-difluoro-2-iodobenzene was used instead of 2-bromo-4-chloro-1-fluorobenzene. MS (m / z): 298.1 [M+H] +
[0271] [Step 2] Preparation of intermediate RE-38B The title compound was obtained by a method similar to that of Step 3 of Reference Example 1, except that Intermediate RE-38A was used instead of Intermediate RE-1B. MS (m / z): 290.1 [M−H] -
[0272] [Step 3] Preparation of intermediate RE-38C Cesium carbonate (236 mg) and methyl bromoacetate (111 mg) were added to a mixture of intermediate RE-38B (176 mg) and DMF (3 mL) under ice-cooling, and the mixture was stirred at room temperature for 1 hour. Saturated aqueous ammonium chloride was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (183 mg). 1 H-NMR (400MHz, CDCl 3) δ7.37 (d, 1H), 7.25-7.15 (m, 2H), 5.10 (s, 2H), 4.41 (t, 2H), 4.29 (t, 2H), 4.13-4.03 (m, 1H), 3.77 (s, 3H), 1.48 (s, 9H)
[0273] [Step 4] Preparation of intermediate RE-38D The title compound was obtained by a method similar to that of Step 5 of Reference Example 1, except that Intermediate RE-38C was used instead of Intermediate RE-1D. MS (m / z): 348.4 [M−H] -
[0274] [Step 5] Preparation of intermediate RE-38E The title compound was obtained by a method similar to Step 6 of Reference Example 1, except that Intermediate RE-38D was used instead of Intermediate RE-1E and (2S)-2-(trifluoromethyl)pyrrolidine hydrochloride was used instead of 2,2,2-trifluoroethanamine hydrochloride. MS (m / z): 471.3 [M+H] +
[0275] [Step 6] Preparation of Compound RE-38 The title compound was obtained by a method similar to Step 4 of Reference Example 37, except that Intermediate RE-38E was used instead of Intermediate RE-37C. MS (m / z): 371.2 [M+H] +
[0276] Reference Example 39 tert-Butyl 2-[3-(1-{2-[3-(azetidin-3-yl)-1H-indazol-1-yl]acetyl}azetidin-3-yl)-1H-indazol-1-yl]acetate (Compound RE-39)
[0277] [Step 1] Preparation of intermediate RE-39A A mixture of 1-benzyloxycarbonylazetidine-3-carboxylic acid (120 mg), di(pyridin-2-yl)carbonate (100 mg), DMAP (6 mg), and dichloromethane (1.2 mL) was stirred at room temperature for 1 hour. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (94 mg). MS (m / z): 313.1 [M+H] +
[0278] [Step 2] Preparation of intermediate RE-39B A mixture of intermediate RE-39A (630 mg), (2-fluorophenyl)boronic acid (560 mg), triphenylphosphine (160 mg), and 1,4-dioxane (6.7 mL) was degassed and then treated with Pd(OAc). 2 (45 mg) was added, and the mixture was stirred overnight at 50° C. under an argon atmosphere. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (207 mg). MS (m / z): 314.0 [M+H] +
[0279] [Step 3] Preparation of intermediate RE-39C A mixture of intermediate RE-39B (5.50 g), hydrazine monohydrate (4.3 mL), and NMP (35 mL) was stirred at 150° C. overnight. Ice water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (3.26 g). MS (m / z): 308.1 [M+H] +
[0280] [Step 4] Preparation of intermediate RE-39D To a mixture of intermediate RE-39C (1.00 g) and DMF (11 mL), cesium carbonate (1.27 g) and tert-butyl 2-bromoacetate (762 mg) were added under ice-cooling, and the mixture was stirred for 30 minutes. The mixture was then stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (875 mg). MS (m / z): 444.2 [M+Na] +
[0281] [Step 5] Preparation of Compound RE-39 To a mixture of intermediate RE-39D (875 mg) and methanol (21 mL), 5% Pd—C (440 mg) was added and the mixture was stirred overnight at room temperature under a hydrogen atmosphere (0.1 MPa). Insoluble matter was removed by filtration through Celite (registered trademark), and the filtrate was concentrated under reduced pressure to give the title compound (473 mg). MS (m / z): 288.2 [M+H] +
[0282] Reference Example 40 tert-Butyl 4-(1-{2-oxo-2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethyl}-1H-indazol-3-yl)-1,2,3,6-tetrahydropyridine-1-carboxylate (Compound RE-40)
[0283] [Step 1] Preparation of intermediate RE-40A Cesium carbonate (1.27 g) and methyl bromoacetate (1.86 g) were added to a mixture of 3-bromo-1H-indazole (2 g) and DMF (34 mL) under ice-cooling, and the mixture was stirred for 30 minutes. The mixture was then stirred at room temperature for 30 minutes. Saturated aqueous ammonium chloride was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (2.88 g). 1 H-NMR (400MHz, CDCl 3 ) δ7.64 (d, 1H), 7.50-7.44 (m, 1H), 7.32 (d, 1H), 7.27 (t, 1H), 5.13 (s, 2H), 3.75 (s, 3H)
[0284] [Step 2] Preparation of intermediate RE-40B Intermediate RE-40A (200 mg), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (345 mg), sodium carbonate (236 mg), Pd(dppf)Cl 2 ・CH 2 Cl 2A mixture of 1,4-dioxane (91 mg), 1,4-dioxane (1.5 mL), and water (0.5 mL) was degassed and then stirred overnight at 95°C under an argon atmosphere. After insoluble matter was filtered off using Celite (registered trademark), the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (255 mg). MS (m / z): 356.3 [M-H] ―
[0285] [Step 3] Preparation of Compound RE-40 HBTU (162 mg) was added to a mixture of intermediate RE-40B (127 mg), DMF (1.2 mL), DIPEA (0.184 mL), and (2S)-2-(trifluoromethyl)pyrrolidine hydrochloride (75 mg), and the mixture was stirred at room temperature for 4 hours. The reaction mixture was purified by silica gel column chromatography to obtain the title compound (105 mg). MS (m / z): 479.3 [M+H] +
[0286] Reference Example 41 tert-Butyl 4-(1-{[methyl(2,2,2-trifluoroethyl)carbamoyl]methyl}-1H-indazol-3-yl)-1,2,3,6-tetrahydropyridine-1-carboxylate (Compound RE-41) To a mixture of intermediate RE-40B (127 mg), DMF (1.2 mL), DIPEA (0.184 mL), and 2,2,2-trifluoroethanamine hydrochloride (64 mg), HBTU (162 mg) was added and stirred at room temperature overnight. The reaction mixture was purified by silica gel column chromatography to obtain the title compound (104 mg). MS (m / z): 475.2 [M+Na] +
[0287] Reference Example 42 2-[3-(azetidin-3-yl)-5-fluoro-1H-indazol-1-yl]-N-methyl-N-(2,2,2-trifluoroethyl)acetamide trifluoroacetate (Compound RE-42)
[0288] [Step 1] Preparation of intermediate RE-42A The title compound was obtained by a method similar to Step 6 of Reference Example 1, except that Intermediate RE-38D was used instead of Intermediate RE-1E and 2,2,2-trifluoro-N-methylethanamine hydrochloride was used instead of 2,2,2-trifluoro-N-methylethanamine hydrochloride. MS (m / z): 467.2 [M+Na] +
[0289] [Step 2] Preparation of Compound RE-42 The title compound was obtained by a method similar to Step 4 of Reference Example 37, except that Intermediate RE-42A was used instead of Intermediate RE-37C. MS (m / z): 345.1 [M+H] +
[0290] Reference Example 43 2-[3-(azetidin-3-yl)-5,6-difluoro-1H-indazol-1-yl]-N-methyl-N-(2,2,2-trifluoroethyl)acetamide trifluoroacetate (Compound RE-43)
[0291] [Step 1] Preparation of intermediate RE-43A To a mixture of 5,6-difluoro-1H-indazole (513 mg), potassium hydroxide (374 mg), and DMF (1.3 mL), iodine (1.01 g) was added under ice-cooling, and the mixture was stirred at room temperature for 2 hours. A saturated aqueous solution of sodium thiosulfate was added to the reaction mixture, and the resulting precipitate was collected by filtration and washed with water. The mixture was dried to obtain the title compound (899 mg). MS (m / z): 281.0 [M+H] +
[0292] [Step 2] Preparation of intermediate RE-43B Intermediate RE-43B was synthesized starting from intermediate RE-43A according to a procedure similar to that described in Steps 1 to 3 of Reference Example 6 for the preparation of compound RE-6C. MS (m / z): 366.2 [M−H] -
[0293] [Step 3] Preparation of intermediate RE-43C The title compound was obtained by a method similar to Step 6 of Reference Example 1, except that Intermediate RE-43B was used instead of Intermediate RE-1E and 2,2,2-trifluoro-N-methylethanamine hydrochloride was used instead of 2,2,2-trifluoroethanamine hydrochloride. MS (m / z): 485.2 [M+Na] +
[0294] [Step 4] Preparation of Compound RE-43 The title compound was obtained by a method similar to Step 4 of Reference Example 37, except that Intermediate RE-43C was used instead of Intermediate RE-37C. MS (m / z): 363.1 [M+H] +
[0295] Reference Example 44 2-[3-(azetidin-3-yl)-5,6-difluoro-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one trifluoroacetate (Compound RE-44) Compound RE-44 was synthesized starting from intermediate RE-43B according to a procedure similar to that described in Steps 5 to 6 of Reference Example 38 for the preparation of compound RE-38. MS (m / z): 389.2 [M+H] +
[0296] Reference Example 45 2-[3-(3-hydroxyazetidin-3-yl)-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one trifluoroacetate (Compound RE-45)
[0297] [Step 1] Preparation of intermediate RE-45A To a mixture of 1-(tert-butyl) 3-methyl 3-hydroxyazetidine-1,3-dicarboxylate (1.0 g) and DMF (14 mL), 60% sodium hydride (260 mg) was added under ice-cooling and stirred for 50 minutes. Subsequently, benzyl bromide (1.10 g) was added, and the mixture was stirred at room temperature for 5 hours. Saturated aqueous ammonium chloride was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (1.07 g).1 H-NMR (400MHz, CDCl 3 ) δ7.40-7.30 (m, 5H), 4.50 (s, 2H), 4.26 (d, 2H), 4.06 (d, 2H), 3.84 (s, 3H), 1.56 (s, 9H)
[0298] [Step 2] Preparation of intermediate RE-45B To a mixture of intermediate RE-45A (1.07 g), methanol (8 mL), and THF (8 mL), 2M aqueous sodium hydroxide solution was added and stirred at room temperature. The solvent was evaporated under reduced pressure, and the mixture was neutralized with 2M hydrochloric acid and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was washed with hexane and dried to obtain the title compound (866 mg). MS (m / z): 306.1 [M-H] ―
[0299] [Step 3] Preparation of intermediate RE-45C A mixture of intermediate RE-45B (866 mg), N,O-dimethylhydroxylamine (412 mg), 1-hydroxybenzotriazole monohydrate (561 mg), EDCI.HCl (702 mg), DIPEA (1.46 mL), and DMF (9.4 mL) was stirred at room temperature overnight. Saturated aqueous sodium bicarbonate was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (961 mg). MS (m / z): 373.0 [M+H] +
[0300] [Step 4] Preparation of intermediate RE-45D The title compound was obtained by a method similar to that of Step 1 of Reference Example 5, except that 1-fluoro-2-iodobenzene was used instead of 2-bromo-4-chloro-1-fluorobenzene and intermediate RE-45C was used instead of tert-butyl 3-[methoxy(methyl)carbamoyl]azetidine-1-carboxylate. MS (m / z): 286.2 [M-Boc + 2H] + , 1H-NMR (400MHz, DMSO-d6) δ7.75-7.68 (m, 2H), 7.35 (dd, 2H), 7.22-7.20 (m, 3H), 6.93-6.90 (m, 2H), 4.36 (d, 2H), 4.23 (s, 2H), 4.13 (d, 2H), 1.41 (s, 9H)
[0301] [Step 5] Preparation of intermediate RE-45E A mixture of intermediate RE-45D (785 mg), hydrazine monohydrate (0.99 mL), potassium carbonate (844 mg), and DMA (15 mL) was reacted in a microwave reactor at 100°C for 1 hour. Saturated aqueous ammonium chloride was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and methyl bromoacetate (467 mg) was added to a mixture of the resulting residue, cesium carbonate (1.99 g), and DMA (7 mL) under ice-cooling, and the mixture was stirred overnight at room temperature. Saturated aqueous ammonium chloride was added to the reaction mixture, and the mixture was extracted with a mixed solvent of ethyl acetate and hexane. The organic layer was washed with saturated saline and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (709 mg). MS (m / z): 474.3 [M+Na] +
[0302] [Step 6] Preparation of intermediate RE-45F To a mixture of intermediate RE-45E (709 mg) and THF (20 mL), 5% Pd—C (600 mg) was added and the mixture was stirred under a hydrogen atmosphere (0.3 MPa) at 40° C. for 6 hours. After stirring at 50° C. for 11 hours, insoluble matter was filtered off using Celite (registered trademark), the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (425 mg). MS (m / z): 384.2 [M+Na] +
[0303] [Step 7] Preparation of intermediate RE-45G The title compound was obtained by a method similar to that of Step 5 of Reference Example 1, except that Intermediate RE-45F was used instead of Intermediate RE-1D. MS (m / z): 346.1 [M−H] -
[0304] [Step 8] Preparation of intermediate RE-45H EDCI.HCl (132 mg) was added to a mixture of intermediate RE-45G (159 mg), (2S)-2-(trifluoromethyl)pyrrolidine hydrochloride (121 mg), HOBt (93 mg), DIPEA (0.24 mL), and DMF (0.3 mL), and the mixture was stirred at room temperature overnight. Saturated aqueous sodium bicarbonate was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (193 mg). MS (m / z): 491.3 [M+Na] +
[0305] [Step 9] Preparation of Compound RE-45 The title compound was obtained by a method similar to Step 4 of Reference Example 37, except that Intermediate RE-45H was used instead of Intermediate RE-37C. MS (m / z): 369.2 [M+H] +
[0306] Reference Example 46 tert-Butyl 3-fluoro-3-(1-{2-oxo-2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethyl}-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-46) To a mixture of intermediate RE-45H (96 mg) and dichloromethane (4 mL), DAST (50 mg) was added at -78°C and stirred for 3 hours. The mixture was then stirred under ice-cooling for 30 minutes. Saturated sodium bicarbonate water was added to the reaction mixture, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (47 mg). MS (m / z): 493.2 [M+Na] +
[0307] Reference Example 47 2-[3-(azetidin-3-yl)-5-methyl-1H-indazol-1-yl]-N-methyl-N-(2,2,2-trifluoroethyl)acetamide trifluoroacetate (Compound RE-47)
[0308] [Step 1] Preparation of intermediate RE-47A The title compound was obtained by a method similar to Step 6 of Reference Example 1, except that Intermediate RE-37B was used instead of Intermediate RE-1E and 2,2,2-trifluoro-N-methylethanamine hydrochloride was used instead of 2,2,2-trifluoroethanamine hydrochloride. MS (m / z): 463.3 [M+Na] +
[0309] [Step 2] Preparation of Compound RE-47 The title compound was obtained by a method similar to Step 4 of Reference Example 37, except that Intermediate RE-47A was used instead of Intermediate RE-37C. MS (m / z): 341.0 [M+H] + Reference Example 48 tert-Butyl 3-(5-methoxy-1-{2-oxo-2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethyl}-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-48)
[0310] [Step 1] Preparation of intermediate RE-48A Intermediate RE-48A was synthesized starting from 3-iodo-5-methoxy-1H-indazole according to a procedure similar to that described in Steps 1 to 3 of Reference Example 6 for the preparation of Intermediate RE-6C. MS (m / z): 360.2 [M-H] ― [Step 2] Preparation of Compound RE-48 The title compound was obtained by a method similar to Step 6 of Reference Example 1, except that Intermediate RE-48A was used instead of Intermediate RE-1E and (2S)-2-(trifluoromethyl)pyrrolidine hydrochloride was used instead of 2,2,2-trifluoroethanamine hydrochloride. MS (m / z): 505.2 [M+Na] +
[0311] Reference Example 49 2-[3-(azetidin-3-yl)-5,5-dimethyl-4,5,6,7-tetrahydro-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one trifluoroacetate (Compound RE-49)
[0312] [Step 1] Preparation of intermediate RE-49A Intermediate RE-49A was synthesized starting from 3-iodo-5,5-dimethyl-1,4,6,7-tetrahydroindazole (synthesized, for example, according to the method described in Journal of Medicinal Chemistry 2013, 56(4), 1677-1692) according to a procedure similar to that described in Steps 1 to 3 of Reference Example 6 for the preparation of Intermediate RE-6C. MS (m / z): 362.3 [M-H] ―
[0313] [Step 2] Preparation of intermediate RE-49B The title compound was obtained by a method similar to Step 6 of Reference Example 1, except that Intermediate RE-49A was used instead of Intermediate RE-1E and (2S)-2-(trifluoromethyl)pyrrolidine hydrochloride was used instead of 2,2,2-trifluoroethanamine hydrochloride. MS (m / z): 485.4 [M+H] +
[0314] [Step 3] Preparation of Compound RE-49 The title compound was obtained by a method similar to Step 4 of Reference Example 37, except that Intermediate RE-49B was used instead of Intermediate RE-37C. MS (m / z): 385.4 [M+H] +
[0315] Reference Example 50 2-[3-(azetidin-3-yl)-4-chloro-5-fluoro-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one trifluoroacetate (Compound RE-50) To a mixture of intermediate RE-1E (200 mg), HATU (258 mg), (2S)-2-(trifluoromethyl)pyrrolidine hydrochloride (119 mg), and DMF (1.7 mL), DIPEA (0.3 mL) was added and the mixture was stirred at room temperature overnight. The reaction mixture was purified by silica gel column chromatography to give tert-butyl 3-(4-chloro-5-fluoro-1-{2-oxo-2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethyl}-1H-indazol-3-yl)azetidine-1-carboxylate (250 mg). To a mixture of this tert-butyl 3-(4-chloro-5-fluoro-1-{2-oxo-2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethyl}-1H-indazol-3-yl)azetidine-1-carboxylate (250 mg) and dichloromethane (0.5 mL), trifluoroacetic acid (1 mL) was added and stirred at room temperature for 4 hours. The solvent was evaporated under reduced pressure, and to the resulting residue, toluene was added and evaporated under reduced pressure. Then, ethyl acetate and hexane were added, and the solvent was evaporated under reduced pressure to give the title compound (260 mg). MS (m / z): 405.1 [M+H] +
[0316] Reference Example 51 2-[3-(azetidin-3-yl)-4-chloro-5-fluoro-1H-indazol-1-yl]-N-methyl-N-(2,2,2-trifluoroethyl)acetamide trifluoroacetate (Compound RE-51)
[0317] [Step 1] Preparation of intermediate RE-51A The title compound was obtained by a method similar to that of Step 6 of Reference Example 1, except that 2,2,2-trifluoro-N-methylethanamine hydrochloride was used instead of 2,2,2-trifluoroethanamine hydrochloride. MS (m / z): 501.2 [M+Na] +
[0318] [Step 2] Preparation of Compound RE-51 The title compound was obtained by a method similar to Step 4 of Reference Example 37, except that Intermediate RE-51A was used instead of Intermediate RE-37C. MS (m / z): 378.9 [M+H] +
[0319] Reference Example 52 tert-Butyl 3-(4,6-difluoro-1-{[(2,2,2-trifluoroethyl)carbamoyl]methyl}-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-52) The title compound was obtained according to a method similar to that of Step 6 of Reference Example 1, except that Intermediate RE-2E was used instead of Intermediate RE-1E. 1 H-NMR (400MHz, CDCl 3 ) δ6.85 (dd, 1H), 6.71-6.65 (m, 1H), 6.50 (brs, 1H), 4.97 (s, 2H), 4.41-4.35 (m, 2H), 4.30-4.16 (m, 3H), 3.96-3.88 (m, 2H) 1.46 (s, 9H)
[0320] Reference Example 53 2-[3-(azetidin-3-yl)-4,6-difluoro-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]propan-1-one hydrochloride (Compound RE-53) Compound RE-53 was synthesized starting from intermediate RE-2C according to procedures similar to those described in Steps 4 to 7 of Reference Example 2 for the preparation of compound RE-2, using methyl 2-chloropropionate instead of ethyl 2-bromoacetate. MS (m / z): 403.2 [M+H] +
[0321] Reference Example 54 tert-Butyl 3-(4,6-difluoro-1-{1-fluoro-2-oxo-2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethyl}-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-54) Compound RE-54 was synthesized starting from intermediate RE-2C following a procedure similar to that described in Steps 4 to 6 of Reference Example 2 for the preparation of intermediate RE-2F, using ethyl bromofluoroacetate instead of ethyl 2-bromoacetate. MS (m / z): 529.2 [M+Na] +
[0322] Reference Example 55 tert-Butyl 3-{1-[(4,4-difluorocyclohexyl)methyl]-4,6-difluoro-1H-indazol-3-yl}azetidine-1-carboxylate (Compound RE-55) A mixture of intermediate RE-2C (50 mg), (4,4-difluorocyclohexyl)methyl 4-methylbenzenesulfonate (59 mg), cesium carbonate (79 mg), and DMF (0.8 mL) was stirred at room temperature overnight. Saturated aqueous ammonium chloride was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (80 mg). MS (m / z): 342.1 [M-Boc + 2H] +
[0323] Reference Example 56 tert-Butyl 3-[4,6-difluoro-1-(3-phenylprop-2-yn-1-yl)-1H-indazol-3-yl]azetidine-1-carboxylate (Compound RE-56) The title compound was obtained by a method similar to that of Reference Example 55, except that 3-phenylprop-2-yn-1-yl 4-methylbenzenesulfonate was used instead of (4,4-difluorocyclohexyl)methyl 4-methylbenzenesulfonate. MS (m / z): 342.1 [M-Boc + 2H] +
[0324] Reference Example 57 tert-Butyl 3-[1-(3-cyclopropylprop-2-yn-1-yl)-4,6-difluoro-1H-indazol-3-yl]azetidine-1-carboxylate (Compound RE-57) The title compound was obtained by a method similar to that of Reference Example 55, except that 3-cyclopropylprop-2-yn-1-yl 4-methylbenzenesulfonate was used instead of (4,4-difluorocyclohexyl)methyl 4-methylbenzenesulfonate. MS (m / z): 288.2 [M-Boc + 2H] +
[0325] Reference Example 58 tert-Butyl 3-{4,6-difluoro-1-[(1-phenylazetidin-3-yl)methyl]-1H-indazol-3-yl}azetidine-1-carboxylate (Compound RE-58)
[0326] [Step 1] Preparation of intermediate RE-58A A mixture of intermediate RE-2C (300 mg), benzyl 3-(p-toluenesulfonyloxymethyl)azetidine-1-carboxylate (437 mg), cesium carbonate (474 mg), and DMF (3.9 mL) was stirred at room temperature for 4 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The mixture was dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give tert-butyl 3-[1-({1-[(benzyloxy)carbonyl]azetidin-3-yl}methyl)-4,6-difluoro-1H-indazol-3-yl]azetidine-1-carboxylate. A mixture of this tert-butyl 3-[1-({1-[(benzyloxy)carbonyl]azetidin-3-yl}methyl)-4,6-difluoro-1H-indazol-3-yl]azetidine-1-carboxylate, 10% Pd—C (200 mg), hydrogen chloride (2 M methanol solution, 0.04 mL), and methanol (3.9 mL) was stirred under a hydrogen atmosphere at room temperature for 4 hours. The insoluble matter was removed by filtration through Celite (registered trademark), and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give the title compound (270 mg). MS (m / z): 379.2 [M+H] +
[0327] [Step 2] Preparation of Compound RE-58 Intermediate RE-58A (30 mg), bromobenzene (15 mg), Pd(OAc) 2 A mixture of 2 mg of methylpropanol, 9 mg of Xantphos, 52 mg of cesium carbonate, and 0.3 mL of 1,4-dioxane was stirred at 90° C. for 3 hours. The reaction mixture was purified by silica gel column chromatography to give the title compound (6 mg). MS (m / z): 455.3 [M+H] +
[0328] Reference Example 59 tert-Butyl 3-(4,6-difluoro-1-{[1-(2,2,2-trifluoroethyl)azetidin-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-59) To a mixture of intermediate RE-58A (30 mg), DIPEA (0.04 mL), and THF (0.3 mL), (2,2,2-trifluoroethyl)trifluoromethanesulfonate (37 mg) was added, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was purified by silica gel column chromatography to obtain the title compound (10 mg). MS (m / z): 461.2 [M+H] +
[0329] Reference Example 60 tert-Butyl 3-{1-[(2,3-dihydro-1H-inden-2-yl)methyl]-4,6-difluoro-1H-indazol-3-yl}azetidine-1-carboxylate (Compound RE-60) The title compound was obtained by a method similar to that of Reference Example 55, except that indan-2-ylmethyl 4-methylbenzenesulfonate was used instead of (4,4-difluorocyclohexyl)methyl 4-methylbenzenesulfonate. MS (m / z): 340.1 [M-Boc + 2H] +
[0330] Reference Example 61 2-[3-(azetidin-3-yl)-4,6-difluoro-1H-indazol-1-yl]-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one trifluoroacetate (Compound RE-61)
[0331] [Step 1] Preparation of intermediate RE-61A To a mixture of intermediate RE-2E (100 mg), DMF (0.9 mL), DIPEA (0.14 mL), and (2R)-2-(trifluoromethyl)morpholine hydrochloride (63 mg), HBTU (124 mg) was added and stirred at room temperature for 2 hours. The reaction mixture was purified by silica gel column chromatography to obtain the title compound (131 mg). MS (m / z): 405.1 [M-Boc + 2H] +
[0332] [Step 2] Preparation of Compound RE-61 The title compound was obtained by a method similar to Step 4 of Reference Example 37, except that Intermediate RE-61A was used instead of Intermediate RE-37C. MS (m / z): 405.1 [M+H] +
[0333] Reference Example 62 2-[3-(azetidin-3-yl)-4,6-difluoro-1H-indazol-1-yl]-N-methyl-N-(2,2,2-trifluoroethyl)acetamide trifluoroacetate (Compound RE-62) Compound RE-62 was synthesized starting from intermediate RE-2E according to a procedure similar to that described in Steps 1 to 2 of Reference Example 51 for the preparation of compound RE-51. MS (m / z): 363.1 [M+H] +
[0334] Reference Example 63 2-[3-(azetidin-3-yl)-1H-indazol-1-yl]-N-tert-butylacetamide trifluoroacetate (Compound RE-63) Compound RE-63 was synthesized starting from intermediate RE-4C according to a procedure similar to that described in Steps 1 and 2 of Reference Example 61 for the preparation of compound RE-61, using 2-methylpropan-2-amine instead of (2R)-2-(trifluoromethyl)morpholine hydrochloride. MS (m / z): 287.2 [M+H] +
[0335] Reference Example 64 2-[3-(azetidin-3-yl)-1H-indazol-1-yl]-N,N-bis(propan-2-yl)acetamide trifluoroacetate (Compound RE-64) Compound RE-64 was synthesized starting from intermediate RE-4C according to a procedure similar to that described in Steps 1 and 2 of Reference Example 51 for the preparation of compound RE-51, using diisopropylamine instead of 2,2,2-trifluoro-N-methylethanamine hydrochloride. MS (m / z): 315.3 [M+H] +
[0336] Reference Example 65 2-[3-(azetidin-3-yl)-1H-indazol-1-yl]-N-tert-butyl-N-methylacetamide trifluoroacetate (Compound RE-65) Compound RE-65 was synthesized starting from intermediate RE-4C according to a procedure similar to that described in Steps 1 and 2 of Reference Example 51 for the preparation of compound RE-51, using N,2-dimethylpropan-2-amine instead of 2,2,2-trifluoro-N-methylethanamine hydrochloride. MS (m / z): 301.2 [M+H] +
[0337] Reference Example 66 2-[3-(azetidin-3-yl)-1H-indazol-1-yl]-N-methyl-N-(2,2,2-trifluoroethyl)acetamide trifluoroacetate (Compound RE-66)
[0338] [Step 1] Preparation of intermediate RE-66A EDCI.HCl (243 mg) was added to a mixture of intermediate RE-4C (350 mg), 2,2,2-trifluoro-N-methylethanamine hydrochloride (190 mg), 1-hydroxybenzotriazole monohydrate (194 mg), NMM (0.35 mL), and acetonitrile (3 mL), and the mixture was stirred at room temperature overnight. Saturated aqueous sodium bicarbonate was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (280 mg). MS (m / z): 449.3 [M+Na] +
[0339] [Step 2] Preparation of Compound RE-66 The title compound was obtained by a method similar to Step 4 of Reference Example 37, except that Intermediate RE-66A was used instead of Intermediate RE-37C. MS (m / z): 327.2 [M+H] +
[0340] Reference Example 67 tert-Butyl 3-(5-chloro-1-{2-oxo-2-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethyl}-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-67) To a mixture of intermediate RE-5D (115 mg), DMF (1 mL), DIPEA (0.16 mL), and (2R)-2-(trifluoromethyl)morpholine hydrochloride (72 mg), HBTU (143 mg) was added and stirred at room temperature for 2 hours. The reaction mixture was purified by silica gel column chromatography to obtain the title compound (86 mg). MS (m / z): 503.2 [M+H] +
[0341] Reference Example 68 2-[3-(azetidin-3-yl)-5-chloro-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one trifluoroacetate (Compound RE-68) To a mixture of intermediate RE-5D (115 mg), DMF (0.6 mL), DIPEA (0.16 mL), and (2S)-2-(trifluoromethyl)pyrrolidine hydrochloride (66 mg), HATU (143 mg) was added and stirred at room temperature overnight. The reaction solution was purified by silica gel column chromatography to obtain a compound (116 mg). To a mixture of the obtained compound (116 mg) and dichloromethane (2 mL), trifluoroacetic acid (0.5 mL) was added and stirred at room temperature. The solvent was evaporated under reduced pressure to obtain the title compound (119 mg). MS (m / z): 387.1 [M+H] +
[0342] Reference Example 69 2-[3-(azetidin-3-yl)-6-fluoro-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one trifluoroacetate (Compound RE-69) Compound RE-69 was synthesized from intermediate RE-6C according to a procedure similar to that described in Steps 1 and 2 of Reference Example 66 for the preparation of compound RE-66, using (2S)-2-(trifluoromethyl)pyrrolidine hydrochloride instead of 2,2,2-trifluoro-N-methylethanamine hydrochloride. MS (m / z): 371.3 [M+H] +
[0343] Reference Example 70 tert-butyl 3-methyl-3-(1-{[methyl(2,2,2-trifluoroethyl)carbamoyl]methyl}-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-70) To a mixture of intermediate RE-7C (100 mg), DMF (1.0 mL), HBTU (132 mg), and 2,2,2-trifluoro-N-methylethanamine hydrochloride (52 mg), DIPEA (0.15 mL) was added and stirred at room temperature overnight. The reaction mixture was purified by silica gel column chromatography to obtain the title compound (109 mg). MS (m / z): 463.4 [M+Na] +
[0344] Reference Example 71 2-[4-fluoro-3-(piperidin-4-yl)-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (Compound RE-71)
[0345] [Step 1] Preparation of intermediate RE-71A Compound RE-71A was synthesized starting from intermediate RE-10C according to a procedure similar to that described in Steps 4 to 5 of Reference Example 2 for the preparation of intermediate RE-2E. MS (m / z): 376.4 [M−H] ―
[0346] [Step 2] Preparation of Compound RE-71 A mixture of intermediate RE-71A (800 mg), HATU (967 mg), DIPEA (1.1 mL), and DMF (4.2 mL) was stirred at room temperature for 15 minutes. (2S)-2-(trifluoromethyl)pyrrolidine hydrochloride (447 mg) was added, and the mixture was stirred at room temperature overnight. Saturated sodium bicarbonate water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and ethyl acetate (5 mL) and hydrogen chloride (4 M ethyl acetate solution, 0.4 mL) were added to the residue, followed by stirring at room temperature for 2 hours. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (280 mg). MS (m / z): 399.2 [M+H] +
[0347] Reference Example 72 tert-Butyl 4-(4-fluoro-1-{2-oxo-2-[(2S)-2-(trifluoromethyl)morpholin-4-yl]ethyl}-1H-indazol-3-yl)piperidine-1-carboxylate (Compound RE-72) A mixture of intermediate RE-10C (80 mg), HATU (97 mg), DIPEA (0.1 mL), and DMF (0.4 mL) was stirred at room temperature for 15 minutes. (2S)-2-(trifluoromethyl)morpholine hydrochloride (49 mg) was added, and the mixture was stirred at room temperature for 2 hours and 30 minutes. The reaction mixture was purified by silica gel column chromatography to obtain the title compound (70 mg). MS (m / z): 415.2 [M-Boc + 2H] +
[0348] Reference Example 73 tert-Butyl 4-(4-fluoro-1-{2-oxo-2-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethyl}-1H-indazol-3-yl)piperidine-1-carboxylate (Compound RE-73) The title compound was obtained by a method similar to that of Reference Example 72, except that (2R)-2-(trifluoromethyl)morpholine hydrochloride was used instead of (2S)-2-(trifluoromethyl)morpholine hydrochloride. MS (m / z): 537.1 [M+Na] +
[0349] Reference Example 74 tert-Butyl 4-(4-fluoro-1-{[6-(trifluoromethyl)pyridin-3-yl]methyl}-1H-indazol-3-yl)piperidine-1-carboxylate (Compound RE-74) The title compound was obtained by a method similar to that of Step 4 of Reference Example 10, except that 5-(chloromethyl)-2-(trifluoromethyl)pyridine was used instead of 2-(bromomethyl)-5-(trifluoromethyl)pyridine. MS (m / z): 501.2 [M+Na] +
[0350] Reference Example 75 tert-Butyl 4-(4-fluoro-1-{2-oxo-2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethyl}-1H-indol-3-yl)-1,2,3,6-tetrahydropyridine-1-carboxylate (Compound RE-75) Compound RE-75 was synthesized starting from intermediate RE-11A according to a procedure similar to that described in Steps 3 to 5 of Reference Example 11 for the preparation of intermediate RE-11E. MS (m / z): 396.2 [M-Boc + 2H] +
[0351] Reference Example 76 tert-Butyl 4-(4-fluoro-1-{2-oxo-2-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethyl}-1H-indol-3-yl)piperidine-1-carboxylate (Compound RE-76) Compound RE-76 was synthesized starting from intermediate RE-11B according to a procedure similar to that described in Steps 3 to 5 of Reference Example 11 for the preparation of intermediate RE-11E, using (2R)-2-(trifluoromethyl)morpholine hydrochloride instead of (2S)-2-(trifluoromethyl)pyrrolidine hydrochloride. MS (m / z): 536.2 [M+Na] +
[0352] Reference Example 77 tert-Butyl 4-(4-fluoro-1-{2-oxo-2-[(2S)-2-(trifluoromethyl)morpholin-4-yl]ethyl}-1H-indol-3-yl)piperidine-1-carboxylate (Compound RE-77) Compound RE-77 was synthesized starting from intermediate RE-11B according to a procedure similar to that described in Steps 3 to 5 of Reference Example 11 for the preparation of intermediate RE-11E, using (2S)-2-(trifluoromethyl)morpholine hydrochloride instead of (2S)-2-(trifluoromethyl)pyrrolidine hydrochloride. MS (m / z): 536.2 [M+Na] +
[0353] Reference Example 78 2-[3-(azetidin-3-yl)-5-methyl-1H-pyrazolo[4,3-b]pyridin-1-yl]-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one dihydrochloride (Compound RE-78)
[0354] [Step 1] Preparation of intermediate RE-78A The title compound was obtained by a method similar to that of Reference Example 67, except that intermediate RE-13D was used instead of intermediate RE-5D. MS (m / z): 484.2 [M+H] +
[0355] [Step 2] Preparation of Compound RE-78 The title compound was obtained by a method similar to Step 7 of Reference Example 1, except that Intermediate RE-78A was used instead of Intermediate RE-1F. MS (m / z): 384.2 [M+H] +
[0356] Reference Example 79 2-[3-(azetidin-3-yl)-5-methyl-1H-pyrazolo[4,3-b]pyridin-1-yl]-1-(3,3-dimethylmorpholin-4-yl)ethan-1-one dihydrochloride (Compound RE-79)
[0357] [Step 1] Preparation of intermediate RE-79A DIPEA (0.08 mL) was added to a mixture of intermediate RE-13D (52 mg), DMF (1.0 mL), HBTU (74 mg), and 3,3-dimethylmorpholine (22 mg), and the mixture was stirred at room temperature overnight. The reaction mixture was purified by silica gel column chromatography to give the title compound (50 mg). MS (m / z): 444.3 [M+H] +
[0358] [Step 2] Preparation of Compound RE-79 The title compound was obtained by a method similar to Step 7 of Reference Example 1, except that Intermediate RE-79A was used instead of Intermediate RE-1F. MS (m / z): 344.2 [M+H] +
[0359] Reference Example 80 tert-Butyl 3-(4-fluoro-1-{2-oxo-2-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethyl}-1H-pyrazolo[3,4-c]pyridin-3-yl)azetidine-1-carboxylate (Compound RE-80)
[0360] [Step 1] Production of intermediate RE-80A Intermediate RE-80A was synthesized starting from intermediate RE-15C according to a procedure similar to that described in Steps 4 to 5 of Reference Example 1 for the preparation of intermediate RE-1E. MS (m / z): 351.0 [M+H] +
[0361] [Step 2] Preparation of Compound RE-80 The title compound was obtained by a method similar to Step 6 of Reference Example 1, except that Intermediate RE-80A was used instead of Intermediate RE-1E and (2R)-2-(trifluoromethyl)morpholine hydrochloride was used instead of 2,2,2-trifluoroethanamine hydrochloride. MS (m / z): 488.2 [M+H] +
[0362] Reference Example 81 tert-Butyl 3-(4-fluoro-1-{2-oxo-2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethyl}-1H-pyrazolo[3,4-c]pyridin-3-yl)azetidine-1-carboxylate (Compound RE-81) The title compound was obtained by a method similar to Step 6 of Reference Example 1, except that Intermediate RE-80A was used instead of Intermediate RE-1E and (2S)-2-(trifluoromethyl)pyrrolidine hydrochloride was used instead of 2,2,2-trifluoroethanamine hydrochloride. MS (m / z): 472.2 [M+H] +
[0363] Reference Example 82 tert-Butyl 3-(4-fluoro-1-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-1H-pyrazolo[3,4-c]pyridin-3-yl)azetidine-1-carboxylate (Compound RE-82) The title compound was obtained by a method similar to that of Step 4 of Reference Example 10, except that Intermediate RE-15C was used instead of Intermediate RE-10C. MS (m / z): 452.2 [M+H] +
[0364] Reference Example 83 tert-Butyl 3-(4-fluoro-1-{[4-(trifluoromethyl)phenyl]methyl}-1H-pyrazolo[3,4-c]pyridin-3-yl)azetidine-1-carboxylate (Compound RE-83) The title compound was obtained by a method similar to that of Step 4 of Reference Example 10, except that Intermediate RE-15C was used instead of Intermediate RE-10C and 1-(bromomethyl)-4-(trifluoromethyl)benzene was used instead of 2-(bromomethyl)-5-(trifluoromethyl)pyridine. MS (m / z): 451.2 [M+H] +
[0365] Reference Example 84 tert-Butyl 3-(4-fluoro-1-{[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]methyl}-1H-pyrazolo[3,4-c]pyridin-3-yl)azetidine-1-carboxylate (Compound RE-84) The title compound was obtained by a method similar to that of Step 6 of Reference Example 15, except that 2-fluorobenzoic acid was used instead of 1-(trifluoromethyl)cyclopropane-1-carboxylic acid. MS (m / z): 469.2 [M+H] +
[0366] Reference Example 85 tert-Butyl 3-(4-fluoro-1-{[3-(3-fluoropyridin-4-yl)-1,2,4-oxadiazol-5-yl]methyl}-1H-pyrazolo[3,4-c]pyridin-3-yl)azetidine-1-carboxylate (Compound RE-85) HATU (48 mg) was added to a mixture of intermediate RE-80A (40 mg), 3-fluoro-N'-hydroxy-pyridine-4-carboxamide (synthesized, for example, according to the method described in European Journal of Medicinal Chemistry, 2018, vol. 157, pp. 1376-1394) (19 mg), DIPEA (0.02 mL), and DMF (0.4 mL), and the mixture was stirred at room temperature overnight. The mixture was then stirred at 120°C for 2 hours. After cooling, the reaction solution was purified by silica gel column chromatography to obtain the title compound (15 mg). MS (m / z): 470.2 [M+H] +
[0367] Reference Example 86 2-[3-(azetidin-3-yl)-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl]-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one dihydrochloride (Compound RE-86) The title compound was obtained by a method similar to that of Step 7 of Reference Example 1, except that compound RE-80 was used instead of intermediate RE-1F. MS (m / z): 388.1 [M+H] +
[0368] Reference Example 87 2-[3-(azetidin-3-yl)-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl]-1-[(2S)-2-[(trifluoromethoxy)methyl]pyrrolidin-1-yl]ethan-1-one dihydrochloride (Compound RE-87)
[0369] [Step 1] Preparation of intermediate RE-87A DIPEA (0.2 mL) was added to a mixture of intermediate RE-80A (80 mg), DMF (0.8 mL), HBTU (130 mg), and (2S)-2-(trifluoromethoxymethyl)pyrrolidine hydrochloride (56 mg), and the mixture was stirred at room temperature overnight. The reaction mixture was purified by silica gel column chromatography to give the title compound (60 mg). MS (m / z): 502.3 [M+H] +
[0370] [Step 2] Preparation of Compound RE-87 The title compound was obtained by a method similar to Step 7 of Reference Example 1, except that Intermediate RE-87A was used instead of Intermediate RE-1F. MS (m / z): 402.2 [M+H] +
[0371] Reference Example 88 3-(azetidin-3-yl)-1-{[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]methyl}-1H-indazole (Compound RE-88)
[0372] [Step 1] Preparation of intermediate RE-88A Compound RE-88A was synthesized starting from intermediate RE-17B according to a procedure similar to that described in Steps 4 to 5 of Reference Example 15 for the preparation of intermediate RE-15E. MS (m / z): 346.2 [M+H] +
[0373] [Step 2] Preparation of Compound RE-88 A mixture of intermediate RE-88A (99 mg), toluene (2 mL), and trifluoroacetic anhydride (66 mg) was stirred at 60° C. overnight. The reaction mixture was purified by silica gel column chromatography to obtain the title compound (49 mg). MS (m / z): 324.0 [M+H] +
[0374] Reference Example 89 tert-Butyl 3-{4-fluoro-1-[(1-phenyl-1H-1,2,3-triazol-4-yl)methyl]-1H-indazol-3-yl}azetidine-1-carboxylate (Compound RE-89) To a mixture of intermediate RE-18D (74 mg), azidobenzene (54 mg), DMF (2 mL), and methanol (0.2 mL), copper(I) iodide (4 mg) was added, and the mixture was stirred under an argon atmosphere at 60° C. for 3 hours. The reaction solution was diluted with ethyl acetate and washed with saturated brine, and then the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (62 mg). 1 H-NMR (400MHz, CDCl 3) δ7.88 (s, 1H), 7.68 (d, 2H), 7.51-7.46 (m, 2H), 7.45-7.29 (m, 3H), 6.77 (dd, 1H), 5.73 (s, 2H), 4.40-4.30 (m, 4H), 4.29-4.22 (m, 1H), 1.46 (s, 9H)
[0375] Reference Example 90 tert-Butyl 3-{1-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]-4-fluoro-1H-indazol-3-yl}azetidine-1-carboxylate (Compound RE-90) The title compound was obtained by a method similar to that of Reference Example 89, except that azidomethylbenzene was used instead of azidobenzene. 1 H-NMR (400MHz, CDCl 3 ) δ7.39-7.22 (m, 8H), 6.75 (t, 1H), 5.61 (s, 2H), 5.47 (s, 2H), 4.38-4.18 (m, 4H), 4.17-4.10 (m, 1H), 1.47 (s, 9H)
[0376] Reference Example 91 tert-Butyl 3-(4-fluoro-1-{[1-(2,2,2-trifluoroethyl)-1H-1,2,3-triazol-4-yl]methyl}-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-91) The title compound was obtained by a method similar to that of Reference Example 89, except that 2-azido-1,1,1-trifluoroethane was used instead of azidobenzene. MS (m / z): 355.0 [M-Boc + 2H] +
[0377] Reference Example 92 tert-Butyl 3-(1-{[1-(cyclobutylmethyl)-1H-1,2,3-triazol-4-yl]methyl}-4-fluoro-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-92) The title compound was obtained by a method similar to that of Reference Example 89, except that azidomethylcyclobutane was used instead of azidobenzene. MS (m / z): 341.1 [M-Boc + 2H] +
[0378] Reference Example 93 tert-Butyl 3-{4-fluoro-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-1H-indazol-3-yl}azetidine-1-carboxylate (Compound RE-93) To a mixture of intermediate RE-18C (50 mg) and THF (0.6 mL), 60% sodium hydride (5 mg) was added under ice-cooling and stirred for 5 minutes. Then, 5-(chloromethyl)-3-methyl-1,2,4-oxadiazole (30 mg) was added and stirred for 2 hours. Saturated sodium bicarbonate water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (41 mg). MS (m / z): 288.0 [M-Boc + 2H] +
[0379] Reference Example 94 tert-Butyl 3-(4-fluoro-1-{[4-(trifluoromethyl)phenyl]methyl}-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-94) The title compound was obtained by a method similar to Step 4 of Reference Example 10, except that Intermediate RE-18C was used instead of Intermediate RE-10C and 1-(bromomethyl)-4-(trifluoromethyl)benzene was used instead of 2-(bromomethyl)-5-(trifluoromethyl)pyridine. MS (m / z): 350.1 [M-Boc + 2H] +
[0380] Reference Example 95 tert-Butyl 3-(4-fluoro-1-{[3-(trifluoromethyl)phenyl]methyl}-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-95) The title compound was obtained by a method similar to Step 4 of Reference Example 10, except that Intermediate RE-18C was used instead of Intermediate RE-10C and 1-(bromomethyl)-3-(trifluoromethyl)benzene was used instead of 2-(bromomethyl)-5-(trifluoromethyl)pyridine. MS (m / z): 350.1 [M-Boc + 2H] +
[0381] Reference Example 96 tert-Butyl 3-(4-fluoro-1-{[2-(trifluoromethyl)phenyl]methyl}-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-96) The title compound was obtained by a method similar to Step 4 of Reference Example 10, except that Intermediate RE-18C was used instead of Intermediate RE-10C and 1-(bromomethyl)-2-(trifluoromethyl)benzene was used instead of 2-(bromomethyl)-5-(trifluoromethyl)pyridine. MS (m / z): 350.1 [M-Boc + 2H] +
[0382] Reference Example 97 tert-Butyl 3-(4-fluoro-1-{[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]methyl}-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-97) The title compound was obtained by a method similar to Step 4 of Reference Example 10, using Intermediate RE-18C instead of Intermediate RE-10C and 5-(chloromethyl)-3-trifluoromethyl-1,2,4-oxadiazole instead of 2-(bromomethyl)-5-(trifluoromethyl)pyridine. MS (m / z): 342.1 [M-Boc + 2H] +
[0383] Reference Example 98 tert-Butyl 3-(4-fluoro-1-{[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-98)
[0384] [Step 1] Preparation of intermediate RE-98A Intermediate RE-98A was synthesized starting from intermediate RE-18C according to a procedure similar to that described in Steps 4 to 5 of Reference Example 15 for the preparation of intermediate RE-15E. MS (m / z): 364.2 [M+H] +
[0385] [Step 2] Preparation of Compound RE-98 A mixture of intermediate RE-98A (51 mg), 4-fluorobenzoic acid (18 mg), DIPEA (0.02 mL), HATU (54 mg), and DMF (0.4 mL) was stirred at room temperature overnight. The mixture was then stirred at 120°C for 2 hours. After cooling, the reaction mixture was purified by silica gel column chromatography to obtain the title compound (13 mg). MS (m / z): 368.1 [M-Boc+2H] +
[0386] Reference Example 99 tert-Butyl 3-[4-fluoro-1-({5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}methyl)-1H-indazol-3-yl]azetidine-1-carboxylate (Compound RE-99) The title compound was obtained by a method similar to that of Reference Example 98, except that 3-trifluoromethylbenzoic acid was used instead of 4-fluorobenzoic acid. MS (m / z): 418.1 [M-Boc + 2H] +
[0387] Reference Example 100 tert-Butyl 3-(4-fluoro-1-{[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]methyl}-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-100) The title compound was obtained by a method similar to Step 4 of Reference Example 10, using Intermediate RE-18C instead of Intermediate RE-10C and 2-(chloromethyl)-5-trifluoromethyl-1,3,4-oxadiazole instead of 2-(bromomethyl)-5-(trifluoromethyl)pyridine. MS (m / z): 440.2 [M-H] -
[0388] Reference Example 101 tert-Butyl 3-(4-fluoro-1-{[5-(oxan-4-yl)-1,2,4-oxadiazol-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-101) The title compound was obtained by a method similar to that of Reference Example 98, except that tetrahydropyran-4-carboxylic acid was used instead of 4-fluorobenzoic acid. MS (m / z): 358.2 [M-Boc + 2H] +
[0389] Reference Example 102 tert-Butyl 3-[4-fluoro-1-({5-[1-(trifluoromethyl)cyclobutyl]-1,2,4-oxadiazol-3-yl}methyl)-1H-indazol-3-yl]azetidine-1-carboxylate (Compound RE-103) (Compound RE-102) The title compound was obtained by a method similar to that of Reference Example 98, except that 1-(trifluoromethyl)cyclobutanecarboxylic acid was used instead of 4-fluorobenzoic acid. MS (m / z): 518.2 [M+Na] +
[0390] Reference Example 103 tert-Butyl 3-[4-fluoro-1-({5-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-3-yl}methyl)-1H-indazol-3-yl]azetidine-1-carboxylate (Compound RE-103) The title compound was obtained by a method similar to that of Reference Example 98, except that 1-(trifluoromethyl)cyclopropanecarboxylic acid was used instead of 4-fluorobenzoic acid. MS (m / z): 504.2 [M+Na] +
[0391] Reference Example 104 tert-Butyl 3-(4-fluoro-1-{[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-104) The title compound was obtained by a method similar to that of Reference Example 98, except that 2-fluorobenzoic acid was used instead of 4-fluorobenzoic acid. MS (m / z): 368.1 [M-Boc+2H] +
[0392] Reference Example 105 tert-Butyl 3-(4-fluoro-1-{[5-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-105) The title compound was obtained by a method similar to that of Reference Example 98, except that 5-fluoropyridine-2-carboxylic acid was used instead of 4-fluorobenzoic acid. MS (m / z): 369.1 [M-Boc+2H] +
[0393] Reference Example 106 tert-Butyl 3-(4-fluoro-1-{[5-(6-methylpyridazin-3-yl)-1,2,4-oxadiazol-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-106) The title compound was obtained by a method similar to that of Reference Example 98, except that 6-methylpyridazine-3-carboxylic acid was used instead of 4-fluorobenzoic acid. MS (m / z): 366.1 [M-Boc + 2H] +
[0394] Reference Example 107 3-(azetidin-3-yl)-4-fluoro-1-{[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]methyl}-1H-indazole (Compound RE-107) A mixture of intermediate RE-98A (70 mg), toluene (1 mL), and trifluoroacetic anhydride (45 mg) was stirred at 60° C. overnight. Trifluoroacetic anhydride (81 mg) was added and the mixture was stirred at 60° C. for 2 hours. The reaction mixture was purified by silica gel column chromatography to obtain the title compound (13 mg). MS (m / z): 342.1 [M+H] +
[0395] Reference Example 108 2-[3-(azetidin-3-yl)-4-fluoro-1H-indazol-1-yl]-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (Compound RE-108) Compound RE-108 was synthesized starting from intermediate RE-20B according to a procedure similar to that described in Steps 6 to 7 of Reference Example 1 for the preparation of compound RE-1. MS (m / z): 331.5 [M+H] +
[0396] Reference Example 109 tert-Butyl 3-[4-fluoro-1-({3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}methyl)-1H-indazol-3-yl]azetidine-1-carboxylate (Compound RE-109) A mixture of intermediate RE-20B (47 mg), N'-hydroxy-3-(trifluoromethyl)benzamidine (30 mg), DIPEA (0.03 mL), HATU (56 mg), and DMF (0.5 mL) was stirred at room temperature overnight, followed by stirring at 120°C for 2 hours. After cooling, the reaction mixture was purified by silica gel column chromatography to obtain the title compound (45 mg). MS (m / z): 418.1 [M-Boc+2H] +
[0397] Reference Example 110 tert-butyl 3-(4-fluoro-1-{[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]methyl}-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-110) The title compound was obtained by a method similar to that of Reference Example 109, except that 4-fluoro-N'-hydroxybenzamidine was used instead of N'-hydroxy-3-(trifluoromethyl)benzamidine. MS (m / z): 368.1 [M-Boc + 2H] +
[0398] Reference Example 111 tert-Butyl 3-(4-fluoro-1-{[3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl]methyl}-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-111) The title compound was obtained by a method similar to that of Reference Example 109, except that N'-hydroxypyridine-4-carboxamidine was used instead of N'-hydroxy-3-(trifluoromethyl)benzamidine. 1H-NMR (400MHz, CDCl 3 ) δ8.76 (d, 2H), 7.90 (d, 2H), 7.42-7.36 (m, 1H), 7.25 (d, 1H), 6.85 (t, 1H), 5.84 (s, 2H), 4.40-4.30 (m, 4H), 4.29-4.21 (m, 1H), 1.46 (s, 9H)
[0399] Reference Example 112 tert-Butyl 3-{1-[({bicyclo[2.2.1]heptan-2-yl}carbamoyl)methyl]-4-fluoro-1H-indazol-3-yl}azetidine-1-carboxylate (Compound RE-112) The title compound was obtained by a method similar to Step 1 of Reference Example 87, except that Intermediate RE-20B was used instead of Intermediate RE-80A and norbornan-2-amine hydrochloride was used instead of (2S)-2-(trifluoromethoxymethyl)pyrrolidine hydrochloride. MS (m / z): 343.2 [M+H] +
[0400] Reference Example 113 tert-Butyl 3-{1-[({bicyclo[1.1.1]pentan-1-yl}carbamoyl)methyl]-4-fluoro-1H-indazol-3-yl}azetidine-1-carboxylate (Compound RE-113) The title compound was obtained by a method similar to Step 1 of Reference Example 87, except that Intermediate RE-20B was used in place of Intermediate RE-80A and bicyclo[1.1.1]pentan-1-amine was used in place of (2S)-2-(trifluoromethoxymethyl)pyrrolidine hydrochloride. MS (m / z): 413.3 [M-H] -
[0401] Reference Example 114 tert-Butyl 3-(1-{[(2,2-difluoroethyl)carbamoyl]methyl}-4-fluoro-1H-indazol-3-yl)azetidine-1-carboxylate (Compound RE-114) The title compound was obtained by a method similar to Step 1 of Reference Example 87, except that Intermediate RE-20B was used instead of Intermediate RE-80A and 2,2-difluoroethanamine was used instead of (2S)-2-(trifluoromethoxymethyl)pyrrolidine hydrochloride. MS (m / z): 313.1 [M-Boc + 2H] +
[0402] Reference Example 115 4-{4-[4-fluoro-1-(prop-2-yn-1-yl)-1H-indazol-3-yl]piperidine-1-carbonyl}pyridin-2-amine (Compound RE-115) To a mixture of intermediate RE-10C (70 mg) and DMF (0.7 mL), potassium carbonate (45 mg) and propargyl bromide (29 mg) were added and stirred overnight at room temperature. Saturated aqueous ammonium chloride was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and to a mixture of the resulting residue (78 mg) and dichloromethane (2 mL), trifluoroacetic acid (0.5 mL) was added and stirred at room temperature for 3 hours. The solvent was evaporated under reduced pressure, and the resulting residue (81 mg) was dissolved in a small amount of DMF. In a separate container, a mixture of 2-aminopyridine-4-carboxylic acid (24 mg), DMF (1.7 mL), DIPEA (0.2 mL), and HBTU (86 mg) was stirred overnight at room temperature, after which a separately prepared DMF solution of the residue was added, and the mixture was stirred overnight at room temperature. The reaction mixture was purified by silica gel column chromatography to obtain the title compound (65 mg). MS (m / z): 378.2 [M+H] +
[0403] Reference Example 116 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}acetic acid (Compound RE-116)
[0404] [Step 1] Preparation of intermediate RE-116A A mixture of intermediate RE-2D (280 mg), ethanol (2 mL), and hydrogen chloride (2 M ethanol solution, 1.8 mL) was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, and a mixture of the residue, ethanol (2 mL), and hydrogen chloride (2 M ethanol solution, 1.8 mL) was stirred at room temperature overnight. The solvent was then evaporated under reduced pressure, and the resulting residue (220 mg) was dissolved in DMF (2 mL). HBTU (327 mg) was added to a mixture of 2-aminopyridine-4-carboxylic acid (119 mg), DMF (2.2 mL), and DIPEA (0.92 mL) in a separate container, and the mixture was stirred at room temperature for 15 minutes. A separately prepared DMF solution of the residue was then added under ice cooling, and the mixture was stirred at room temperature overnight. The reaction mixture was purified by silica gel column chromatography to give the title compound (130 mg). MS (m / z): 416.1 [M+H] +
[0405] [Step 2] Preparation of Compound RE-116 To a mixture of intermediate RE-116A (343 mg) and methanol (4.1 mL), 2 M aqueous sodium hydroxide solution (0.5 mL) was added under ice-cooling, and the mixture was stirred at room temperature overnight. 2 M hydrochloric acid was added to neutralize the mixture, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (183 mg). MS (m / z): 388.1 [M+H] +
[0406] Reference Example 117 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}acetic acid trifluoroacetate (Compound RE-117)
[0407] [Step 1] Preparation of intermediate RE-117A DIPEA (0.85 mL) was added to a mixture of compound RE-39 (473 mg), compound RE-24 (349 mg), HOBt (289 mg), EDCI.HCl (410 mg), and DMF (5.5 mL), and the mixture was stirred at room temperature for 2 hours. Saturated sodium bicarbonate water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (409 mg). MS (m / z): 426.2 [M+H] +
[0408] [Step 2] Preparation of Compound RE-117 Trifluoroacetic acid (0.5 mL) was added to a mixture of intermediate RE-117A (389 mg) and dichloromethane (2 mL), and the mixture was stirred at room temperature for 1 hour. Trifluoroacetic acid (0.5 mL) was added, and the mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, and toluene was added to the resulting residue, which was evaporated under reduced pressure. Then, ethyl acetate and hexane were added, and the solvent was evaporated under reduced pressure. The residue was washed with diethyl ether and then dried to obtain the title compound (396 mg). MS (m / z): 370.2 [M+H] +
[0409] Reference Example 118 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-indazol-1-yl}acetic acid (Compound RE-118)
[0410] [Step 1] Preparation of intermediate RE-118A A mixture of intermediate RE-20A (300 mg) and hydrogen chloride (2 M ethanol solution, 2 mL) was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, and the resulting residue (232 mg) was dissolved in a small amount of DMF. In a separate vessel, a mixture of 2-aminopyridine-4-carboxylic acid (80 mg), DMF (5.8 mL), DIPEA (0.8 mL), and HBTU (286 mg) was stirred at room temperature for 2 hours, after which a separately prepared DMF solution of the residue was added, and the mixture was stirred at room temperature overnight. Saturated sodium bicarbonate water was added to the reaction solution, and the mixture was extracted with a mixture of ethyl acetate and hexane. The organic layer was washed with water and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give the title compound (83 mg). MS (m / z): 397.8 [M+H] +
[0411] [Step 2] Preparation of Compound RE-118 To a mixture of intermediate RE-118A (83 mg) and methanol (2 mL), 2 M aqueous sodium hydroxide solution (0.1 mL) was added under ice-cooling, and the mixture was stirred at room temperature overnight. 2 M hydrochloric acid was added to neutralize the mixture, and the solvent was evaporated under reduced pressure to give the title compound (77 mg). MS (m / z): 370.0 [M+H] +
[0412] Reference Example 119 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}acetic acid (Compound RE-119) Compound RE-119 was synthesized starting from intermediate RE-2D according to a procedure similar to that described in Steps 1 and 2 of Reference Example 116 for the preparation of compound RE-116, using 2-amino-3-methylpyridine-4-carboxylic acid instead of 2-aminopyridine-4-carboxylic acid. MS (m / z): 402.1 [M+H] +
[0413] Reference Example 120 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}acetic acid (Compound RE-120) Compound RE-120 was synthesized starting from intermediate RE-2D according to a procedure similar to that described in Steps 1 to 2 of Reference Example 116 for the preparation of compound RE-116, using compound RE-24 instead of 2-aminopyridine-4-carboxylic acid. MS (m / z): 406.1 [M+H] +
[0414] Reference Example 121 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}acetic acid (Compound RE-121) Compound RE-121 was synthesized starting from intermediate RE-4B according to a procedure similar to that described in Steps 1 to 2 of Reference Example 116 for the preparation of compound RE-116. MS (m / z): 352.1 [M+H] +
[0415] Reference Example 122 4-{3-[4-fluoro-1-(prop-2-yn-1-yl)-1H-indazol-3-yl]azetidine-1-carbonyl}pyridin-2-amine (Compound RE-122) A mixture of intermediate RE-18D (100 mg) and hydrogen chloride (4 M 1,4-dioxane solution, 2 mL) was stirred at room temperature for 3 hours. The solvent was evaporated under reduced pressure, and the resulting residue (80 mg) was dissolved in a small amount of DMF. In a separate vessel, a mixture of 2-aminopyridine-4-carboxylic acid (32 mg), DMF (2.3 mL), DIPEA (0.4 mL), and HBTU (114 mg) was stirred at room temperature for 2 hours, after which a separately prepared DMF solution of the residue was added, and the mixture was stirred at room temperature for 4 hours. The reaction solution was purified by silica gel column chromatography to obtain the title compound (34 mg). MS (m / z): 350.1 [M+H] +
[0416] Example 1 2-(4-chloro-3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-5-fluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (Compound E-1) [Step 1] Preparation of 2-(4-chloro-3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-5-fluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide (Compound E-1A) To a mixture of compound RE-1 (30 mg) obtained in Step 7 of Reference Example 1, compound RE-23 (16 mg) obtained in Step 2 of Reference Example 23, DMF (1 mL), and DIPEA (0.091 mL), HATU (37 mg) was added and stirred at room temperature for 1.5 hours. The reaction solution was purified by silica gel column chromatography to obtain the title compound (15 mg).
[0417] [Step 2] Preparation of Compound E-1 Compound E-1A (15 mg) was dissolved in methanol (2 mL), and 1 M hydrochloric acid (0.032 mL) was added thereto, followed by stirring at room temperature for 5 minutes. The solvent was evaporated under reduced pressure to give the title compound (13 mg). MS (m / z): 525.5 [M+H] + Elemental analysis value (C 23 H 21 ClF 4 N 6 O 2 HCl + 1.3H 2 Calculated values (%): C: 47.24, H: 4.24, N: 14.37 Measured values (%): C: 47.37, H: 4.58, N: 13.98
[0418] Example 2 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (Compound E-2) [Step 1] Preparation of 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (Compound E-2A) DIPEA (0.098 mL) was added to a mixture of 2-aminopyridine-4-carboxylic acid (13 mg), HBTU (35 mg), and DMF (1 mL), and the mixture was stirred at room temperature for 15 minutes. Compound RE-2 (30 mg) obtained in Step 7 of Reference Example 2 was added thereto, and the mixture was stirred at room temperature for 3 hours. The reaction solution was purified by silica gel column chromatography to obtain the title compound (34 mg).
[0419] [Step 2] Preparation of Compound E-2 Compound E-2A (34 mg) was dissolved in methanol (2 mL), and 1 M hydrochloric acid (0.074 mL) was added thereto, followed by stirring at room temperature for 5 minutes. The solvent was evaporated under reduced pressure to give the title compound (28 mg). MS (m / z): 509.1 [M+H] + Optical rotation [α] 58925 = -4.7° (0.01 g, methanol, 1 mL, 50 mm) Elemental analysis value (C 23 H 21 F 5 N 6 O 2 HCl + 1.2H 2 Calculated values (%): C: 48.76, H: 4.34, N: 14.83 Measured values (%): C: 48.50, H: 4.73, N: 14.68
[0420] Example 3 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (Compound E-3) To a mixture of compound RE-4 (20 mg) obtained in Step 5 of Reference Example 4, compound RE-24 (9.1 mg) obtained in Reference Example 24, HOBt (7.5 mg), EDCI.HCl (10.7 mg), and DMF (0.5 mL), DIPEA (0.022 mL) was added and stirred overnight at room temperature. The reaction mixture was purified by silica gel column chromatography to obtain the title compound (12 mg). MS (m / z): 491.1 [M+H] +
[0421] Example 4 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-5-chloro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (Compound E-4) The title compound (24 mg) was obtained by a method similar to that described in Example 3, except that compound RE-5 (43 mg) obtained in Step 6 of Reference Example 5 was used instead of compound RE-4, and 2-aminopyrimidine-4-carboxylic acid (15 mg) was used instead of compound RE-24. MS (m / z): 482.3 [M+H] +
[0422] Example 5 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-6-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (Compound E-5) The title compound (32 mg) was obtained by a method similar to that of Example 3, except that compound RE-6 (40 mg) obtained in Step 5 of Reference Example 6 was used instead of compound RE-4. MS (m / z): 483.3 [M+H] +
[0423] Example 6 2-{3-[1-(2-aminopyridine-4-carbonyl)-3-methylazetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (Compound E-6) The title compound (7 mg) was obtained by a method similar to that of Step 1 of Example 2, except that Compound RE-7 (55 mg) obtained in Step 5 of Reference Example 7 was used instead of Compound RE-2. MS (m / z): 487.4 [M+H] +
[0424] Example 7 2-{3-[1-(2-amino-4-methyl-1,3-thiazole-5-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-(3,3-dimethylmorpholin-4-yl)ethan-1-one (Compound E-7) The procedure described in Example 3 was repeated except that Compound RE-8 (15 mg) obtained in Step 2 of Reference Example 8 was used instead of Compound RE-4, and 2-amino-4-methyl-1,3-thiazole-5-carboxylic acid (5.9 mg) was used instead of Compound RE-24 to give the title compound (12 mg). MS (m / z): 469.2 [M+H] +
[0425] Example 8 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (Compound E-8) The procedure was carried out in accordance with Step 1 of Example 2, except that Compound RE-9 (20 mg) obtained in Step 2 of Reference Example 9 was used instead of Compound RE-2, and Compound RE-25 (14 mg) obtained in Step 3 of Reference Example 25 was used instead of 2-aminopyridine-4-carboxylic acid to give the title compound (15 mg). MS (m / z): 503.2 [M+H] +
[0426] Example 9 4-[4-(4-fluoro-1-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-1H-indazol-3-yl)piperidine-1-carbonyl]pyridin-2-amine (Compound E-9) The title compound (25 mg) was obtained by a method similar to that of Step 1 of Example 2, except that Compound RE-10 (35 mg) obtained in Step 5 of Reference Example 10 was used instead of Compound RE-2. MS (m / z): 499.3 [M+H] +
[0427] Example 10 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)piperidin-4-yl]-4-fluoro-1H-indol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (Compound E-10) The title compound (17 mg) was obtained by a method similar to that of Example 3, except that compound RE-11 (46 mg) obtained in Step 6 of Reference Example 11 was used instead of compound RE-4. MS (m / z): 536.3 [M+H] +
[0428] Example 11 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (Compound E-11) To a mixture of compound RE-12 (50 mg) obtained in Step 5 of Reference Example 12 and ethyl acetate (0.4 mL), hydrogen chloride (4 M ethyl acetate solution, 0.14 mL) was added and the mixture was stirred at room temperature for 2 hours. The solvent was evaporated under reduced pressure to give 2-[3-(azetidin-3-yl)-1H-indol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride. Subsequently, the title compound (14 mg) was obtained by a method similar to Step 1 of Example 2, except that 2-[3-(azetidin-3-yl)-1H-indol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride obtained above was used instead of compound RE-2. MS (m / z): 472.3 [M+H] +
[0429] Example 12 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-5-methyl-1H-pyrazolo[4,3-b]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (Compound E-12) To a mixture of compound RE-13 (100 mg) obtained in Step 6 of Reference Example 13 and methanol (1 mL), hydrogen chloride (2 M methanol solution, 0.53 mL) was added and the mixture was stirred at room temperature overnight. Hydrogen chloride (2 M methanol solution, 0.53 mL) was added to the remaining starting material, and the mixture was stirred at room temperature for 7 hours. Further hydrogen chloride (2 M methanol solution, 0.53 mL) was added, and the mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure to give 2-[3-(azetidin-3-yl)-5-methyl-1H-pyrazolo[4,3-b]pyridin-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride. Subsequently, in a manner similar to Step 1 of Example 2, the title compound (12 mg) was obtained using 2-[3-(azetidin-3-yl)-5-methyl-1H-pyrazolo[4,3-b]pyridin-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (33 mg) obtained above instead of compound RE-2. MS (m / z): 488.2 [M+H] +
[0430] Example 13 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-pyrazolo[4,3-c]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (Compound E-13) [Step 1] Preparation of 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-pyrazolo[4,3-c]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (compound E-13A) The title compound (22 mg) was obtained by a method similar to that of Step 1 of Example 2, except that Compound RE-14 (30 mg) obtained in Step 8 of Reference Example 14 was used instead of Compound RE-2.
[0431] [Step 2] Preparation of Compound E-13 The title compound (18 mg) was obtained by a method similar to Step 2 of Example 2, except that Compound E-13A (22 mg) was used instead of Compound E-2A. MS (m / z): 474.2 [M+H] +
[0432] Example 14 4-{3-[4-fluoro-1-({5-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-3-yl}methyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]azetidine-1-carbonyl}pyridin-2-amine (Compound E-14) The title compound (22.3 mg) was obtained by a method similar to that of Step 1 of Example 2, except that Compound RE-15 (27.5 mg) obtained in Step 7 of Reference Example 15 was used instead of Compound RE-2. MS (m / z): 503.2 [M+H] +
[0433] Example 15 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-methyl-1H-pyrazolo[3,4-b]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (Compound E-15) The title compound (27 mg) was obtained by a method similar to that of Step 1 of Example 2, except that Compound RE-16 (43 mg) obtained in Step 7 of Reference Example 16 was used instead of Compound RE-2. MS (m / z): 488.1 [M+H] +
[0434] Example 16 2-{3-[1-(6-aminopyridazine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (Compound E-16) The title compound (5 mg) was obtained by a method similar to that of Step 1 of Example 2, except that Compound RE-3 (20 mg) obtained in Reference Example 3 was used instead of Compound RE-2, and 6-aminopyridazine-4-carboxylic acid (8.3 mg) was used instead of 2-aminopyridine-4-carboxylic acid. MS (m / z): 510.3 [M+H] +
[0435] Example 17 2-[4,6-difluoro-3-(1-{1H-pyrazolo[3,4-b]pyridine-4-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (Compound E-17) To a mixture of 1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid (7.8 mg), EDCI.HCl (9.2 mg), HOBt (6.5 mg), and DMF (0.5 mL), DIPEA (0.021 mL) was added and stirred at room temperature for 10 minutes. Compound RE-3 (20 mg) obtained in Reference Example 3 was added thereto and stirred at room temperature for 3 hours. The reaction solution was purified by silica gel column chromatography to obtain the title compound (8 mg). MS (m / z): 534.3 [M+H] +
[0436] Example 18 5-fluoro-4-[3-(1-{[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (Compound E-18) The title compound (12 mg) was obtained by a method similar to that of Step 1 of Example 2, except that Compound RE-17 (49 mg) obtained in Step 4 of Reference Example 17 was used instead of Compound RE-2, and Compound RE-24 (32 mg) obtained in Reference Example 24 was used instead of 2-aminopyridine-4-carboxylic acid. MS (m / z): 462.2 [M+H] +
[0437] Example 19 4-{3-[1-({1-[(3,3-difluorocyclobutyl)methyl]-1H-1,2,3-triazol-4-yl}methyl)-4-fluoro-1H-indazol-3-yl]azetidine-1-carbonyl}pyridin-2-amine hydrochloride (Compound E-19) [Step 1] Preparation of 4-{3-[1-({1-[(3,3-difluorocyclobutyl)methyl]-1H-1,2,3-triazol-4-yl}methyl)-4-fluoro-1H-indazol-3-yl]azetidine-1-carbonyl}pyridin-2-amine (compound E-19A) By a method similar to Step 7 of Reference Example 1, 3-(azetidin-3-yl)-1-({1-[(3,3-difluorocyclobutyl)methyl]-1H-1,2,3-triazol-4-yl}methyl)-4-fluoro-1H-indazole hydrochloride was obtained using compound RE-18 (56 mg) instead of intermediate RE-1F. Subsequently, by a method similar to Step 1 of Example 2, the title compound (14 mg) was obtained by using the 3-(azetidin-3-yl)-1-({1-[(3,3-difluorocyclobutyl)methyl]-1H-1,2,3-triazol-4-yl}methyl)-4-fluoro-1H-indazole hydrochloride obtained above instead of compound RE-2.
[0438] [Step 2] Preparation of Compound E-19 The title compound (5.4 mg) was obtained by a method similar to Step 2 of Example 2, except that Compound E-19A (14 mg) was used instead of Compound E-2A. MS (m / z): 497.1 [M+H] +
[0439] Example 20 4-[3-(4-fluoro-1-{[5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (Compound E-20) The title compound (53 mg) was obtained by a method similar to that of Step 1 of Example 2, except that Compound RE-19 (67 mg) obtained in Step 2 of Reference Example 19 was used instead of Compound RE-2. MS (m / z): 488.2 [M+H] +
[0440] Example 21 2-{3-[1-(2-amino-5-fluoropyrimidine-4-carbonyl)azetidin-3-yl]-5-chloro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (Compound E-21) The title compound (6 mg) was obtained by a method similar to that described in Example 3, except that compound RE-5 (43 mg) obtained in Step 6 of Reference Example 5 was used instead of compound RE-4, and compound RE-26 (17 mg) obtained in Step 3 of Reference Example 26 was used instead of compound RE-24. MS (m / z): 500.3 [M+H]+
[0441] Example 22 2-{3-[1-(2-amino-5-fluoropyrimidine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (Compound E-22) The title compound (22 mg) was obtained by a method similar to that of Example 3, except that compound RE-26 (16 mg) obtained in Step 3 of Reference Example 26 was used instead of compound RE-24. MS (m / z): 492.2 [M+H] +
[0442] Example 23 2-{3-[1-(2-amino-5-fluoropyrimidine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (Compound E-23) The title compound (19 mg) was obtained by a method similar to that described in Example 3, except that compound RE-20 (41 mg) obtained in Step 4 of Reference Example 20 was used instead of compound RE-4, and compound RE-26 (17 mg) obtained in Step 3 of Reference Example 26 was used instead of compound RE-24. MS (m / z): 484.3 [M+H] +
[0443] Example 24 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,5,6,7-tetrahydro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (Compound E-24) The title compound (9 mg) was obtained by a method similar to that of Example 3, except that compound RE-21 (16 mg) obtained in Step 6 of Reference Example 21 was used instead of compound RE-4. MS (m / z): 495.3 [M+H] +
[0444] Example 25 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5,5-difluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (Compound E-25) The title compound (40 mg) was obtained by a method similar to that of Example 3, except that compound RE-22 (62 mg) obtained in Step 8 of Reference Example 22 was used instead of compound RE-4. MS (m / z): 531.3 [M+H] +
[0445] Example 26 2-(4-chloro-3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-5-fluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide p-toluenesulfonate (Compound E-26) Compound E-1A (145 mg) was dissolved in THF (10 mL) with heating, and p-toluenesulfonic acid monohydrate (58 mg) was added and stirred at room temperature for 5 minutes. The solvent was evaporated under reduced pressure, and the residue was washed with a mixture of methanol and diethyl ether and dried to obtain the title compound (150 mg). MS (m / z): 525.4 [M+H] + Elemental analysis value (C 23 H 21 ClF 4 N 6 O 2 ・C 7 H 8 O 3 S+2.7H 2 Calculated values (%): C: 48.32, H: 4.65, N: 11.27 Measured values (%): C: 48.35, H: 4.44, N: 10.95
[0446] Example 27 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one methanesulfonate (Compound E-27) Compound E-2A (1.80 g) was dissolved in THF (36 mL) with heating, and methanesulfonic acid (344 mg) was added at room temperature, followed by stirring at room temperature for 1 hour. The solvent was evaporated under reduced pressure, and the residue was dissolved in acetonitrile with heating. The precipitated solid was allowed to cool, filtered, and dried to obtain the title compound (1.45 g). MS (m / z): 509.3 [M+H] + 1 H-NMR (400MHz, DMSO-D 6 ) δ8.01 (d, 1H), 8.00 (brs, 1H), 7.38 (d, 1H), 7.12 (s, 1H), 7.04 (t, 1H), 6.95 (d, 1H), 5.44 (s, 2H), 4.81 -4.69 (m, 2H), 4.60-4.45 (m, 2H), 4.43-4.30 (m, 2H), 3.80-3.70 (m, 1H), 2.32 (s, 3H), 2.11-2.00 (m, 4H) Optical rotation [α] 589 25 = -4.4° (0.01 g, methanol, 1 mL, 50 mm) Elemental analysis value (C 23 H 21 F 5 N 6 O 2 ・CH 4 O 3 S+0.5H 2 Calculated values (%): C: 46.98, H: 4.27, N: 13.70 Measured values (%): C: 46.73, H: 3.89, N: 13.62
[0447] Example 28 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (Compound E-28) The title compound was obtained by a method similar to Step 2 of Example 2, except that Compound E-3 was used instead of Compound E-2A. MS (m / z): 474.2 [M+H] + Optical rotation [α] 589 25 = -2.78° (0.01 g, methanol, 1 mL, 50 mm) Elemental analysis value (C 23 H 22 F 4 N 6 O2 HCl + 0.9H 2 Calculated values (%): C: 50.86, H: 4.60, N: 15.47 Measured values (%): C: 51.13, H: 4.75, N: 15.14
[0448] Example 29 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one methanesulfonate (Compound E-29) Compound E-3 (50 mg) was dissolved in THF (2 mL), methanesulfonic acid (11 mg) was added, and the mixture was stirred at room temperature for 30 minutes. The solvent was evaporated under reduced pressure, and the residue was washed with a mixture of methanol and diethyl ether. The resulting product was dissolved in methanol, and the solvent was evaporated under reduced pressure. The residue was washed with a mixture of 2-propanol and hexane, and dried to give the title compound (22 mg). MS (m / z): 491.2 [M+H] + Optical rotation [α]589 20 : -2.2° (0.3 g, methanol, 10 mL, 100 mm) Elemental analysis value (C 23 H 22 F 4 N 6 O 2 ・CH 4 O 3 S) Calculated values (%) C: 49.14, H: 4.47, N: 14.33 Measured values (%) C: 49.10, H: 4.50, N: 14.36
[0449] Example 30 2-(3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-4,6-difluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (Compound E-30)
[0450] [Step 1] Preparation of 2-(3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-4,6-difluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide (Compound E-30A) Compound RE-52 (125 mg) was dissolved in methanol (1 mL), hydrogen chloride (2 M methanol solution, 1 mL) was added, and the mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, and HATU (59 mg) was added to a mixture of the obtained residue (50 mg), compound RE-23 (28 mg), DIPEA (0.16 mL), and DMF (1 mL) at room temperature, and the mixture was stirred at room temperature overnight. The reaction solution was purified by silica gel column chromatography to obtain the title compound (32 mg). [Step 2] Preparation of Compound E-30 The title compound was obtained by a method similar to Step 2 of Example 2, using compound E-30A instead of compound E-2A. MS (m / z): 509.5 [M+H] +
[0451] Example 31 2-(3-{1-[6-(cyclopropylamino)pyrimidine-4-carbonyl]azetidin-3-yl}-4,6-difluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide (Compound E-31) [Step 1] Preparation of 6-(cyclopropylamino)pyrimidine-4-carboxylic acid trifluoroacetate A mixture of compound RE-27 (46 mg), dichloromethane (2 mL), and trifluoroacetic acid (1 mL) was stirred at room temperature overnight. The solvent was evaporated under reduced pressure to give the title compound (56 mg). [Step 2] Preparation of compound E-31 Compound RE-52 (125 mg) was dissolved in methanol (1 mL), and hydrogen chloride (2 M methanol solution, 1 mL) was added, followed by stirring at room temperature overnight. The solvent was evaporated under reduced pressure, and HBTU (30 mg) was added to a mixture of the resulting residue (20 mg), 6-(cyclopropylamino)pyrimidine-4-carboxylic acid trifluoroacetate (23 mg), DIPEA (0.04 mL), and DMF (1 mL) at room temperature, followed by stirring at room temperature for 3 hours. The reaction solution was purified by silica gel column chromatography to give the title compound (16 mg). MS (m / z): 510.1 [M+H] +
[0452] Example 32 2-[4,6-difluoro-3-(1-{2-[(oxetan-3-yl)amino]pyridine-4-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-N-(2,2,2-trifluoroethyl)acetamide (Compound E-32)
[0453] [Step 1] Preparation of 2-{3-[1-(2-bromopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-N-(2,2,2-trifluoroethyl)acetamide (Compound E-32A) Compound RE-52 (125 mg) was dissolved in methanol (1 mL), hydrogen chloride (2 M methanol solution, 1 mL) was added, and the mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, and the resulting residue (84 mg) was dissolved in DMF (2 mL). In a separate container, DIPEA (0.1 mL) was added to a mixture of 2-bromopyridine-4-carboxylic acid (57 mg), HBTU (108 mg), and DMF (3 mL), and the mixture was stirred at room temperature for 15 minutes. A separately prepared DMF solution of the residue was added, and the mixture was stirred at room temperature overnight. The reaction solution was purified by silica gel column chromatography to obtain the title compound (72 mg). MS (m / z): 532.0 [M+H] +
[0454] [Step 2] Preparation of Compound E-32 A mixture of compound E-32A (25 mg), rac-BINAP (18 mg), cesium carbonate (46 mg), 3-oxetanamine (10 mg), and 1,4-dioxane (2 mL) was degassed with argon and then treated with Pd(OAc) 2 (2 mg) was added and the mixture was stirred at 100° C. for 3 hours. Insoluble matter was filtered off through Celite (registered trademark), the solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (3 mg). MS (m / z): 525.1 [M+H] +
[0455] Example 33 2-[4,6-difluoro-3-(1-{1H-pyrrolo[2,3-b]pyridine-4-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (Compound E-33)
[0456] [Step 1] Preparation of 2-[4,6-difluoro-3-(1-{1H-pyrrolo[2,3-b]pyridine-4-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (Compound E-33A) A mixture of 1H-pyrrolo[2,3-b]pyridine-4-carboxylic acid (17 mg), HOBt (14 mg), DIPEA (0.05 mL), DMF (0.3 mL), and EDCI.HCl (20 mg) was stirred at room temperature for 10 minutes, and then compound RE-2 (30 mg) was added and stirred at room temperature for 1 hour. The reaction solution was purified by silica gel column chromatography to obtain the title compound (37 mg).
[0457] [Step 2] Preparation of Compound E-33 The title compound was obtained by a method similar to Step 2 of Example 2, except that Compound E-33A was used instead of Compound E-2A. MS (m / z): 533.2 [M+H] +
[0458] Example 34 4-(3-{4-fluoro-1-[(1-phenyl-1H-1,2,3-triazol-4-yl)methyl]-1H-indazol-3-yl}azetidine-1-carbonyl)pyridin-2-amine (Compound E-34)
[0459] [Step 1] Preparation of tert-butyl N-[4-(3-{4-fluoro-1-[(1-phenyl-1H-1,2,3-triazol-4-yl)methyl]-1H-indazol-3-yl}azetidine-1-carbonyl)pyridin-2-yl]carbamate (Compound E-34A) A mixture of compound RE-89 (62 mg) and hydrogen chloride (2 M ethanol solution, 2 mL) was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, and the resulting residue (49 mg) was dissolved in a small amount of DMF. A separately prepared DMF solution of the residue was added to a mixture of 2-(tert-butoxycarbonylamino)pyridine-4-carboxylic acid (39 mg), DMF (5.4 mL), DIPEA (0.2 mL), and HATU (62 mg) in a separate container, and the mixture was stirred at room temperature overnight. The reaction solution was purified by silica gel column chromatography to obtain the title compound (48 mg). MS (m / z): 569.2 [M+H] +
[0460] [Step 2] Preparation of Compound E-34 A mixture of compound E-34A (48 mg) and hydrogen chloride (2 M 1,4-dioxane solution, 2 mL) was stirred at room temperature for 6 hours. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (14 mg). MS (m / z): 469.2 [M+H] +
[0461] Example 35 4-(3-{1-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]-4-fluoro-1H-indazol-3-yl}azetidine-1-carbonyl)pyridin-2-amine hydrochloride (Compound E-35)
[0462] [Step 1] Preparation of tert-butyl N-[4-(3-{1-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]-4-fluoro-1H-indazol-3-yl}azetidine-1-carbonyl)pyridin-2-yl]carbamate (Compound E-35A) The title compound was obtained by a method similar to that in Step 1 of Example 34, except that Compound RE-90 was used instead of Compound RE-89. MS (m / z): 583.3 [M+H] +
[0463] [Step 2] Preparation of Compound E-35 A mixture of compound E-35A (141 mg), hydrogen chloride (4 M in 1,4-dioxane, 2 mL), and 1,4-dioxane (2 mL) was stirred at room temperature overnight. 4 M hydrochloric acid (3 mL) was added and the mixture was stirred. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (64 mg). MS (m / z): 483.2 [M+H] +
[0464] Example 36 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]ethan-1-one (Compound E-36) DMTMM (21 mg) was added to a mixture of compound RE-116 (20 mg), D-prolinol (8 mg), DIPEA (0.03 mL), and methanol (0.5 mL), and the mixture was stirred at room temperature overnight. The reaction mixture was purified by silica gel column chromatography to obtain the title compound (5 mg). MS (m / z): 471.2 [M+H] +
[0465] Example 37 4-[3-(1-{[1-(cyclopropylmethyl)-1H-1,2,3-triazol-4-yl]methyl}-4-fluoro-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine hydrochloride (Compound E-37)
[0466] [Step 1] Preparation of 4-[3-(1-{[1-(cyclopropylmethyl)-1H-1,2,3-triazol-4-yl]methyl}-4-fluoro-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (compound E-37A) To a mixture of compound RE-122 (120 mg), azidomethylcyclopropane (83 mg), DMF (2 mL), and methanol (0.2 mL), copper(I) iodide (7 mg) was added, and the mixture was stirred overnight at 60° C. under an argon atmosphere. The reaction solution was purified by silica gel column chromatography to obtain the title compound (28 mg). MS (m / z): 447.2 [M+H]+
[0467] [Step 2] Preparation of Compound E-37 A mixture of compound E-37A (28 mg), 4 M hydrochloric acid (0.02 mL), and 1,4-dioxane (2 mL) was stirred at room temperature for 20 minutes. The solvent was evaporated under reduced pressure, and the residue was dried to give the title compound (14 mg). MS (m / z): 447.2 [M+H] +
[0468] Example 38 4-{3-[4-fluoro-1-({1-[(oxetan-3-yl)methyl]-1H-1,2,3-triazol-4-yl}methyl)-1H-indazol-3-yl]azetidine-1-carbonyl}pyridin-2-amine (Compound E-38) The title compound was obtained by a method similar to that of Step 1 of Example 37, except that 3-(azidomethyl)oxetane was used instead of azidomethylcyclopropane. MS (m / z): 463.2 [M+H] +
[0469] Example 39 4-{4-[1-({1-[(3,3-difluorocyclobutyl)methyl]-1H-1,2,3-triazol-4-yl}methyl)-4-fluoro-1H-indazol-3-yl]piperidine-1-carbonyl}pyridin-2-amine (Compound E-39) The title compound was obtained by a method similar to that of Step 1 of Example 37, except that compound RE-115 was used instead of compound RE-122 and 3-(azidomethyl)-1,1-difluorocyclobutane was used instead of azidomethylcyclopropane. MS (m / z): 525.3 [M+H] +
[0470] Example 40 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (Compound E-40) The title compound was obtained by a method similar to that of Step 1 of Example 2, except that Compound RE-4 was used instead of Compound RE-2. MS (m / z): 473.2 [M+H] +
[0471] Example 41 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (Compound E-41) Compound E-40 (3.2 g) was dissolved in methanol (23 mL), and 2 M hydrochloric acid (3.6 mL) was added, followed by stirring at room temperature for 10 minutes. The solvent was evaporated under reduced pressure, and the residue was dissolved in 2-propanol. Hexane was added, and the precipitated solid was collected by filtration. The mixture was dried under reduced pressure to obtain the title compound (3.47 g). MS (m / z): 473.2 [M+H] + [α] 589 25 : -3.93° (0.02 g, methanol, 5 mL, 100 mm) Elemental analysis value (C 23 H 23 F 3 N 6 O 2 HCl + 3H 2 Calculated values (%): C: 49.07, H: 5.37, N: 14.93 Measured values (%): C: 49.54, H: 5.81, N: 14.51
[0472] Example 42 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (Compound E-42) The title compound was obtained by a method similar to that of Example 3, except that compound RE-61 was used instead of compound RE-4. MS (m / z): 543.2 [M+H] +
[0473] Example 43 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one p-toluenesulfonate (Compound E-43) Compound E-42 (32 mg) was dissolved in THF (2 mL), and p-toluenesulfonic acid monohydrate (13 mg) was added thereto and stirred at room temperature for 1 hour. The precipitated solid was collected by filtration and dried under reduced pressure to obtain the title compound (36 mg). MS (m / z): 543.2 [M+H] + [α] 589 25 = +7.42° (0.001 g, methanol, 1 mL, 100 mm) Elemental analysis value (C 23 H 20 F 6 N 6 O 3 ・C 7 H 8 O 3 S+1.4H 2 Calculated values (%): C: 48.70, H: 4.20, N: 11.36 Measured values (%): C: 49.01, H: 4.05, N: 10.89
[0474] Example 44 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2S)-2-[(trifluoromethoxy)methyl]pyrrolidin-1-yl]ethan-1-one di-p-toluenesulfonate (Compound E-44)
[0475] [Step 1] Preparation of 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2S)-2-[(trifluoromethoxy)methyl]pyrrolidin-1-yl]ethan-1-one (Compound E-44A) A mixture of Compound RE-25 (14 mg), HBTU (20 mg), DIPEA (0.07 mL), and DMF (1 mL) was stirred at room temperature for 10 minutes, and Compound RE-87 (19 mg) was added, followed by stirring at room temperature for 4 hours. The reaction solution was purified by silica gel column chromatography to obtain the title compound (17 mg). [Step 2] Preparation of Compound E-44 Compound E-44A (17 mg) was dissolved in ethyl acetate (2 mL), and p-toluenesulfonic acid monohydrate (13 mg) was added, followed by stirring at room temperature. The precipitated solid was collected by filtration and dried under reduced pressure to give the title compound (19 mg). MS (m / z): 536.2 [M+H] +
[0476] Example 45 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (Compound E-45) To a mixture of compound RE-121 (20 mg), 2,2,2-trifluoro-N-methylethanamine hydrochloride (13 mg), HBTU (33 mg), and DMF (0.3 mL), DIPEA (0.05 mL) was added and stirred at room temperature overnight. The reaction mixture was purified by silica gel column chromatography to obtain the title compound (16 mg). MS (m / z) 447.2 [M+H] +
[0477] Example 46 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide p-toluenesulfonate (Compound E-46) Compound E-45 (50 mg) was dissolved in THF (1.1 mL), p-toluenesulfonic acid monohydrate (23 mg) was added, and the mixture was stirred at room temperature for 10 minutes. The solvent was evaporated under reduced pressure, the residue was dissolved in methanol, diethyl ether was added, and the precipitated solid was collected by filtration. The mixture was dried under reduced pressure to obtain the title compound (69 mg). MS (m / z): 447.2 [M+H] + Elemental analysis value (C 21 H 21 F 3 N 6 O 2 (C7H8O3S + 3.5H2O) Calculated values (%): C: 49.33, H: 5.32, N: 12.33 Measured values (%): C: 49.34, H: 5.01, N: 11.93
[0478] Example 47 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)-1,2,3,6-tetrahydropyridin-4-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (Compound E-47) A mixture of compound RE-40 (105 mg), dichloromethane (2 mL), and trifluoroacetic acid (0.5 mL) was stirred at room temperature. Toluene was added to the residue obtained by distilling off the solvent under reduced pressure, and the mixture was then distilled off under reduced pressure. Ethyl acetate and hexane were then added, and the solvent was distilled off under reduced pressure. In a separate container, EDCI.HCl (50 mg) was added to a mixture of compound RE-24 (51 mg), DIPEA (0.1 mL), HOBt (35 mg), and DMF (0.5 mL), and the mixture was stirred at room temperature for 30 minutes to prepare a mixture. The mixture was added to the residue obtained above, and the mixture was stirred at room temperature overnight. The reaction solution was purified by silica gel column chromatography to obtain the title compound (12 mg). MS (m / z): 517.3 [M+H]
[0479] Example 48 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)piperidin-4-yl]-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (Compound E-48)
[0480] [Step 1] Preparation of 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)-1,2,3,6-tetrahydropyridin-4-yl]-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (Compound E-48A) The title compound was obtained by a method similar to that of Example 47, except that compound RE-41 was used instead of compound RE-40. MS (m / z): 491.3 [M+H] +
[0481] [Step 2] Preparation of Compound E-48 10% Pd—C (13 mg) was added to Compound E-48A (47 mg), methanol (3 mL), and ammonium formate (79 mg), and the mixture was stirred at 80° C. overnight. Insoluble matter was filtered off, the solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (24 mg). MS (m / z): 493.3 [M+H] +
[0482] Example 49 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)piperidin-4-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (Compound E-49) The title compound was obtained by a method similar to that of Step 2 of Example 48, except that Compound E-47 was used instead of Compound E-48A. MS (m / z): 519.3 [M+H] +
[0483] Example 50 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (Compound E-50) A mixture of compound RE-116 (20 mg), (2R)-2-(trifluoromethyl)pyrrolidine hydrochloride (14 mg), HATU (29 mg), DIPEA (0.03 mL), and DMF (0.3 mL) was stirred at room temperature for 3 hours. The reaction mixture was purified by silica gel column chromatography to obtain the title compound (21 mg). MS (m / z): 509.1 [M+H] +
[0484] Example 51 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one hydrochloride (Compound E-51)
[0485] [Step 1] Preparation of 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (Compound E-51A) A mixture of compound RE-119 (19 mg), (2R)-2-(trifluoromethyl)morpholin hydrochloride (46 mg), HATU (27 mg), DIPEA (0.04 mL), and DMF (1 mL) was stirred at room temperature overnight. The reaction solution was purified by silica gel column chromatography to obtain the title compound (31 mg).
[0486] [Step 2] Preparation of Compound E-51 Compound E-51A (31 mg) was dissolved in methanol (2 mL), and 1 M hydrochloric acid (0.06 mL) was added and stirred at room temperature for 5 minutes. The solvent was evaporated under reduced pressure, and the residue was washed with a mixture of ethanol and diethyl ether and dried to obtain the title compound (18 mg). MS (m / z): 539.2 [M+H] +
[0487] Example 52 4-[3-(1-{[1-(2,2,2-trifluoroethyl)-1H-1,2,3-triazol-4-yl]methyl}-4-fluoro-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine hydrochloride (Compound E-52)
[0488] [Step 1] Preparation of 4-[3-(1-{[1-(2,2,2-trifluoroethyl)-1H-1,2,3-triazol-4-yl]methyl}-4-fluoro-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (Compound E-52A) Compound RE-91 (42 mg) was dissolved in 1,4-dioxane (1 mL), and 4 M hydrochloric acid (1 mL) was added thereto, followed by stirring at 50°C for 3 hours. The solvent was evaporated under reduced pressure, and the resulting residue was dissolved in DMF. In a separate vessel, a mixture of 2-aminopyridine-4-carboxylic acid (10 mg), HBTU (36 mg), DIPEA (0.1 mL), and DMF (0.7 mL) was stirred at room temperature for 2 hours, and a separately prepared DMF solution of the residue was added thereto, followed by stirring at room temperature overnight. The reaction solution was purified by silica gel column chromatography to obtain the title compound (17 mg). [Step 2] Preparation of Compound E-68 A mixture of compound E-52A (17 mg) and hydrogen chloride (4 M solution in 1,4-dioxane, 0.02 mL) was stirred at room temperature. The solvent was evaporated under reduced pressure, and the residue was washed with a mixture of methanol and diethyl ether and dried to give the title compound (8 mg). MS (m / z): 475.1 [M+H] +
[0489] Example 53 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (Compound E-53) A mixture of compound RE-33 (97 mg), dichloromethane (2 mL), and trifluoroacetic acid (0.2 mL) was stirred at room temperature for 8 hours. The solvent was evaporated under reduced pressure, and toluene was added to the resulting residue, which was then evaporated under reduced pressure. Ethyl acetate and hexane were then added, and the solvent was evaporated under reduced pressure to obtain a solid (132 mg). In a separate container, a mixture of 2-aminopyridine-4-carboxylic acid (13 mg), DIPEA (0.13 mL), HBTU (36 mg), and DMF (1 mL) was stirred at room temperature for 30 minutes, and the previously obtained residue (44 mg) was added, followed by stirring at room temperature overnight. The reaction solution was purified by silica gel column chromatography to obtain the title compound (25 mg). MS (m / z): 488.1 [M+H] +
[0490] Example 54 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (Compound E-54)
[0491] [Step 1] Preparation of 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (Compound E-54A) Compound RE-81 (51 mg) was dissolved in dichloromethane (2 mL), trifluoroacetic acid (0.2 mL) was added, and the mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, and the resulting residue was dissolved in DMF. In a separate container, a mixture of 2-aminopyridine-4-carboxylic acid (30 mg), HBTU (82 mg), DIPEA (0.19 mL), and DMF (0.5 mL) was stirred at room temperature for 2 hours, and a separately prepared DMF solution of the residue was added, followed by stirring at room temperature overnight. The reaction solution was purified by silica gel column chromatography to obtain the title compound (30 mg).
[0492] [Step 2] Preparation of Compound E-54 A mixture of compound E-54A (30 mg) and hydrogen chloride (4 M 1,4-dioxane solution, 2 mL) was stirred at room temperature for 30 minutes. The solvent was evaporated under reduced pressure, and the residue was washed with a mixture of methanol and diethyl ether and dried to obtain the title compound (28 mg). MS (m / z): 492.2 [M+H] +
[0493] Example 55 4-{3-[4-fluoro-1-({3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}methyl)-1H-indazol-3-yl]azetidine-1-carbonyl}pyridin-2-amine (Compound E-55) Compound RE-109 (45 mg) was dissolved in dichloromethane (2 mL), trifluoroacetic acid (0.2 mL) was added, and the mixture was stirred at room temperature for 2 hours. The solvent was evaporated under reduced pressure, and the resulting residue was dissolved in DMF. In a separate container, a mixture of 2-aminopyridine-4-carboxylic acid (16 mg), HBTU (43 mg), DIPEA (0.15 mL), and DMF (0.3 mL) was stirred at room temperature for 2 hours, and a separately prepared DMF solution of the residue was added, followed by stirring at room temperature overnight. The reaction solution was purified by silica gel column chromatography to obtain the title compound (18 mg). MS (m / z): 538.2 [M+H] +
[0494] Example 56 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-[(trifluoromethoxy)methyl]pyrrolidin-1-yl]ethan-1-one (Compound E-56) To a mixture of compound RE-116 (30 mg), HBTU (38 mg), and DMF (0.5 mL), DIPEA (0.1 mL) was added and stirred at room temperature for 5 minutes. (2S)-2-(trifluoromethoxymethyl)pyrrolidine hydrochloride (19 mg) was added and stirred at room temperature for 2 hours. The reaction solution was purified by silica gel column chromatography to obtain the title compound (19 mg). MS (m / z): 539.2 [M+H] +
[0495] Example 57 4-(3-{1-[(4,4-difluorocyclohexyl)methyl]-4,6-difluoro-1H-indazol-3-yl}azetidine-1-carbonyl)pyridin-2-amine (Compound E-57) Compound RE-55 (80 mg) was dissolved in methanol (0.7 mL), hydrogen chloride (4 M in ethyl acetate, 0.03 mL) was added, and the mixture was stirred at room temperature for 4 hours. The solvent was evaporated under reduced pressure, and the resulting residue was dissolved in DMF (0.5 mL). In a separate vessel, a mixture of 2-aminopyridine-4-carboxylic acid (30 mg), HBTU (103 mg), DIPEA (0.25 mL), and DMF (1.2 mL) was stirred at room temperature for 1.5 hours, and a separately prepared DMF solution of the residue was added, followed by stirring at room temperature overnight. The reaction solution was purified by silica gel column chromatography to give the title compound (48 mg). MS (m / z): 462.3 [M+H] +
[0496] Example 58 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2S)-2-[(trifluoromethoxy)methyl]pyrrolidin-1-yl]ethan-1-one di-p-toluenesulfonate (Compound E-58) [Step 1] Preparation of 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2S)-2-[(trifluoromethoxy)methyl]pyrrolidin-1-yl]ethan-1-one (Compound E-58A) EDCI.HCl (12 mg) was added to a mixture of Compound RE-87 (19 mg), Compound RE-24 (8 mg), HOBt (8 mg), DIPEA (0.02 mL), and DMF (0.5 mL), and the mixture was stirred at room temperature for 4 hours. The reaction solution was purified by silica gel column chromatography to give the title compound (11 mg). [Step 2] Preparation of Compound E-58 Compound E-58A (11 mg) was dissolved in ethyl acetate (2 mL), and p-toluenesulfonic acid monohydrate (8 mg) was added thereto, followed by stirring at room temperature. The precipitated solid was collected by filtration and dried under reduced pressure to obtain the title compound (19 mg). MS (m / z): 540.2 [M+H] + 1 H-NMR (400MHz, DMSO-D 6 ) δ8.92 (d, 1H), 8.22 (d, 1H), 8.09 (d, 1H), 7.47 (d, 4H), 7.11 (s, 4H), 5.55 (d, 2H), 4.61-4.52 (m , 2H), 4.50-4.40 (m, 1H), 4.37-4.28 (m, 2H), 4.20-4.07 (m, 2H), 2.29 (s, 6H), 2.11-1.84 (m, 5H) Elemental analysis value (C 23 H 22 F 5 N 7 O 3 ・C 14 H 16 O 6 S 2 +3.0H 2 Calculated values (%): C: 47.38, H: 4.73, N: 10.45 Measured values (%): C: 47.14, H: 4.72, N: 10.36
[0497] Example 59 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (Compound E-59) A mixture of intermediate RE-20C (81 mg), dichloromethane (2 mL), and trifluoroacetic acid (0.7 mL) was stirred at room temperature for 2.5 hours. The solvent was evaporated under reduced pressure, and toluene was added to the resulting residue, which was then evaporated under reduced pressure. Ethyl acetate and hexane were then added, and the solvent was evaporated under reduced pressure. A mixture of a portion of the resulting residue (41 mg), compound RE-24 (21 mg), HOBt (16 mg), DIPEA (0.08 mL), DMF (1 mL), and EDCI.HCl (22 mg) was stirred at room temperature for 2.5 hours. The reaction solution was purified by silica gel column chromatography to give the title compound (18 mg). MS (m / z): 483.2 [M+H] +
[0498] Example 60 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (Compound E-60) A mixture of compound RE-117 (50 mg), (2R)-2-(trifluoromethyl)pyrrolidine hydrochloride (24 mg), HOBt (18 mg), DIPEA (0.07 mL), DMF (0.5 mL), and EDCI.HCl (26 mg) was stirred at room temperature overnight. The reaction mixture was purified by silica gel column chromatography to obtain the title compound (20 mg). MS (m / z): 491.0 [M+H] +
[0499] The compounds of each example shown in Tables 1 to 32 below (in the tables, "XXX" in "E-XXX" indicates the example number) were produced by combining a reference example compound with a reactive fragment, and carrying out a condensation reaction, and, if necessary, deprotection and salification, according to procedures similar to those described in the above-mentioned examples. In the tables, a reference example indicates that the compound was produced by the method described in that example number, or by a method similar to that production method using the corresponding starting materials; for example, an example compound with a reference example number of 1 means that it was produced by a method similar to that of Example 1. In the tables, data indicates instrumental analysis data of the compound, such as mass spectrometry data (m / z value).
[0500]
[0501]
[0502]
[0503]
[0504]
[0505]
[0506]
[0507]
[0508]
[0509]
[0510]
[0511]
[0512]
[0513]
[0514]
[0515]
[0516]
[0517]
[0518]
[0519]
[0520]
[0521]
[0522]
[0523]
[0524]
[0525]
[0526]
[0527]
[0528]
[0529]
[0530]
[0531]
[0532] Similarly, the compounds of each example shown in Tables 33 to 48 below (in the tables, "XXX" in "E-XXX" indicates the example) were prepared by combining a reference example compound with a reactive fragment and carrying out a condensation reaction, and, if necessary, deprotection and salification, according to procedures similar to those described in the above-mentioned examples.
[0533]
[0534]
[0535]
[0536]
[0537]
[0538]
[0539]
[0540]
[0541]
[0542]
[0543]
[0544]
[0545]
[0546]
[0547]
[0548]
[0549] The numbers and chemical names of the example compounds are shown in Tables 49 to 72 below. In the tables, the chemical names represent the names of the compounds corresponding to the compound numbers.
[0550]
[0551]
[0552]
[0553]
[0554]
[0555]
[0556]
[0557]
[0558]
[0559]
[0560]
[0561]
[0562]
[0563]
[0564]
[0565]
[0566]
[0567]
[0568]
[0569]
[0570]
[0571]
[0572]
[0573]
[0574] The following are examples of biological tests of the compounds used in the present invention.
[0575] Test Example 1 Evaluation of DDR1 Kinase Inhibitory Effect 1. Preparation of Test Substances Test substances were prepared at 10 mM with dimethyl sulfoxide (DMSO, Nacalai Tesque, 13445-74), and six concentrations were selected for each compound, which were then diluted with DMSO to final concentrations of 1000, 100, 10, 1, 0.1, 0.01, and 0.001 μM, respectively. Furthermore, this solution was diluted with a buffer containing 50 mM HEPES (Fujifilm Wako Pure Chemical Industries, 340-01371), 1 mM EGTA (DOJINDO, G002), 10 mM magnesium chloride hexahydrate (Nacalai Tesque, 20908-65), 2 mM dithiothreitol (Nacalai Tesque, 14112-52), and 0.01% Tween 20 (Tokyo Chemical Industry, T0543) to six concentrations selected for each compound: 330,000, 33,000, 330, 3, 0.3, and 0.03 nM, to prepare test substance solutions. Measurement of inhibitory effect on kinase activity of DDR1 kinase Six concentrations were selected for each compound, and the prepared test substance solutions were added to a 384-well plate (Corning, 4512) at 3 μL / well to final concentrations of 10,000, 1,000, 100, 10, 1, 0.1, and 0.01 nM. DDR1 protein (Carna Biosciences, 08-113) was added at 2 μL / well to a final concentration of 0.5 nM. LANCE Ultra ULight was used as a substrate. TMPoly-GAT (PerkinElmer, TRF0101) and ATP (Sigma-Aldrich, A6559) were mixed to final concentrations of 50 nM and 100 μM, respectively, and added at 5 μL / well. After 2 hours of incubation at room temperature, 10 μL / well of LANCE Detection Buffer (PerkinElmer, CR97-100) containing a final concentration of 10 mM EDTA (DOJINDO, K001) and a final concentration of 1 nM Europium (PerkinElmer, AD0068) was added. After 1 hour of incubation at room temperature, fluorescence intensity at 615 nm and 665 nm was measured using an Envision (PerkinElmer) or SpectraMax iD5 (Molecular Devices). The test was performed in duplicate. 3. Analysis of measurement results The fluorescence intensity at 665 nM was divided by the fluorescence intensity at 615 nM to calculate the inhibition rate of each test substance, with the maximum inhibition rate being 100% and the minimum inhibition rate being 0%. 50 The values (50% inhibitory concentration) were calculated by logistic regression analysis. The results for each example compound are shown in Tables 73 to 78 below.
[0576]
[0577]
[0578]
[0579]
[0580]
[0581]
[0582] Test Example 2: Evaluation of DDR1 kinase inhibitory effect in DDR1-expressing U2OS cells 1. Preparation of test substance The test substance was prepared at 10 mM with DMSO and diluted with DMSO to final concentrations of 1000, 100, 10, 1, and 0.1 μM. This solution was further diluted with E-MEM medium (Fujifilm Wako Pure Chemical Industries, Ltd., 051-07615) containing 10% fetal bovine serum (FBS, Gibco, 10270106) to concentrations of 60,000, 6,000, 600, 60, 6, and 0.6 nM to prepare test substance solutions. Measurement of DDR1 kinase inhibitory effect in DDR1-expressing U2OS cells DDR1-expressing U2OS cells (DiscoverX, 93-0894C3) suspended in 10% FBS + E-MEM medium at 2.5 × 10^5 cells / mL were seeded in 20 μL aliquots onto a 384-well plate (DiscoverX, 92-0013) and incubated at 37°C and 5% CO 2 The next day, the prepared test substance solutions were added at 5 μL / well to give final concentrations of 10,000, 1,000, 100, 10, 1, and 0.1 nM, respectively. 2 After incubation for 1 hour at 4°C, type I collagen (Nitta Gelatin, 631-00771) was added at 5 μL / well to a final concentration of 50 μg / mL, and the plates were incubated at 37°C, 5% CO 2 The plates were cultured overnight at 4°C. The next day, the plates were left at room temperature for 1 hour, and then 5 μL / well of detection solution was added according to the operating instructions for the PathHunter (registered trademark) Detection Kit (DiscoverX, 93-0001). After 2 hours of incubation at room temperature, the luminescence intensity was measured using Envision (PerkinElmer). The test was performed in duplicate. 3. Analysis of measurement results The inhibition rate of the test substance was calculated by setting the blank (only type I collagen stimulation) as 100% and the negative control group (no type I collagen stimulation) as 0%. The IC of the test substance 50 The values (50% inhibitory concentration) were calculated by logistic regression analysis. The results for each example compound are shown in Tables 79 to 81 below.
[0583]
[0584]
[0585]
[0586] Test Example 3: In Vivo Efficacy Study Using an Anti-Glomerular Basement Membrane Antibody-Induced Nephritis Model 1. Preparation of Test Substance The test substance was weighed and suspended in 0.5% methylcellulose (Shin-Etsu Chemical Co., Ltd.) + 99.5% Otsuka Distilled Water (Otsuka Pharmaceutical Factory) to prepare a test substance administration solution. 2. Preparation of Animal Model WKY / NCrlCrlj rats (7-week-old males) were intravenously administered 300 μL of phosphate-buffered saline (Wako, 045-29795) containing 33.3-100 μg / mL of anti-glomerular basement membrane antibody (Chondrex, 70221). Starting on day 7, the test substance was administered twice daily for seven days. From day 6 to day 7 after the start of administration, the rats were moved to a metabolism / urine collection cage, and urine was collected for 24 hours. The weight of the collected urine was measured. 3. Measurement of urinary albumin content: 150 μL of urine was transferred to a sample cup (650-M, BMBio ST). The albumin concentration in urine was quantified using a JCA-BM6050 automatic analyzer (JEOL). The amount of albumin in urine was calculated by correcting for the measured urine weight. 4. Analysis of measurement results: The amount of albumin in urine in the test substance-treated group was calculated as a percentage, with the amount of albumin in urine in the anti-glomerular basement membrane antibody-untreated group and the vehicle-treated group set at 0% and 100%, respectively. The experimental results are shown in Table X.
[0587]
Claims
1. Formula (I) [Wherein A is (In the formula, Y 1 , Y 2 , Y 3 and Y 4 are each independently N or C—R 5 wherein the Y 1 , Y 2 , Y 3 and Y 4 Of these, a maximum of two are N, and the rest are C-R. 5 and R 5 is hydrogen, halogen, cyano, alkoxy, or optionally substituted C 1 -C 6 alkyl, where the dashed line indicates the point of attachment, or (In the formula, R 6a , R 6b , R 6c , R 6d , R 6e , R 6f , R 6g and R 6h are each independently hydrogen, halogen, cyano or optionally substituted C 1 -C 6 alkyl, the dashed line indicates the point of attachment, B is an optionally substituted 3-8 membered saturated or unsaturated monocyclic nitrogen-containing heterocycle, X is N or C-R 7 where R 7 is hydrogen, halogen, cyano or optionally substituted C 1 -C 6 alkyl, R 1 are each independently hydrogen, halogen, cyano, oxo, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 1 -C 6 Alkoxy, hydroxy, carboxy, alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, aminoalkyl, alkylcarbonylamino, C 3 -C 10 Cycloalkyl, C 3 -C 6 is selected from the group consisting of cycloalkenyl, heterocycloalkyl, aryl, and heteroaryl, each of which is optionally substituted; R 2 and R 3 are each independently hydrogen, halogen or optionally substituted C 1 -C 6 alkyl, R 4 is hydrogen, halogen, cyano, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 1 -C 6 or R is selected from the group consisting of alkoxy, hydroxy, carboxy, alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, aminoalkyl, alkylcarbonylamino, monocyclic or bicyclic saturated carbocycle, monocyclic or bicyclic unsaturated carbocycle, monocyclic or bicyclic saturated heterocycle, and monocyclic or bicyclic unsaturated heterocycle, each of which is optionally substituted; or 4 is -CONR 8 R 9 where R 8 and R 9 each independently represents hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 10 Cycloalkyl, C 3 -C 6 selected from the group consisting of cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, each of which is optionally substituted; or R 8 and R 9 are taken together with the atoms to which they are attached to form an optionally substituted 5- to 10-membered monocyclic or bicyclic saturated heterocycle or a 5- to 10-membered monocyclic or bicyclic unsaturated heterocycle, m is an integer from 0 to 3, n is an integer from 0 to 3, and Het is a 5- to 10-membered monocyclic or bicyclic saturated heterocycle or a 5- to 10-membered monocyclic or bicyclic unsaturated heterocycle, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
2. The compound of formula (I) is a compound of formula (II): [In the formula, B, R 1 , R 2 , R 3 , R 4 , Het, X, Y 1 , Y 2 , Y 3 , Y 4 , m and n are as defined in formula (I), or a pharmaceutically acceptable salt thereof, or a solvate thereof.
3. The compound of formula (I) is a compound of formula (III) [In the formula, B, R 1 , R 2 , R 3 , R 4 , R 6a , R 6b , R 6c , R 6d , R 6e , R 6f , R 6g , R 6h , Het, X, m and n are as defined in formula (I), or a pharmaceutically acceptable salt thereof, or a solvate thereof.
4. R 1 are each independently hydrogen, halogen, oxo, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, amino, monoalkylamino, dialkylamino, aminoalkyl, alkylcarbonylamino, C 3 -C 10 The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein the compound is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, each of which is optionally substituted.
5. R 4 But hydrogen, halogen, cyano, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 1 -C 6 Alkoxy, hydroxy, carboxy, alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, aminoalkyl, alkylcarbonylamino, C 3 -C 10 Cycloalkyl, C 3 -C 6 The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein the compound is selected from the group consisting of cycloalkenyl, heterocycloalkyl, aryl, and heteroaryl, each of which is optionally substituted.
6. R 4 Ga-CONR 8 R 9 where R 8 and R 9 each independently represents hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 10 Cycloalkyl, C 3 -C 6 is selected from the group consisting of cycloalkenyl, heterocycloalkyl, aryl, and heteroaryl, each of which is optionally substituted; or R 8 and R 9 and R 1 and R 2 together with the atom to which they are attached form an optionally substituted 5- to 10-membered monocyclic or bicyclic saturated heterocycle or an optionally substituted 5- to 10-membered monocyclic or bicyclic unsaturated heterocycle, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
7. The compound according to any one of claims 1 to 6, wherein X is N, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
8. X is C-R 7 where R 7 is hydrogen, halogen, cyano or optionally substituted C 1 -C 6 The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein R is alkyl.
9. A compound selected from the group consisting of the following compounds (1) to (295), or a pharmaceutically acceptable salt thereof, or a solvate thereof. (1) 2-(4-chloro-3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-5-fluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (2) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (3) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (4) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-5-chloro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (5) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-6-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (6) 2-{3-[1-(2-aminopyridine-4-carbonyl)-3-methylazetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (7) 2-{3-[1-(2-amino-4-methyl-1,3-thiazole-5-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-(3,3-dimethylmorpholin-4-yl)ethan-1-one (8) 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (9) 4-[4-(4-fluoro-1-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-1H-indazol-3-yl)piperidine-1-carbonyl]pyridin-2-amine(10) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)piperidin-4-yl]-4-fluoro-1H-indol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (11) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (12) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-5-methyl-1H-pyrazolo[4,3-b]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (13) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-pyrazolo[4,3-c]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (14) 4-{3-[4-fluoro-1-({5-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-3-yl}methyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]azetidine-1-carbonyl}pyridin-2-amine (15) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-methyl-1H-pyrazolo[3,4-b]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (16) 2-{3-[1-(6-aminopyridazine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (17) 2-[4,6-difluoro-3-(1-{1H-pyrazolo[3,4-b]pyridine-4-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one(18) 5-fluoro-4-[3-(1-{[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (19) 4-{3-[1-({1-[(3,3-difluorocyclobutyl)methyl]-1H-1,2,3-triazol-4-yl}methyl)-4-fluoro-1H-indazol-3-yl]azetidine-1-carbonyl}pyridin-2-amine hydrochloride (20) 4-[3-(4-fluoro-1-{[5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (21) 2-{3-[1-(2-amino-5-fluoropyrimidine-4-carbonyl)azetidin-3-yl]-5-chloro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (22) 2-{3-[1-(2-amino-5-fluoropyrimidine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (23) 2-{3-[1-(2-amino-5-fluoropyrimidine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (24) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,5,6,7-tetrahydro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (25) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5,5-difluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one(26) 2-(4-chloro-3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-5-fluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide p-toluenesulfonate (27) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one methanesulfonate (28) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (29) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one methanesulfonate (30) 2-(3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-4,6-difluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (31) 2-(3-{1-[6-(cyclopropylamino)pyrimidine-4-carbonyl]azetidin-3-yl}-4,6-difluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide (32) 2-[4,6-difluoro-3-(1-{2-[(oxetan-3-yl)amino]pyridine-4-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-N-(2,2,2-trifluoroethyl)acetamide (33) 2-[4,6-difluoro-3-(1-{1H-pyrrolo[2,3-b]pyridine-4-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride(34) 4-(3-{4-fluoro-1-[(1-phenyl-1H-1,2,3-triazol-4-yl)methyl]-1H-indazol-3-yl}azetidine-1-carbonyl)pyridin-2-amine (35) 4-(3-{1-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]-4-fluoro-1H-indazol-3-yl}azetidine-1-carbonyl)pyridin-2-amine hydrochloride (36) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]ethan-1-one (37) 4-[3-(1-{[1-(cyclopropylmethyl)-1H-1,2,3-triazol-4-yl]methyl}-4-fluoro-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine hydrochloride (38) 4-{3-[4-fluoro-1-({1-[(oxetan-3-yl)methyl]-1H-1,2,3-triazol-4-yl}methyl)-1H-indazol-3-yl]azetidine-1-carbonyl}pyridin-2-amine (39) 4-{4-[1-({1-[(3,3-difluorocyclobutyl)methyl]-1H-1,2,3-triazol-4-yl}methyl)-4-fluoro-1H-indazol-3-yl]piperidine-1-carbonyl}pyridin-2-amine (40) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (41) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (42) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one(43) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one p-toluenesulfonate (44) 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2S)-2-[(trifluoromethoxy)methyl]pyrrolidin-1-yl]ethan-1-one dip-toluenesulfonate (45) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (46) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide p-toluenesulfonate (47) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)-1,2,3,6-tetrahydropyridin-4-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (48) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)piperidin-4-yl]-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (49) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)piperidin-4-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (50) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one(51) 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one hydrochloride (52) 4-[3-(1-{[1-(2,2,2-trifluoroethyl)-1H-1,2,3-triazol-4-yl]methyl}-4-fluoro-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine hydrochloride (53) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (54) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (55) 4-{3-[4-fluoro-1-({3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}methyl)-1H-indazol-3-yl]azetidine-1-carbonyl}pyridin-2-amine (56) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-[(trifluoromethoxy)methyl]pyrrolidin-1-yl]ethan-1-one (57) 4-(3-{1-[(4,4-difluorocyclohexyl)methyl]-4,6-difluoro-1H-indazol-3-yl}azetidine-1-carbonyl)pyridin-2-amine (58) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2S)-2-[(trifluoromethoxy)methyl]pyrrolidin-1-yl]ethan-1-one di-p-toluenesulfonate(59) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (60) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (61) 2-[4-chloro-3-(1-{1H-pyrrolo[2,3-b]pyridine-4-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-N-(2,2,2-trifluoroethyl)acetamide (62) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-chloro-1H-indazol-1-yl}-N-(2,2,2-trifluoroethyl)acetamide (63) 2-(4-chloro-3-{1-[2-(methylamino)pyridine-4-carbonyl]azetidin-3-yl}-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide (64) 2-(4-chloro-3-{1-[2-(ethylamino)pyridine-4-carbonyl]azetidin-3-yl}-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (65) 2-(3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-4-fluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (66) 2-(3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-4,7-difluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (67) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-chloro-5-fluoro-1H-indazol-1-yl}-N-(2,2,2-trifluoroethyl)acetamide hydrochloride(68) 2-(3-{1-[2-(cyclobutylamino)pyridine-4-carbonyl]azetidin-3-yl}-4-fluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (69) 2-(4-bromo-3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-5-fluoro-1H-indazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (70) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-bromo-5-fluoro-1H-indazol-1-yl}-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (71) 2-[4-fluoro-3-(1-{2-[(oxan-4-yl)amino]pyridine-4-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-N-(2,2,2-trifluoroethyl)acetamide hydrochloride (72) 2-(3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-4,6-difluoro-1H-indazol-1-yl)-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (73) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one hydrochloride (74) 2-[4,6-difluoro-3-(1-{2-[(1-methylcyclopropyl)amino]pyridine-4-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (75) 2-[3-(1-{2-[(4,4-difluorocyclohexyl)amino]pyridine-4-carbonyl}azetidin-3-yl)-4,6-difluoro-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride(76) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-(pyrrolidin-1-yl)ethan-1-one (77) 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (78) 2-{3-[1-(2-amino-5-methylpyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride (79) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-methylmorpholin-4-yl]ethan-1-one hydrochloride (80) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(3R)-3-methylmorpholin-4-yl]ethan-1-one hydrochloride (81) 2-{3-[1-(2-aminopyridine-4-carbonyl)piperidin-4-yl]-4-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (82) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (83) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(3R)-3-(propan-2-yl)morpholin-4-yl]ethan-1-one (84) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R,6S)-2,6-dimethylmorpholin-4-yl]ethan-1-one(85) 2-{3-[1-(6-aminopyridine-3-carbonyl)piperidin-4-yl]-4-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (86) 2-(3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]piperidin-4-yl}-4-fluoro-1H-indazol-1-yl)-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (87) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (88) 2-[4,6-difluoro-3-(1-{2-[(oxan-4-yl)amino]pyridine-4-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (89) 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one hydrochloride (90) 2-{3-[1-(2-aminopyridine-4-carbonyl)piperidin-4-yl]-4-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (91) 2-{3-[1-(2-aminopyridine-4-carbonyl)piperidin-4-yl]-4-fluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (92) 4-[3-(1-{[1-(cyclobutylmethyl)-1H-1,2,3-triazol-4-yl]methyl}-4-fluoro-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine hydrochloride(93) 2-(3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-4-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl)-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (94) 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-4-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (95) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one hydrochloride (96) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (97) 2-{3-[1-(2-amino-1,3-thiazole-5-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (98) 2-(3-{1-[2-(cyclopropylamino)-1,3-thiazole-5-carbonyl]azetidin-3-yl}-4,6-difluoro-1H-indazol-1-yl)-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (99) 2-(3-{1-[2-(cyclopropylamino)-4-methyl-1,3-thiazole-5-carbonyl]azetidin-3-yl}-4,6-difluoro-1H-indazol-1-yl)-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (100) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one(101) 2-[4,6-difluoro-3-(1-{imidazo[1,2-a]pyridine-3-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (102) 2-[4,6-difluoro-3-(1-{pyrazolo[3,2-b][1,3]thiazole-7-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (103) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]propan-1-one hydrochloride (104) 4-[3-(4-fluoro-1-{[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (105) 2-{3-[1-(2-amino-1,3-oxazole-5-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (106) 2-{3-[1-(2-amino-4-methyl-1,3-thiazole-5-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (107) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-2-fluoro-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (108) 2-{3-[1-(2-aminopyridine-4-carbonyl)piperidin-4-yl]-4-fluoro-1H-indol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one(109) 4-(3-{4-fluoro-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-1H-indazol-3-yl}azetidine-1-carbonyl)pyridin-2-amine (110) 2-{3-[1-(2-amino-4-methyl-1,3-oxazole-5-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (111) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-4,4-difluoro-2-(fluoromethyl)pyrrolidin-1-yl]ethan-1-one (112) 4-[3-(4-fluoro-1-{[4-(trifluoromethyl)phenyl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine hydrochloride (113) 4-[3-(4-fluoro-1-{[3-(trifluoromethyl)phenyl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine hydrochloride (114) 4-[3-(4-fluoro-1-{[2-(trifluoromethyl)phenyl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine hydrochloride (115) 4-[3-(4-fluoro-1-{[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine hydrochloride (116) 4-[3-(4-fluoro-1-{[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (117) 4-{3-[4-fluoro-1-({5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}methyl)-1H-indazol-3-yl]azetidine-1-carbonyl}pyridin-2-amine(118) 2-{3-[1-(2-amino-1,3-thiazole-5-carbonyl)piperidin-4-yl]-4-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (119) 2-{3-[1-(2-amino-4-methyl-1,3-thiazole-5-carbonyl)piperidin-4-yl]-4-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (120) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-pyrazolo[4,3-b]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (121) 2-(3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (122) 2-{3-[1-(2-amino-4-methyl-1,3-thiazole-5-carbonyl)azetidin-3-yl]-1H-pyrazolo[4,3-b]pyridin-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (123) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(3S)-3-(trifluoromethyl)morpholin-4-yl]ethan-1-one (124) 2-{3-[1-(2-aminopyridine-4-carbonyl)-1,2,3,6-tetrahydropyridin-4-yl]-4-fluoro-1H-indol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (125) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(3S)-3-(difluoromethoxy)pyrrolidin-1-yl]ethan-1-one(126) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(3R)-3-(difluoromethoxy)pyrrolidin-1-yl]ethan-1-one (127) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-(2,2-dimethylpyrrolidin-1-yl)ethan-1-one (128) 4-[3-(4-fluoro-1-{[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (129) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (130) 2-(3-{1-[2-(cyclopropylamino)pyridine-4-carbonyl]azetidin-3-yl}-5-methyl-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (131) 2-{3-[1-(6-aminopyrimidine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (132) 2-{4,6-difluoro-3-[1-(pyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (133) 2-{4,6-difluoro-3-[1-(3-methoxypyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (134) 4-[4-(4-fluoro-1-{[6-(trifluoromethyl)pyridin-3-yl]methyl}-1H-indazol-3-yl)piperidine-1-carbonyl]pyridin-2-amine(135) 2-{3-[1-(2-aminopyridine-4-carbonyl)piperidin-4-yl]-4-fluoro-1H-indol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (136) 2-{3-[1-(2-aminopyridine-4-carbonyl)piperidin-4-yl]-4-fluoro-1H-indol-1-yl}-1-[(2S)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (137) 4-[3-(4-fluoro-1-{[5-(oxan-4-yl)-1,2,4-oxadiazol-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (138) 4-[3-(4-fluoro-1-{[3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl]methyl}-1H-indazol-3-yl)azetidin-1-carbonyl]pyridin-2-amine (139) 2-(3-{1-[2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carbonyl]azetidin-3-yl}-4,6-difluoro-1H-indazol-1-yl)-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (140) 2-{4,6-Difluoro-3-[1-(1H-indazole-5-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (141) 2-[4,6-Difluoro-3-(1-{1H-pyrazolo[4,3-b]pyridine-5-carbonyl}azetidin-3-yl)-1H-indazol-1-yl]-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (142) 2-{4,6-difluoro-3-[1-(3-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one(143) 2-{3-[1-(3-chloropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (144) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-chloro-5-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (145) 2-{3-[1-(2-amino-3-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (146) 4-{3-[4-fluoro-1-({5-[1-(trifluoromethyl)cyclobutyl]-1,2,4-oxadiazol-3-yl}methyl)-1H-indazol-3-yl]azetidine-1-carbonyl}pyridin-2-amine hydrochloride (147) 4-{3-[4-fluoro-1-({5-[1-(trifluoromethyl)cyclopropyl]-1,2,4-oxadiazol-3-yl}methyl)-1H-indazol-3-yl]azetidine-1-carbonyl}pyridin-2-amine (148) 4-[3-(4-fluoro-1-{[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (149) 2-{3-[1-(2-amino-4-chloro-1,3-thiazole-5-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (150) 4-[3-(4-fluoro-1-{[5-(trifluoromethyl)pyridin-2-yl]methyl}-1H-pyrazolo[3,4-c]pyridin-3-yl)azetidine-1-carbonyl]pyridin-2-amine (151) 4-[3-(4-fluoro-1-{[4-(trifluoromethyl)phenyl]methyl}-1H-pyrazolo[3,4-c]pyridin-3-yl)azetidine-1-carbonyl]pyridin-2-amine(152) 4-{3-[4,6-difluoro-1-(3-phenylprop-2-yn-1-yl)-1H-indazol-3-yl]azetidine-1-carbonyl}pyridin-2-amine (153) 4-[3-(4-fluoro-1-{[5-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (154) 4-[3-(4-fluoro-1-{[5-(6-methylpyridazin-3-yl)-1,2,4-oxadiazol-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (155) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (156) 4-{3-[1-(3-cyclopropylprop-2-yn-1-yl)-4,6-difluoro-1H-indazol-3-yl]azetidine-1-carbonyl}pyridin-2-amine (157) 4-(3-{4,6-difluoro-1-[(1-phenylazetidin-3-yl)methyl]-1H-indazol-3-yl}azetidine-1-carbonyl)pyridin-2-amine (158) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-(1,2,3,4-tetrahydroquinolin-1-yl)ethan-1-one (159) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-(3,4-dihydro-2H-1,4-benzoxazin-4-yl)ethan-1-one (160) 4-[3-(4-fluoro-1-{[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]methyl}-1H-pyrazolo[3,4-c]pyridin-3-yl)azetidine-1-carbonyl]pyridin-2-amine(161) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-(6-bromo-2,3-dihydro-1H-indol-1-yl)ethan-1-one (162) 2-{4,6-difluoro-3-[1-(oxane-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (163) 2-{4,6-Difluoro-3-[1-(2-hydroxypyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (164) 2-{4,6-Difluoro-3-[1-(1H-pyrazole-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (165) 2-{4,6-Difluoro-3-[1-(5-methyl-1H-pyrazole-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (166) 2-(4,6-Difluoro-3-{1-[5-(trifluoromethyl)-1H-pyrazole-4-carbonyl]azetidin-3-yl}-1H-indazol-1-yl)-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (167) 4-[3-(4,6-difluoro-1-{[1-(2,2,2-trifluoroethyl)azetidin-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (168) 4-[3-(5-methyl-1-{[4-(trifluoromethyl)phenyl]methyl}-1H-pyrazolo[3,4-c]pyridin-3-yl)azetidine-1-carbonyl]pyridin-2-amine(169) 2-{3-[1-(1H-1,2,3-benzotriazole-5-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (170) 4-[3-(4-fluoro-1-{[3-(3-fluoropyridin-4-yl)-1,2,4-oxadiazol-5-yl]methyl}-1H-pyrazolo[3,4-c]pyridin-3-yl)azetidine-1-carbonyl]pyridin-2-amine (171) 4-(3-{1-[(2,3-dihydro-1H-inden-2-yl)methyl]-4,6-difluoro-1H-indazol-3-yl}azetidine-1-carbonyl)pyridin-2-amine (172) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-(6-cyclopropyl-2,3-dihydro-1H-indol-1-yl)ethan-1-one (173) 2-{3-[1-(2-amino-4-methyl-1,3-thiazole-5-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (174) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)piperidin-4-yl]-4-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (175) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-[(trifluoromethoxy)methyl]pyrrolidin-1-yl]ethan-1-one (176) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-(2,2-dimethylmorpholin-4-yl)ethan-1-one(177) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-(3,3-dimethylmorpholin-4-yl)ethan-1-one (178) 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-5-methyl-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one dihydrochloride (179) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]ethan-1-one (180) 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (181) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (182) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(3S,5S)-3,5-dimethylmorpholin-4-yl]ethan-1-one (183) 2-{3-[1-(2-amino-4-methyl-1,3-thiazole-5-carbonyl)azetidin-3-yl]-4-fluoro-1H-pyrazolo[3,4-c]pyridin-1-yl}-1-[(2S)-2-[(trifluoromethoxy)methyl]pyrrolidin-1-yl]ethan-1-one p-toluenesulfonate (184) 2-{3-[1-(2-amino-3-fluoropyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one p-toluenesulfonate(185) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5-methyl-1H-pyrazolo[4,3-b]pyridin-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one p-toluenesulfonate (186) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5-methyl-1H-pyrazolo[4,3-b]pyridin-1-yl}-1-(3,3-dimethylmorpholin-4-yl)ethan-1-one p-toluenesulfonate (187) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-(3,3-dimethylmorpholin-4-yl)ethan-1-one (188) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-(3,3-dimethylmorpholin-4-yl)ethan-1-one (189) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-N-tert-butylacetamide (190) 2-{3-[1-(2-amino-3-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-(3,3-dimethylmorpholin-4-yl)ethan-1-one (191) 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-(3,3-dimethylmorpholin-4-yl)ethan-1-one (192) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (193) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one(194) 2-{3-[1-(2-amino-3-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (195) 2-{3-[1-(2-amino-3-methylpyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (196) 2-{3-[1-(2-amino-3-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (197) 2-{3-[1-(2-amino-4-methyl-1,3-thiazole-5-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (198) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-tert-butylacetamide (199) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-tert-butylacetamide (200) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-5-methyl-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (201) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5-methyl-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (202) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-5-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one(203) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (204) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5-chloro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (205) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-5-chloro-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (206) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5-chloro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (207) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-5-chloro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (208) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(1-methoxy-2-methylpropan-2-yl)acetamide (209) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(4-methyloxan-4-yl)acetamide (210) 2-{3-[1-(2-amino-5-chloropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (211) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(2,2,2-trifluoroethyl)acetamide(212) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-[(2R)-1,1,1-trifluoropropan-2-yl]acetamide (213) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-[(2S)-1,1,1-trifluoropropan-2-yl]acetamide (214) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(3,3-difluorocyclobutyl)acetamide (215) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2R)-2-(trifluoromethyl)morpholin-4-yl]ethan-1-one (216) 4-[3-(4-fluoro-1-{[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (217) 4-[3-(1-{[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (218) 4-[3-(1-{[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]methyl}-1H-indazol-3-yl)azetidine-1-carbonyl]pyridin-2-amine (219) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]ethan-1-one (220) tert-Butyl 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}acetate (221) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-(2,2-dimethylpyrrolidin-1-yl)ethan-1-one(222) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2R)-2-ethylpyrrolidin-1-yl]ethan-1-one (223) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-{2-azabicyclo[3.1.0]hexan-2-yl}ethan-1-one (224) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(dicyclopropylmethyl)acetamide (225) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(2,2-difluorocyclopentyl)acetamide (226) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(4-fluorophenyl)acetamide (227) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-[2-(trifluoromethoxy)ethyl]acetamide (228) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]ethan-1-one (229) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(cyclopropylmethyl)-N-methylacetamide (230) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(3S)-3-methoxypyrrolidin-1-yl]ethan-1-one (231) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(3R)-3-methoxypyrrolidin-1-yl]ethan-1-one(232) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-{2-oxa-6-azaspiro[3.4]octan-6-yl}ethan-1-one (233) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(oxan-4-yl)acetamide (234) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(2-cyclopropylpropan-2-yl)acetamide (235) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(4,4-difluorocyclohexyl)acetamide (236) (2S)-1-(2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}acetyl)pyrrolidine-2-carbonitrile (237) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-4,4-difluoro-2-(fluoromethyl)pyrrolidin-1-yl]ethan-1-one (238) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-indazol-1-yl}-N-{bicyclo[2.2.1]heptan-2-yl}acetamide (239) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-indazol-1-yl}-N-{bicyclo[1.1.1]pentan-1-yl}acetamide (240) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (241) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-5-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one(242) 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4-fluoro-1H-indazol-1-yl}-N-(2,2-difluoroethyl)acetamide (243) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-[trans-2-fluorocyclopropyl]acetamide (244) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(1-cyanocyclopropyl)acetamide (245) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-[(1R,2S)-2-fluorocyclopropyl]acetamide (246) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-[(1S,2R)-2-fluorocyclopropyl]acetamide (247) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(1-methyl-1H-pyrazol-5-yl)acetamide (248) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(2,2-difluorocyclopropyl)acetamide (249) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-ethyl-N-(2,2,2-trifluoroethyl)acetamide (250) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(3,3-difluorocyclobutyl)-N-methylacetamide (251) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-cyclopropyl-N-(2,2,2-trifluoroethyl)acetamide(252) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-cyclopropyl-N-methylacetamide (253) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-(propan-2-yl)acetamide (254) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-(oxetan-3-yl)acetamide (255) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-(oxan-4-yl)acetamide (256) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-[(3,3-difluorocyclobutyl)methyl]-N-methylacetamide (257) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-(4,4-difluoropiperidin-1-yl)ethan-1-one (258) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-{8-oxa-3-azabicyclo[3.2.1]octan-3-yl}ethan-1-one (259) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[3-(trifluoromethyl)piperidin-1-yl]ethan-1-one (260) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-(4-methylpiperazin-1-yl)ethan-1-one (261) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-[(2S)-1,1,1-trifluoropropan-2-yl]acetamide(262) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-[(2R)-1,1,1-trifluoropropan-2-yl]acetamide (263) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N,N-diethylacetamide (264) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-[2-(morpholin-4-yl)ethyl]acetamide (265) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(2-methoxyethyl)-N-methylacetamide (266) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2R,6S)-2,6-dimethylpiperidin-1-yl]ethan-1-one (267) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N,N-bis(propan-2-yl)acetamide (268) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-tert-butyl-N-methylacetamide (269) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-(2,2-difluoroethyl)-N-methylacetamide (270) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)-3-methylazetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (271) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)-3-methylazetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one(272) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(difluoromethyl)pyrrolidin-1-yl]ethan-1-one (273) 2-{3-[1-(2-aminopyridine-4-carbonyl)-3-methylazetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (274) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5-chloro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (275) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-6-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (276) 2-{3-[1-(2-amino-5-fluoropyrimidine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (277) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (278) 2-{3-[1-(2-amino-5-fluoropyrimidine-4-carbonyl)azetidin-3-yl]-5-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (279) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5,6-difluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (280) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one(281) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)-3-hydroxyazetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (282) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-5,6-difluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (283) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-5,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (284) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-6-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (285) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)-3-fluoroazetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (286) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-6-fluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (287) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-4-chloro-5-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (288) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-5-methyl-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (289) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide(290) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-5-chloro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (291) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5-methoxy-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (292) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-5-methyl-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one (293) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-5-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (294) 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-5,5-dimethyl-4,5,6,7-tetrahydro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one, and (295) 2-{3-[1-(2-aminopyrimidine-4-carbonyl)azetidin-3-yl]-5,5-dimethyl-4,5,6,7-tetrahydro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one.
10. 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
11. 2-{3-[1-(2-aminopyridine-4-carbonyl)azetidin-3-yl]-4,6-difluoro-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one hydrochloride, or a solvate thereof.
12. 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-6-fluoro-1H-indazol-1-yl}-N-methyl-N-(2,2,2-trifluoroethyl)acetamide, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
13. 2-{3-[1-(2-aminopyridine-4-carbonyl)-3-methylazetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
14. 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
15. 2-{3-[1-(2-amino-5-fluoropyridine-4-carbonyl)azetidin-3-yl]-1H-indazol-1-yl}-1-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethan-1-one methanesulfonate, or a solvate thereof.
16. A pharmaceutical composition comprising a compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
17. A DDR1 kinase inhibitor comprising the compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient.
18. A method for inhibiting DDR1 kinase, comprising administering to a subject in need thereof a compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
19. A preventive or therapeutic agent for a disease involving DDR1 kinase, comprising the compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
20. A therapeutic agent for treating Alport syndrome, IgA nephropathy, Goodpasture syndrome, anti-glomerular basement membrane nephritis, lupus nephritis, ANCA-associated nephritis, diabetic nephropathy, purpura nephritis, focal segmental glomerulosclerosis, chronic renal failure, minimal change nephrotic syndrome, mesangial proliferative glomerulonephritis, membranoproliferative glomerulonephritis, crescentic glomerulonephritis, membranous nephropathy, pulmonary fibrosis, myelofibrosis, hepatic fibrosis, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, glioma, non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, prostate cancer, colorectal cancer, or osteoarthritis, comprising as an active ingredient the compound according to any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof, or a solvate thereof.
21. A method for preventing or treating a disease associated with DDR1 kinase, comprising administering to a subject in need thereof the compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, or a solvate thereof. twenty two. A method for preventing or treating Alport syndrome, IgA nephropathy, Goodpature syndrome, anti-glomerular basement membrane nephritis, lupus nephritis, ANCA-associated nephritis, diabetic nephropathy, purpura nephritis, focal segmental glomerulosclerosis, chronic renal failure, minimal change nephrotic syndrome, mesangial proliferative glomerulonephritis, membranoproliferative glomerulonephritis, crescentic glomerulonephritis, membranous nephropathy, pulmonary fibrosis, myelofibrosis, hepatic fibrosis, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, glioma, non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, prostate cancer, colorectal cancer, or osteoarthritis, comprising administering the compound according to any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof, or a solvate thereof to a subject in need thereof.
23. A compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, or a solvate thereof, for use in the prevention or treatment of a disease involving DDR1 kinase.
24. The compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, or a solvate thereof, for use in the prevention or treatment of Alport syndrome, IgA nephropathy, Goodpature syndrome, anti-glomerular basement membrane nephritis, lupus nephritis, ANCA-associated nephritis, diabetic nephropathy, purpura nephritis, focal segmental glomerulosclerosis, chronic renal failure, minimal change nephrotic syndrome, mesangial proliferative glomerulonephritis, membranoproliferative glomerulonephritis, crescentic glomerulonephritis, membranous nephropathy, pulmonary fibrosis, myelofibrosis, hepatic fibrosis, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, glioma, non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, prostate cancer, colorectal cancer, or osteoarthritis.
25. Use of the compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, or a solvate thereof, in the manufacture of an agent for the prophylaxis or treatment of a disease involving DDR1 kinase.
26. Use of the compound according to any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof, or a solvate thereof in the manufacture of an agent for the prophylaxis or treatment of Alport syndrome, IgA nephropathy, Goodpature syndrome, anti-glomerular basement membrane nephritis, lupus nephritis, ANCA-associated nephritis, diabetic nephropathy, purpura nephritis, focal segmental glomerulosclerosis, chronic renal failure, minimal change nephrotic syndrome, mesangial proliferative glomerulonephritis, membranoproliferative glomerulonephritis, crescentic glomerulonephritis, membranous nephropathy, pulmonary fibrosis, myelofibrosis, hepatic fibrosis, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, glioma, non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, prostate cancer, colorectal cancer, or osteoarthritis.
